Jeffrey E. Gershenwald, M.D.
Department of Surgical Oncology, Division of Surgery
About Dr. Jeffrey E. Gershenwald
Jeffrey E. Gershenwald, MD, FACS, FAAAS, FRACS(Hon) is a surgical oncologist and John M. Skibber Endowed Professor in the Department of Surgical Oncology at MD Anderson and Distinguished Senior Lecturer at The UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences. Celebrating 30 years at MD Anderson, he specializes in the surgical treatment of melanoma and locoregionally advanced cutaneous malignancies, with a focus on multidisciplinary care. His team science-based research programs center on melanoma staging and classification, clinicopathologic and multi-omic risk modeling to enhance decision-making, and clinical and translational research to improve treatment options for melanoma patients. He has made significant contributions to the American Joint Committee on Cancer (AJCC) melanoma staging system (currently serving as overall volunteer Chair of the AJCC), the Cancer Genome Atlas Project, and to clinical trials that have helped inform contemporary clinical care. Dr. Gershenwald has also been extensively engaged in public policy initiatives promoting skin cancer prevention in Texas, across the US, and in Europe. He currently serves as Chair of the Bylaws Committee, Chair-elect of the Executive Committee of the Medical Staff (ECMS), member of the President’s Advisory Council (PAC), Medical Director of the Melanoma and Skin Center, and as Co-inaugural leader of the Melanoma Informatics, Tissue Resource and Translational Pathology Core (MelCore). Previously, he served as co-leader of the MD Anderson Melanoma Moon Shot and Chair of the Medical Records Committee.
Present Title & Affiliation
Primary Appointment
Professor (term-tenured), Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Chief, Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center
Dr. John M. Skibber Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor (term-tenured), Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor (term-tenured), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1990 | Cornell University Medical College, New York, New York, US, MD |
| 1984 | Cornell University, Ithaca, New York, US, Nutritional Biochemistry, BS |
Postgraduate Training
| 1995-1998 | Fellow in Surgical Oncology/Junior Faculty Associate, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1994-1995 | Administrative Chief Resident (General Surgery), The New York Hospital-Cornell Medical Center, New York, New York |
| 1991-1994 | Resident in General Surgery, The New York Hospital-Cornell Medical Center, New York, New York |
| 1990-1991 | Intern in General Surgery, The New York Hospital-Cornell Medical Center, New York, New York |
Licenses & Certifications
| 2024 | Medical Licensure/Florida Board of Medicine |
| 2023 | Medical Licensure/Georgia Composite Medical Board |
| 2023 | Medical License/Mississippi State Board of Medical Licensure |
| 2023 | Medical License/Oklahoma State Board of Medical Licensure |
| 2023 | Medical License/Tennessee Board of Medical Examiners |
| 2023 | Medical License/Arizona Board of Medical Examiners |
| 2023 | Medical License/Louisiana State Board of Medical Examiners |
| 2023 | Medical License/Alabama Board of Medical Examiners |
| 2023 | Medical License/Washington State Department of health |
| 1996 | American Board of Surgery |
| 1995 | Texas Medical |
| 1992 | Medical License/New York Division of Professional Licensing |
Experience & Service
Faculty Academic Appointments
Associate Professor (term-tenured), Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2007
Associate Professor (term-tenured), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2007
Associate Member, Graduate Faculty, Department of Surgical Oncology, Graduate School of Biomedical Sciences, The University of Texas-Houston, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2017
Assistant Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000 - 2003
Assistant Professor (tenure track), Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2003
Administrative Appointments/Responsibilities
Director, Melanoma Surgery Service, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Chief, Melanoma Surgery Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Medical Director, Melanoma & Skin Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - Present
Melanoma Disease Site Liaison to the International Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - Present
Cancer Liaison Physician, Department of American College of Surgeons-Commission on Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002 - 2006
Chairman, Melanoma Informatics, Tissue Resource, and Pathology Core, Department of Oversight Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000 - Present
Co-Director, Melanoma Informatics, Tissue Resource, and Pathology Core, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - Present
Administrative Chief Resident, General Surgery, The New York Hospital/Cornell Medical Center, New York, NY, 1994 - 1995
Presidential Hospital Improvement Committee, The New York Hospital/Cornell Medical Center, New York, NY, 1994 - 1995
Other Professional Positions
Scientific Advisory Board and Neodream clinical trial steering committee, Philogen, 2025 - Present
Consultantships, Merck KEYVIBE-010, Scientific Advisory Committee, Whitehouse Station, NJ, 2022 - 2024
Consultantships, Merck, MK-3475-716 Scientific Advisory Committee, Whitehouse Station, NJ, 2018 - Present
Consultantships, Merck & Co., US Melanoma Advisory Board, Whitehouse Station, NJ, 2016 - Present
Member, The Wistar Institute/SPORE on Skin Cancer External Advisory Meeting, Philadelphia, PA, 2016
Member, Melanoma Institute of Australia Search Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016
Consultantships, Merck & Co., Malignant Melanoma Global Advisory Board, Whitehouse Station, NJ, 2014 - 2016
Consultantships, Navidea, Dublin, OH, 2012
Consultantships, GlaxoSmithKline Biologicals S.A, Belgium, 2009 - 2010
Professor (term-tenured), The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2023
MD Anderson Site Visit Team, American College of Surgeons, Commission on Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006
Judge, Student Poster Contest, Graduate School of Biomedical Sciences, Houston, TX, 2004
Trainee Recognition Day Judges Panel, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004
Trainee Recognition Day Judges Panel, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003
Provided guidance related to clinical melanoma treatment patterns and potential for application of novel molecular prognostic markers, Melanoma Advisory Exchange, Becton Dickinson Biosciences, Sparks, MD, 2000 - 2001
Provided and edited website content for patient-oriented clinical website, Scientific Advisory Board, MelanomaCenter.org, 2000 - 2001
Extramural Institutional Committee Activities
Chair, Bylaws Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Chair-elect, Executive Committee of the Medical Staff (ECMS), The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Executive Committee of the Medical Staff (ECMS), The University of Texas MD Anderson Cancer Center, 2024 - Present
Co-Chair, Dermatology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Vice-Chair, Bylaws Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Member, Department of Melanoma Medical Oncology Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2022
Co-leader, FY22 Joint Commission Chapter Co-Leader, Record of Care, Treatment, and Services (RC), The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Bylaws Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Co-leader, FY22 CMS Chapter Co-Leader, Medical Record Services Condition of Participation, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Department of Surgical Oncology Executive Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Global Oncology Strategy Workgroup, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Administrative Core of the Melanoma SPORE, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Internal Advisory Board for the MD Anderson GI SPORE, The University of Texas MD Anderson Cancer Center, 2019 - Present
Chair, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2021
Member, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2018 - 2021
Member, EHR-Laboratory System Working Group, The University of Texas MD Anderson Cancer Center, 2017 - 2017
Member, Path Lab Medicine LIS Working Group, The University of Texas MD Anderson Cancer Center, 2017 - 2017
Member, Faculty Achievement Awards Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2017
Member, Molecular Testing and Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2017
Member, Information Security Compliance Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, PA14-0241 Data and Biospecimen Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Charles A LeMaistre Outstanding Achievement Award in Cancer Committee, The University of Texas MD Anderson Cancer Center, 2017
Member, Research Data Management Systems Consortium, The University of Texas MD Anderson Cancer Center, 2014
Member, EHR Project Governance - Integrated Research Team Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Continuity of Care Team, The University of Texas MD Anderson Cancer Center, 2014
Member, Tissue Station Implementation Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015
Member, EPIC Integrated Research Team, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Melanoma Center Clinical Process Analysis Group, The University of Texas MD Anderson Cancer Center, 2012 - 2013
Member, Research Costs Working Group, The University of Texas MD Anderson Cancer Center, 2012 - 2013
Member, Moon Shot Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2017
Member, Electronic Medical Record (EMR) Clinical Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013
Member, Institutional Biospecimen Utilization Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013
Member, Pathology Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Vice-Chair, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2018
Member, Council of Committee Chairs, The University of Texas MD Anderson Cancer Center, 2011 - 2015
Member, Electronic Medical Record (EMR) Strategy Review Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2011
Member, Institutional Tissue Utilization Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Member, Melanoma Center Survivorship Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present
Member, Tissue Station Steering Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015
Chairman, Operative Report Enhancement Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Member, Clinical and Research Informatics Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011
Member, Professional Liability Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2019
Member, MD Anderson SPORE IT working Group, The University of Texas MD Anderson Cancer Center, 2010 - 2011
Member, Molecular Testing Task Force, The University of Texas MD Anderson Cancer Center, 2010
Member, Department of Surgical Oncology Educational Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present
Member, Pathology Tissue Banks Subcommittee, The University of Texas MD Anderson Cancer Center, 2008 - 2009
Member, Biospecimen Repository Advisory Committee (BRAC), The University of Texas MD Anderson Cancer Center, 2008 - 2012
Co-Chair, Biospecimen Repository Advisory Committee (BRAC), The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Perioperative Enterprise Surgery Scheduling Policies and Procedures Committee, The University of Texas MD Anderson Cancer Center, 2007
Chairman, Selection Committee for the Ethel Fleming Arceneaux Outstanding Nurse Oncologist Award, The University of Texas MD Anderson Cancer Center, 2004
Member, Melanoma SPORE Executive Committee, The University of Texas MD Anderson Cancer Center, 2003 - Present
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2022
Member, Selection Committee for the Ethel Fleming Arceneaux Outstanding Nurse Oncologist Award, The University of Texas MD Anderson Cancer Center, 2003
Member, Dermatome Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2003
Member, Department of Surgical Oncology Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2002 - Present
Member, Selection Committee of The University of Texas M. D. Anderson Cancer Center Postgraduate Physician Assistant Oncology Program, The University of Texas MD Anderson Cancer Center, 2001
Chairman, Melanoma Informatics, Tissue Resource, and Pathology Core Oversight Committee, The University of Texas MD Anderson Cancer Center, 2000 - Present
Member, Melanoma Research Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2000 - Present
Member, 3rd Foundations of Clinical Cancer Research Symposium Program Planning Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Anatomic Pathology System Review Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Clinical Research Day Organizing Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Tumor Registry Steering Committee, The University of Texas MD Anderson Cancer Center, 1998 - Present
Editorial Activities
Version 9 Editorial Board, American Joint Committee on Cancer (AJCC) Editorial Committee, 2019 - Present
Editorial Board, AJCC 8th Edition Cancer Staging Manual, 2016 - 2018
Editorial Board Member, CancerProgress.net, 2011 - Present
Editorial Board, American Society of Clinical Oncology, CancerProgress.Net, 2010 - Present
Editorial Board, Journal of Clinical Oncology, 2010 - 2013
Editorial Board (Assistant Editor), Melanoma Commons, 2010 - Present
Editorial Board Member, Cancer.net, 2010 - Present
Editorial Board, American Society of Clinical Oncology, Cancer.Net, 2009 - 2012
Associate Section Editor - Melanoma, Annals of Surgical Oncology, 2009 - 2015
Editorial Board, Annals of Surgical Oncology, 2000 - 2005
Editorial Board, Journal of the National Cancer Institute - Mexico [Revista del Instituto Nacional de Cancerologia de Mexico], 1999 - 2004
Honors & Awards
| 2025 | Press Ganey CGCAHPS top 10% Provider Nationally for Exceptional Care |
| 2024 | Press Ganey CGCAHPS top 1% Provider Nationally for Exceptional Care |
| 2022 | Honorary Fellowship of the Royal Australasian College of Surgeons, Royal Australasian College of Surgeons (RACS) |
| 2021 | President’s Recognition of Faculty Excellence - Prevention Outreach - Recognized by World Health Organization (WHO), The University of Texas MD Anderson Cancer Center |
| 2021 | Press Ganey CGCAHPS top 1% Provider Nationally for Exceptional Care, The University of Texas MD Anderson Cancer Center |
| 2020 | AACR Team Science Award, American Association for Cancer Research |
| 2020 | Press Ganey CGCAHPS Top 10% Provider |
| 2018 | Society for Melanoma Research Skin Cancer Prevention Leadership Award, Society for Melanoma Research |
| 2018 - Present | Fellow, American Association for the Advancement of Science (AAAS) |
| 2018 | Elected Fellow, American Association for the Advancement of Science (AAAS) |
| 2017 | 2017 Daniel Ingraham Memorial Lecture, Dallas/Fort Worth Dermatological Society |
| 2017 - 2020 | Listed, Best Doctors in America |
| 2016 | Faculty Achievement Award in Cancer Prevention, MD Anderson Cancer Center |
| 2016 | Tannlege Olaf Aase og Fruens minneforelesning Memorial Lectureship, Trondheim, Norway, Norwegian Cancer Congress |
| 2016 | Invited Presenter, American College of Surgeons Honorary Fellowship, Professor John F. Thompson, Melanoma Institute Australia |
| 2016 - 2023 | Listed, Texas Super Doctors |
| 2014 | Kay Family Melanoma Lectureship, Johns Hopkins |
| 2012 | MD Anderson Inaugural Moon Shot Program - Co-Leader Melanoma Moon Shot, The University of Texas MD Anderson Cancer Center |
| 2010 | University of Sydney International Visiting Research Fellow, Sydney, Australia |
| 2008 | National Health Information Award for "Questions and answers: melanoma booklet", The University of Texas M. D. Anderson Cancer Center |
| 2005 - 2010 | American Cancer Society Research Scholar |
| 2005 | Mentor Award of Appreciation, Center for Biomedical Engineering - Summer Internship |
| 2004 | Hassan Naama Memorial Lectureship, Cornell University-Weill Cornell Campus |
| 2002 | Listed, Houston’s Best Doctors |
| 2002 | J. B. Howell Melanoma Lectureship, Baylor University Medical Center |
| 2002 | Young Investigator Award, 3rd International Sentinel Node Congress, Yokohama, Japan |
| 2000 - 2024 | Listed, America's Top Doctors |
| 1999 | Physician-Scientist Program Award, The University of Texas MD Anderson Cancer Center |
| 1998 | University Cancer Foundation, Scientific Achievement Fellowship, The University of Texas MD Anderson Cancer Center |
| 1998 | Meadows Foundation Fellowship for Melanoma Research, The University of Texas MD Anderson Cancer Center |
| 1997 - 1998 | Texas Division Oncology Fellowship, American Cancer Society |
| 1997 | Bristol-Myers Squibb Award for Outstanding Clinical Research, The University of Texas M. D. Anderson Cancer Center |
| 1997 | Merit Award, American Society of Clinical Oncology |
| 1996 | Molecular Biology in Clinical Oncology Workshop, American Association for Cancer Research |
| 1996 | Clinical Fellows Research Award, The University of Texas MD Anderson Cancer Center |
| 1993 - 1994 | American Cancer Society Clinical Fellowship in Oncology, Cornell University Medical College |
| 1990 | Award for Research in Basic Science in Nutrition, New York Academy of Medicine/Regional Center for Clinical Nutrition Education |
| 1990 | Gustav Cudkowitz Memorial Award in Research, Cornell University Medical College |
| 1990 | Honors Thesis, Cornell University Medical College |
| 1989 | Papanicolaou Teaching Fellow in Gross Anatomy, Cornell University Medical College |
| 1989 | James Ewing Foundation, Society of Surgical Oncology Research Fellowship |
| 1986 | NIH Summer Research Fellow, Cornell University Medical College |
| 1984 | Quaker Oats Nutrition/Medical Scholarship, Cornell University |
| 1984 | Honors Thesis, Cornell University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. What’s New with AJCC Staging and Melanoma Synoptic Reporting. Invited. Cancer Registry. Houston, Texas, US.
- 2024. Reflections of a melanoma surgical oncologist: Texas, the nation, and the world. Conference. Reflections of a melanoma surgical oncologist: Texas, the nation, and the world. Houston, TX, US.
- 2023. Updates on AJCC Staging and CoC Surgical Standard 5.5. Conference. Updates on AJCC Staging and CoC Surgical Standard 5.5. Houston, TX, US.
- 2022. What’s New and the Impact on Multidisciplinary Care: Surgical Oncology. Invited. Melanoma Virtual Integration Retreat.
- 2022. Melanoma Staging and Surgical Perspectives, Mastering Melanoma: A Symposium for Patients and Caregivers. Conference. Melanoma Staging and Surgical Perspectives, Mastering Melanoma: A Symposium for Patients and Caregivers. Houston, TX, US.
- 2022. Melanoma Priority Project #3. Conference. Melanoma Priority Project #3. Houston, TX, US.
- 2022. Invited speaker, Melanoma Primer. Conference. Invited speaker, Melanoma Primer. Houston, TX, US.
- 2021. Invited participant. Conference. Invited participant. Houston, TX, US.
- 2021. Melanoma Priority Project #3. Conference. Melanoma Priority Project #3. Houston, TX, US.
- 2020. Melanoma Priority Project #3. Conference. Melanoma Priority Project #3. Houston, TX, US.
- 2020. Core B - MelCore. Conference. Core B - MelCore. Houston, TX, US.
- 2019. Personalized melanoma surgery in the modern era: What are the roles of SLNB and LND?. Conference. Personalized melanoma surgery in the modern era: What are the roles of SLNB and LND?. Houston, TX, US.
- 2019. Hot topics - Melanoma Oncology. Conference. Hot topics - Melanoma Oncology. Houston, TX, US.
- 2019. Discipline Breakout, Surgical Oncology/Orthopedic Oncology. Conference. Discipline Breakout, Surgical Oncology/Orthopedic Oncology. Houston, TX, US.
- 2019. Invited Discussant, MD Anderson multidisciplinary care discussion panel. Conference. Invited Discussant, MD Anderson multidisciplinary care discussion panel. Houston, TX, US.
- 2019. Leveraging the seed and soil [and beyond] to reduce the burden of melanoma metastasis. Conference. Leveraging the seed and soil [and beyond] to reduce the burden of melanoma metastasis. Houston, TX, US.
- 2018. Melanoma prevention 2018: Lessons learned...and still learning. Conference. Melanoma prevention 2018: Lessons learned...and still learning. Houston, TX, US.
- 2018. Highlights of the 8th Edition AJCC Melanoma Staging System/Department of Surgical Oncology Grand Rounds. Conference. Highlights of the 8th Edition AJCC Melanoma Staging System/Department of Surgical Oncology Grand Rounds. Houston, TX, US.
- 2017. Staging of Melanoma: Risk based assessment. Conference. Staging of Melanoma: Risk based assessment. Houston, TX, US.
- 2016. Overview of multidisciplinary melanoma care. Conference. Overview of multidisciplinary melanoma care. Houston, TX, US.
- 2016. UV protection. Conference. UV protection. Houston, TX, US.
- 2016. Primary prevention - A national call to action. Conference. Primary prevention - A national call to action. Houston, TX, US.
- 2016. AJCC Staging and Integrated Risk Modeling. Conference. AJCC Staging and Integrated Risk Modeling. Houston, TX, US.
- 2016. Panel Member: Tumor Board & Case Presentation. Conference. Panel Member: Tumor Board & Case Presentation. Houston, TX, US.
- 2016. Melanoma Medical Oncology. Conference. Melanoma Medical Oncology. Houston, TX, US.
- 2016. The MD Anderson Melanoma Moon Shot Program. Conference. The MD Anderson Melanoma Moon Shot Program. Houston, TX, US.
- 2016. Melanoma Moon Shot/Breakout Session. Conference. Melanoma Moon Shot/Breakout Session. Houston, TX, US.
- 2015. Welcome and summit overview. Conference. Welcome and summit overview. Houston, TX, US.
- 2015. MelCore Didactic Session - Staging and early-stage disease. Conference. MelCore Didactic Session - Staging and early-stage disease. Houston, TX, US.
- 2015. Moon Shot Updates: Melanoma. Conference. Moon Shot Updates: Melanoma. Houston, TX, US.
- 2015. Primary prevention - a national call to action. Conference. Primary prevention - a national call to action. Houston, TX, US.
- 2014. Latest treatment prevention and advancement in melanoma/Breakout Session - Cluster 1. Conference. Latest treatment prevention and advancement in melanoma/Breakout Session - Cluster 1. Houston, TX, US.
- 2014. Melanoma Moon Shot Program update. Conference. Melanoma Moon Shot Program update. Houston, TX, US.
- 2013. Melanoma Moon Shot update. Conference. Melanoma Moon Shot update. Houston, TX, US.
- 2013. Multidisciplinary Panel --- Case presentations: Management of high-risk patients and early-stage disease. Conference. Multidisciplinary Panel --- Case presentations: Management of high-risk patients and early-stage disease. Houston, TX, US.
- 2013. SLN biopsy update: Why and who?. Conference. SLN biopsy update: Why and who?. Houston, TX, US.
- 2013. Medical Panel member. Conference. Medical Panel member. Houston, TX, US.
- 2012. Breakout Session 3/Melanoma. Conference. Breakout Session 3/Melanoma. Houston, TX, US.
- 2012. Breakout Session 1/Melanoma. Conference. Breakout Session 1/Melanoma. Houston, TX, US.
- 2012. Stopping the sun to get to the moon. Conference. Stopping the sun to get to the moon. Houston, TX, US.
- 2012. Moon Shot Faculty Symposium. Conference. Moon Shot Faculty Symposium. Houston, TX, US.
- 2012. Melanoma Survivorship. Conference. Melanoma Survivorship. Houston, TX, US.
- 2012. Melanoma for the practicing dermatologist: Update 2012. Conference. Melanoma for the practicing dermatologist: Update 2012. Houston, TX, US.
- 2004. Evolving Concepts in Surgical Management and Staging for Melanoma. Conference. Evolving Concepts in Surgical Management and Staging for Melanoma. Houston, TX, US.
Regional Presentations
- 2025. Melanoma Classification, Staging, and Integrative Risk Modeling. Invited. Melanoma Research Alliance Site Visit. Houston, TX, US.
- 2024. MD Anderson Moon Shot Program. Conference. MD Anderson Moon Shot Program. Virtual, US.
- 2013. Melanoma Cancer Genome Atlas project (TCGA). Conference. Melanoma Cancer Genome Atlas project (TCGA), US.
- 2005. Management of Early-Stage Melanoma. Conference. Management of Early-Stage Melanoma. Abilene, TX, US.
National Presentations
- 2026. Best Paper Oral Podium Presentation/Neoadjuvant Pembrolizumab in Stage IIB/C Melanoma: Updated Clinical Outcomes and Translational Data from Phase 2 Trial NCT03757689. Invited. SSO 2026 Annual Meeting. Phoenix, Arizona, US.
- 2026. De-Escalation of Lymphadenectomy after Neoadjuvant Therapy for Advanced Stage III Melanoma: Ready for Prime Time?. Invited. 22nd Oncology Updates: Advances and Controversies. Houston, Texas, US.
- 2025. Proteogenomics uncovers resistance mechanisms and identifies biomarkers for improving immune checkpoint inhibitor treatment of metastatic melanoma. Poster. ASMS Conference on Mass Spectrometry and Allied Topics. Baltimore, Maryland, US.
- 2025. AJCC: Who are we and what do we do?. Invited. ACS Cancer Conference 2025. Phoenix, AZ, US.
- 2025. Panel Q&A + Case Presentations. Panelist. 21st Oncology Updates: Advances and Controversies. Steamboat Springs, CO, US.
- 2025. De-Escalation of Surgery for High-Risk Stage II and Advanced Stage III Melanoma: Ready for Prime Time?. Invited. 21st Oncology Updates: Advances and Controversies. Steamboat Springs, CO, US.
- 2024. It’s All About the Data: Perspectives on Structured Data Across the Cancer Patient Continuum. Invited. Future of Cancer Data Summit: Harnessing the Power of Pathology Data. Las Vegas, Nevada, US.
- 2024. Integrating biobanking and clinical informatics to empower clinical and translational research: Lessons learned…and still learning. Invited. DoD Melanoma Academy Workshop. New Orleans, LA, US.
- 2024. Melanoma as a Paradigm for Leveraging Cancer Research and Prevention Collaboration: From Texas to Poland…and Beyond!. Invited. US- Central/Eastern Europe Cancer Research Symposium. Buffalo, NY, US.
- 2024. MD Anderson SPORE in Melanoma: Overview & Update. Invited. Philadelphia, PA, US.
- 2024. Session 8: Cutaneous Oncology - Panel Q&A and Case Presentations. Conference. 20th Oncology Congress. Steamboat Springs, CO, US.
- 2024. Session 3: Biomarker Driven Risk Stratification, Treatment, and Prophylaxis: Evidence for Clinical Utility - Efforts by the AJCC to Incorporate Biomarkers into Staging Criteria. Conference. 20th Oncology Congress. Steamboat Springs, CO, US.
- 2023. It's all about the data: International Melanoma Database and Discovery Platform (IMDDP) Quality Assurance (QA) Initiative. Conference. SMR 20th International Congress 2023. Philadelphia, PA, US.
- 2023. Session VIII-Cutaneous Melanoma, New Controversies in the management of high-risk stage II melanoma?. Conference. 19th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2022. Panel Discussion - Multi-modality, integrated nature of management. Conference. MRF Mucosal Melanoma Meeting. New York, NY, US.
- 2022. Staging. Conference. MRF Mucosal Melanoma Meeting. New York, NY, US.
- 2022. Plenary Session: AJCC Future Directions and TNM Staging System Updates. Conference. National Cancer Registrars Association Conference 2022. Washington, DC, US.
- 2021. Role of surgery in the era of precision medicine in melanoma. Conference. Brazilian Congress of Skin Cancer. Virtual.
- 2020. The Great Debate, Does AJCC classification offer an improvement for better staging: Yes or no?. Conference. Melanoma Bridge 2020. Virtual.
- 2020. Live Panel Discussion. Conference. Art and Science of Managing the New Melanoma Landscape - 7th Annual Collaborative Virtual Conference. Virtual, US.
- 2020. Educational updates on Cancer Moonshots. Conference. Melanoma Symposium 2020. Houston, TX, US.
- 2020. Melanoma primary prevention initiatives: Education and legislation. Conference. 18th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2019. Hot Topics. Conference. Sarcoma/Melanoma Retreat. Houston, TX, US.
- 2019. Multidisciplinary Care Discussion Panel. Conference. Sarcoma/Melanoma Retreat. Houston, TX, US.
- 2019. Improving prognostic models to enhance clinical decision-making in melanoma. Conference. Art and Science of the Melanoma Landscape conference. Houston, TX, US.
- 2019. Melanoma Cancer Staging. Conference. ACS Quality and Safety Conference. Washington, DC, US.
- 2019. Panelist: Q&A Panel Discussion. Conference. ACS Quality and Safety Conference. Washington, DC, US.
- 2019. Melanoma prevention through public policy. Conference. GAP 2019. Houston, TX, US.
- 2019. The adjuvant melanoma landscape. Conference. Merck US Melanoma Advisory Board. New York, US.
- 2019. Practice Changing Studies of 2018: Melanoma. Conference. SSO 2019 Annual Meeting. San Diego, CA, US.
- 2019. Prevention and Screening/Melanoma primary prevention initiatives: Education and legislation. Conference. 17th Oncology Update: Advances and Controversies. Breckenridge, CO, US.
- 2018. What's new in the 8th edition AJCC Melanoma Staging System. Conference. The Art and Science of Managing the New Melanoma Landscape-5th Annual Collaborative Conference. Houston, TX, US.
- 2018. Industry roundtable breakfast. Conference. Tenth Annual Scientific Retreat. Washington, DC, US.
- 2018. Primary and secondary prevention strategies. Conference. 16th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2017. Evolving Concepts in the Eighth Edition American Joint Committee on Cancer (AJCC) Staging Manual Systems: Breast Cancer, Colorectal, Melanoma/Melanoma overview. Conference. 2017 ACS Clinical Congress. San Diego, CA, US.
- 2017. Session 1: Melanoma Prevention, Screening, Diagnosis, and Staging/The new AJCC Melanoma Staging System. Conference. The Art and Science of Managing the New Melanoma Landscape 4th Annual Collaborative Conference. Houston, TX, US.
- 2017. Molecular Biomarkers to Incorporate to Patient Care/New 8th ed. AJCC Staging System. Conference. Skin SPORE Retreat. New Haven, CT, US.
- 2017. Special plenary track on the AJCC Cancer Staging Manual, 8th edition/Staging Melanoma. Conference. NCRA 43rd Annual Educational Conference. Washington, DC, US.
- 2017. Case Presentations - Panel Speaker. Conference. 15th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2017. Session IV-Melanoma - Advances in melanoma prognosis: AJCC and beyond. Conference. 15th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2016. Update on AJCC staging and relevance to neoadjuvant efforts. Conference. Symposia on Neoadjuvant Therapy for Melanoma. Boston, MA, US.
- 2016. MD Anderson Moon Shot Program. Conference. Melanoma Prevention Working Group. Boston, MA, US.
- 2016. Melanoma staging and prognostic factors. Conference. Melanoma: Biology & Patient Management 2016. Washington, DC, US.
- 2016. Invited presenter, Clinical Congress Convocation. Conference. 2016 Clinical Congress. Washington, DC, US.
- 2016. Melanoma and immunotherapy. Conference. Marking Cancer History Seminar. Atlanta, GA, US.
- 2016. 8th edition AJCC melanoma staging system: Updates related to early-stage disease. Conference. The Art and Science of Managing the New Melanoma Landscape: A Case-Based Multidisciplinary Approach. Houston, TX, US.
- 2016. Melanoma prevention: Mini primer. Conference. The Art and Science of Managing the New Melanoma Landscape: A Case-Based Multidisciplinary Approach. Houston, TX, US.
- 2016. Multidisciplinary Panel - Case Presentations. Conference. The Art and Science of Managing the New Melanoma Landscape. Houston, TX, US.
- 2016. Invited panelist, general session. Conference. ACC Annual Meeting. Chicago, IL, US.
- 2016. Session I: Sharing Data Handling, databases, and datasets toward collaborative Inter-SPORE research; TCGA and AJCC 8th edition as prototypes for data sharing. Conference. Annual Inter-Skin SPORE Scientific Retreat. Pittsburgh, PA, US.
- 2016. Survivorship. Conference. Understanding Melanoma: From Prevention to Cure. Houston, TX, US.
- 2016. Integrative risk modeling and clinical tool development: AJCC and other initiatives relevant to the surgical oncology community. Conference. 69th Annual SSO Meeting. Boston, MA, US.
- 2016. Managing SLN positive melanoma: Is it time to abandon completion lymph node dissections?. Conference. 14th Oncology Update: Advances & Controversies. Steamboat Springs, CO, US.
- 2015. MelCore: Experience to date. Conference. Annual Inter-Skin SPORE Scientific Retreat. Philadelphia, PA, US.
- 2015. Advances in the treatment of melanoma. Conference. 24th Annual National Conference. Minneapolis, MN, US.
- 2015. Genomic classification of melanoma. Conference. 2nd Annual Global Summit on Melanoma. Pasadena, CA, US.
- 2015. Discussant, Long-term outcomes of helper peptide vaccination for metastatic melanoma. Conference. 135th Annual ASA Meeting. San Diego, CA, US.
- 2015. Cost implications of newer systemic therapies in melanoma. Conference. 68th Annual SSO Meeting. Houston, TX, US.
- 2015. Sentinel lymph node biopsy should be performed on all patients with cutaneous melanoma ≥ 1 mm thick: Con (Plenary Debate). Conference. 68th Annual SSO Meeting. Houston, TX, US.
- 2015. Surgical management of melanoma: A 2015 primer. Conference. 7th Annual Scientific Retreat. Washington, DC, US.
- 2015. Data quality. Conference. AJCC 8th edition Precision Medicine Core meeting. Phoenix, AZ, US.
- 2015. The Cancer Genome Project for melanoma: What have we learned?. Conference. 13th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2014. Multidisciplinary Panel, Melanoma Diagnosis and Management of Early Disease in the Sentinel Node Era. Conference. PROVA Education - The Art and Science of the Evolving Melanoma Landscape: A Case-based Multidisciplinary Approach. Houston, TX, US.
- 2014. SLN and other prognostic markers, Melanoma Diagnosis and Management of Early Disease in the Sentinel Node Era. Conference. PROVA Education - The Art and Science of the Evolving Melanoma Landscape: A Case-based Multidisciplinary Approach. Houston, TX, US.
- 2014. Tanning beds - Rest in Peace, Melanoma Diagnosis and Management of Early Disease in the Sentinel Node Era. Conference. PROVA Education - The Art and Science of the Evolving Melanoma Landscape: A Case-based Multidisciplinary Approach. Houston, TX, US.
- 2014. Melanoma staging and prognosis: Current status, controversies and novel directions. Conference. The Future of Novel Approaches and Technologies in the Multidisciplinary Management of Cancer Patients. Boston, MA, US.
- 2014. Prognostic markers and staging: What's new?. Conference. 12th Oncology Conference. Steamboat Springs, CO, US.
- 2013. Session 1-Enhancing understanding of uveal melanoma (UM) biology - Updates from UM TCGA. Conference. Workshop: Emerging Research in Uveal Melanoma and Implications for Treatment: Current Status and Future Directions. Philadelphia, PA, US.
- 2013. Contemporary surgical approach to the patient with localized melanoma. Conference. 2013 ACS Clinical Congress. Washington, DC, US.
- 2013. TCGA update. Conference. MD Anderson Cancer Center Skin SPORE Workshop. Houston, US.
- 2013. Controversies in the surgical management of melanoma: Completion LND. Conference. MDACC/MDAPN - Bringing the Future of Oncology to Practice Now. Orlando, FL, US.
- 2013. Challenging Melanoma Case Presentations with Interactive Audience Participation. Conference. MDACC/MDAPN - Bringing the Future of Oncology to Practice Now. Orlando, FL, US.
- 2013. Melanoma Moon shot Program. Conference. MDACC/MDAPN - Bringing the Future of Oncology to Practice Now. Orlando, FL, US.
- 2013. Novel therapeutic approaches for stage III and stage IV melanoma. Conference. Satellite symposium at the 2013 SSO Annual Cancer Symposium. Washington, DC, US.
- 2013. Surgery for stage IV disease: When and who?. Conference. 11th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2012. Plenary Session - The Cancer Genome Atlas Program - Update. Conference. Society for Melanoma Research 2012 Congress. Hollywood, CA, US.
- 2012. Melanoma staging and prognosis in the sentinel lymph node era: Update 2012. Conference. Frontiers of Interdisciplinary Personalized Cancer Therapy Symposium. Chicago, IL, US.
- 2012. High throughput melanoma sequencing, new biological pathways and how the information can be applied to the clinic - TCGA Update. Conference. SPORES in Skin Cancer Summer Workshop 2012. New Haven, CT, US.
- 2012. Controversies in the surgical management of melanoma: Sentinel lymph node biopsy and completion lymph node dissection. Conference. Frontiers of Interdisciplinary Personalized Cancer Therapy Symposium. Chicago, IL, US.
- 2012. Microscopic node disease in melanoma. Conference. 2012 SSO Annual Cancer Symposium. Orlando, FL, US.
- 2012. Clinicopathologic and molecular staging and prognosis in early-stage melanoma. Conference. 4th Annual MRA Annual Retreat. Washington, DC, US.
- 2012. Controversies in the surgical management of melanoma: Sentinel lymph node biopsy and completion dissection. Conference. 10th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2011. Meet the Professor - "Evidence-based use of SLN in melanoma". Conference. 63rd Annual Cancer Symposium of the Society of Surgical Oncology. San Antonio, TX, US.
- 2010. The role of completion lymph node dissection in patients with microscopic lymph node involvement. Conference. 6th Annual Oncology Congress. San Francisco, CA, US.
- 2010. The new AJCC Staging System and beyond. Conference. M D Anderson Cancer Center Physicians Network 6th Annual Symposium. New York, NY, US.
- 2010. MelaGrid/Inter-SPORE Wiki update. Conference. MD Anderson Cancer Center Skin SPORE Summer Workshop. Houston, TX, US.
- 2009. Management of site-specific metastasis. Conference. Perspectives in Melanoma XIII Annual Meeting. Baltimore, MD, US.
- 2009. Informatics Approach to Research Data, Arrays, and High Throughput Analyses: GO ARRAY collaborative TMA. Conference. SPOREs in Skin Cancer Summer Workshop. Pittsburgh, PA, US.
- 2009. Informatics approach to research data, arrays, and high throughput analyses: MelCore - Current status & common data elements. Conference. SPOREs in Skin Cancer Summer Workshop. Pittsburgh, PA, US.
- 2009. Evidence-based follow-up of the melanoma patient. Conference. 62nd Annual Cancer Symposium of the Society of Surgical Oncology. Phoenix, AZ, US.
- 2009. Surgical management of melanoma. Conference. 33rd Hawaii Dermatology Seminar. Maui, HI, US.
- 2008. MelCore Database/Biospecimen Workflow: Lessons learned, and still learning!. Conference. NCI Translational Science Meeting - SPOREs in Skin Cancer Satellite Meeting. Washington, DC, US.
- 2008. Current management of cutaneous melanomas, including those of the head and neck: Diagnostic testing for staging and follow-up. Conference. 94th Annual Meeting of the American College of Surgeons. San Francisco, CA, US.
- 2008. Advances in Staging and Surgery, AJCC Staging: Preview of The Factors That May Change in 2009. Conference. Perspectives in Melanoma XII. The Hague.
- 2008. Biomarkers from the laboratory into the clinical arena, AJCC - Update 2008. Conference. SPOREs in Skin Cancer Workshop. New Haven, CT, US.
- 2008. How to best collect, manage and analyze vast data generated from different melanoma/melanocyte omics platforms: Melanoma Informatics, Tissue Resource, and Pathology Core (MelCore). Conference. SPOREs in Skin Cancer Workshop. New Haven, CT, US.
- 2008. Current management of melanoma. Conference. 7th Annual Mid-Atlantic Oncology Update. Baltimore, MD, US.
- 2008. Case presentations - Melanoma. Conference. 8th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
- 2008. Treatment of squamous cell carcinoma of the skin. Conference. 8th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
- 2007. Update on Melanoma Staging. Conference. Advances in Melanoma. Houston, TX, US.
- 2007. SSO Surgical Oncology Fellowship requirements. Conference. American College of Surgeons 93rd Annual Meeting. New Orleans, LA, US.
- 2007. Surgical update - Melanoma. Conference. Third Annual Oncology Congress. San Francisco, CA, US.
- 2007. Imaging studies for melanoma staging and follow-up/Advances in Melanoma Therapy. Conference. 2007 Society of Surgical Oncology Annual Cancer Symposium. Washington, DC, US.
- 2007. Optimal use of imaging studies for melanoma patients: Does every melanoma patient need a PET/CT scan?. Conference. 60th Annual Society of Surgical Oncology Cancer Symposium. Atlanta, GA, US.
- 2007. Invited Participant. Conference. Pediatric Melanoma Working Group. Houston, TX, US.
- 2007. Case presentations - Melanoma. Conference. 7th Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2006. Updates in melanoma staging and prognostic models. Conference. Second Annual Oncology Congress. New York, NY, US.
- 2006. Genomics and platform development - Melanoma. Conference. NCI 14th SPORE Investigators' Workshop. Baltimore, MD, US.
- 2006. Lessons from melanoma. Conference. AJCC Statistical Task Force Meeting, AJCC Prognostic and Predictive Factors in Cancer. Washington, DC, US.
- 2006. Evidence-based staging system from a physician's perspective. Conference. AJCC Statistical Task Force Meeting, AJCC Prognostic and Predictive Factors in Cancer. Washington, DC, US.
- 2006. Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. Conference. Keystone Symposium Advances in the Understanding and Treatment of Melanoma. Santa Fe, NM, US.
- 2005. Invited Speaker. Conference. Melanoma Research Foundation Medical Scientific Workshop. Hilton Head Island, SC, US.
- 2005. Discussant, Surgical Forum (Surgical Oncology II). Conference. 91st Annual Clinical Congress of the ACS. San Francisco, CA, US.
- 2005. Controversies in Surgical Oncology: Can we define a standard of care? Sentinel lymphadenectomy is the standard of care in the initial surgical management of intermediate thickness cutaneous melanoma. Conference. 58th Annual Meeting of the SSO. Atlanta, GA, US.
- 2005. Sentinel lymph node biopsy for melanoma and other cutaneous malignancies. Conference. 5th Annual Oncology Update: Advances and Controversies. Houston, TX, US.
- 2005. Invited Participant. Conference. Resources for Melanoma Research Workshop. Gaithersburg, MD, US.
- 2004. Contemporary issues in the management of melanoma. Conference. South Texas Chapter of the American College of Surgeons. Houston, TX, US.
- 2004. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Conference. Abstract: 57th Annual Society of Surgical Oncology Cancer Symposium. New York, NY, US.
- 2004. Surgical clinical trials in melanoma: Where have we been and where are we going. Conference. 57th Annual Society of Surgical Oncology Cancer Symposium. New York, NY, US.
- 2004. Multivariate prognostic model for patients with thick cutaneous melanoma: Results of a large multi-institutional study. Conference. Abstract: 57th Annual Society of Surgical Oncology Cancer Symposium. New York, NY, US.
- 2004. Management of sentinel lymph node positive patients. Conference. 4th Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2003. General Session - Advances in the surgical staging of melanoma. Conference. 89th Annual Clinical Congress of the ACS. Chicago, IL, US.
- 2003. Invited Discussant - Surgical Forum (Surgical Oncology II). Conference. 89th Annual Clinical Congress of the ACS. Chicago, IL, US.
- 2003. Update on melanoma. Conference. Plastic Surgery Educational Foundation - Aesthetic Facial Reconstruction Symposium. Phoenix, AZ, US.
- 2003. Melanoma staging system. Conference. 3rd Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2002. Sentinel lymph node (SLN) microscopic tumor burden predicts non-SLN involvement in melanoma patients undergoing therapeutic lymphadenectomy. Conference. 55th Annual Meeting of the SSO. Denver, CO, US.
- 2002. Current concepts in melanoma. Conference. Plastic Surgery Educational Foundation - Aesthetic Facial Reconstruction Symposium. Nashville, TN, US.
- 2002. Meet the Professor Session - Melanoma update. Conference. 3rd Combined Annual Meeting of the American Society of Dermatologic Surgery and American College of Mohs Micrographic Surgery & Cutaneous Oncology. Chicago, IL, US.
- 2001. Operative technique: How to do it and interesting cases. Conference. 87th Annual Clinical Congress of the ACS. New Orleans, LA, US.
- 2001. New Staging Criteria. Conference. 2nd Symposium on Advances in the Biology and Treatment of Cutaneous Melanoma. Boston, MA, US.
- 2001. General Session, Current treatment of melanoma: A new staging system for melanoma. Conference. 87th Annual Clinical Congress of the ACS. New Orleans, LA, US.
- 2001. Sentinel lymph node biopsy in melanoma - where are we now?. Conference. First Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2001. Revisions of melanoma staging. Conference. First Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2000. Current evaluation of prognostic factors and the proposed AJCC staging system of 2000. Conference. Perspectives in Melanoma IV. Pittsburgh, PA, US.
- 2000. Melanoma. Conference. TexMed 2000/South Texas Chapter of the American College of Surgeons. San Antonio, TX, US.
- 2000. Dominant-negative transcription factor AP-2 (AP-2B) augments tumorigenicity and metastatic potential in primary cutaneous melanoma. Conference. 91st Annual Meeting of the AACR. San Francisco, CA, US.
- 2000. Role of sentinel lymph node biopsy in patients with thin (<1mm) cutaneous melanoma. Conference. 53rd Annual Meeting of the SSO. New Orleans, LA, US.
- 2000. Background and overview of the current and proposed staging systems for melanoma. Conference. Statistical Subcommittee of the American Joint Committee on Cancer Melanoma Task Force. Orlando, FL, US.
- 1999. Changing Trends in Melanoma Management, Lymphatic mapping and sentinel node biopsy in melanoma - experience to date. Conference. 1999 Clinical Congress of the ACS. San Francisco, CA, US.
- 1999. Sentinel node status best predicts survival in patients with thick (≥ 4mm) melanoma. Conference. 52nd Annual Cancer Symposium of the SSO. Orlando, FL, US.
- 1999. Course Instructor-Lymphatic Mapping Workshop. Conference. 51st Annual Meeting of the SWSC. Coronado, CA, US.
- 1998. Regulation of in vivo growth and metastasis by the transcription factor AP-2 in melanoma. Conference. 51st Annual Meeting of the SSO. San Diego, CA, US.
- 1998. Regulation of tumor growth and metastasis of human melanoma cells by the transcription factor AP-2. Conference. 89th Annual Meeting of the AACR. New Orleans, LA, US.
- 1998. Improved sentinel lymph node localization in primary melanoma patients with the use of radiolabeled colloid. Conference. SUS Annual Meeting. Milwaukee, WI, US.
- 1997. IL-8 expression by human melanoma cells regulates MMP-2 activity and increases tumor growth and metastases. Conference. 88th Annual Meeting of the AACR. San Diego, CA, US.
- 1997. Factors influencing the decision to perform prophylactic contralateral mastectomy (PCM) in women with early stage breast cancer undergoing immediate breast reconstruction. Conference. 50th Annual Meeting of The SSO. Chicago, IL, US.
- 1996. Patterns of failure in melanoma patients after successful lymphatic mapping and negative sentinel node biopsy. Conference. The 49th Annual Meeting of The SSO. Atlanta, GA, US.
International Presentations
- 2025. Debate: Gene expression profiling in the primary lesion: No. Invited. Melanoma Bridge 2025.
- 2025. Beyond the American Joint Committee on Cancer (AJCC) 8th Edition Melanoma Staging System. Poster. Society for Melanoma Research 22nd International Congress. Amsterdam, NL.
- 2025. PANELIST : Multidisciplinary Panel Case-Based Discussion. Panelist. 2025 Annual TNM Meeting. Geneva, CH.
- 2025. AJCC and 9th version. Invited. 2025 Annual TNM Meeting. Geneva, CH.
- 2025. Beyond the 8th edition American Joint Committee on Cancer (AJCC) melanoma staging system. Invited. 11th WCM & 21st EADO. Athen, GR.
- 2024. Emergent strategies and frontiers in cancer staging and classification: as a paradigm. Invited. Melanoma Bridge 2024. Naples, IT.
- 2024. Staging Updates. Invited. INMC Meeting at ESMO. Barcelona, ES.
- 2024. Neoadjuvant data and staging criteria - the time to act is now. Invited. Innovate - International Neoadjuvant Immunotherapy Across Cancers. Naples, IT.
- 2023. The Great Debate SLN biopsy is NO longer necessary for pts with high-risk primary cutaneous melanoma in an era of effective adjuvant immunotherapy, "NO". Conference. Melanoma Bridge 2023. Naples, IT.
- 2023. The Great Debate: Do we need a new melanoma classification? - NO. Conference. 19th EADO Congress. Rome, IT.
- 2022. A History of the Australian and North American Melanoma Partnership. Conference. Royal Australasian College of Surgeons Annual Scientific Congress 2022. Brisbane, AU.
- 2022. Melanoma Masterclass. Current melanoma staging and a practical application of the resource. Conference. Royal Australasian College of Surgeons Annual Scientific Congress 2022. Brisbane, AU.
- 2021. Lymphadenectomy: before or later?. Conference. Great Debates, Melanoma Bridge 2021. Naples, IT.
- 2021. What will be the gold standard technics to sentinel lymph node biopsy approach for the next years?, in Sentinel node biopsy: techniques and future perspectives. Conference. 10th World Congress of Melanoma & 17th EADO Congress. Virtual.
- 2021. Beyond TNM: framework for "next-gen" AJCC initiatives, in Advances in melanoma staging and prognosis: AJCC V8, integrative risk modeling, and beyond. Conference. 10th World Congress of Melanoma & 17th EADO Congress. Virtual.
- 2019. Invited Discussant, Do we really need to treat stage IIA patients with adjuvant?. Conference. Melanoma Bridge 2019. Naples, IT.
- 2019. The Great Debate, Do we really need to treat stage IIIA patients with adjuvant: Yes or Not?. Conference. Melanoma Bridge 2019. Naples, IT.
- 2019. 8th Edition AJCC Melanoma Staging, Next Steps, and Collaborative Opportunities. Conference. 4th Annual Sarcoma/Melanoma Conference. Shanghai, CN.
- 2019. International melanoma database and discovery platform. Conference. International Thyroid Oncology Group. New York, US.
- 2019. International melanoma database and discovery platform (IMDDP). Conference. Padova Melanoma International meeting. Padova, IT.
- 2019. 8th Edition AJCC new Staging System. Conference. Padova Melanoma International meeting. Padova, IT.
- 2018. Breakout Session 3: Insights into melanoma data management/Integrated clinical and biospecimen data management. Lessons learned and collaborative opportunities: MD Anderson. Conference. 14th EADO. Barcelona, ES.
- 2018. Breakout Session 5: Running a skin cancer centre/What are the pros and cons of "large" cancer centres?. Conference. 14th EADO. Barcelona, ES.
- 2018. Debate - Is the new AJCC a progress?. Conference. 14th EADO. Barcelona, ES.
- 2018. Tumour bank and biomarkers. Conference. Nordic Melanoma Meeting. Copenhagen, DK.
- 2018. Melanoma center, trials team and database at MD Anderson. Conference. Nordic Melanoma Meeting. Copenhagen, DK.
- 2018. AJCC 8th Edition. Conference. Nordic Melanoma Meeting. Copenhagen, DK.
- 2018. Prevention of melanoma. Conference. Nordic Melanoma Meeting. Copenhagen, DK.
- 2018. Melanoma prevention: Lifestyle changes and legislation. Conference. 2018 American Society of Clinical Oncology Annual Meeting. Chicago, US.
- 2018. Personalized prognostic assessment and prevention initiatives in the era of personalized melanoma therapy: lessons learned and collaborative opportunities. Conference. GAP2018. Stockholm, SE.
- 2017. Debate - Lymphadenectomy Pros and Cons. Conference. 7th Melanoma Bridge meeting. Naples, IT.
- 2017. Round Table - New 8th Edition AJCC melanoma staging system. Conference. XIII BSSO 2017. Rio de Janeiro, BR.
- 2017. Round Table - The role of the surgeon in the era of effective systemic therapy for melanoma. Conference. XIII BSSO 2017. Rio de Janeiro, BR.
- 2017. Round Table - Sentinel lymph node biopsy in non-melanoma skin cancer. Conference. XIII BSSO 2017. Rio de Janeiro, BR.
- 2017. SY5, Surgical Oncology: The Role of Surgery for Stage IV Disease/Changing paradigms in surgery: implications of effective systemic therapy on surgical decision-making in patients with stage IV disease. Conference. 9th World Congress of Melanoma. Brisbane, AU.
- 2017. PL03, Staging, Surgery and Targeted Therapies for Melanoma/The new AJCC melanoma classification. Conference. 9th World Congress of Melanoma. Brisbane, AU.
- 2017. The new (8th Edition) AJCC Melanoma Staging System...and beyond. Conference. 2nd Annual meeting of Alleanza Contro il Cancro/New Technologies and Strategies to Fight Cancer. Rome, IT.
- 2017. Keynote Address - The MD Anderson Melanoma Moon Shot Research Program: team science in action. Conference. 2nd Annual meeting of Alleanza Contro il Cancro/New Technologies and Strategies to Fight Cancer. Rome, IT.
- 2017. Plenary Lectures II/The new (8th edition) AJCC melanoma staging system. Conference. 13th Congress of the EADO. Athens, GR.
- 2017. Surgery of melanoma/SLN beyond melanoma: clinical application in skin cancers other than melanoma. Conference. 13th Congress of the EADO. Athens, GR.
- 2016. Melanoma Moon Shot - Prevention. Conference. Onkologisk Forum - 2016. Trondheim, NO.
- 2016. Melanoma Moon Shot. Conference. Melanoma Moon Shot. Oslo, NO.
- 2016. Melanoma prevention and staging: Election day 2016 update. Conference. 2016 International SMR Congress. Boston, US.
- 2016. Role of surgery in the era of precision medicine. Conference. 34th National Oncology Congress, Melanoma session. Tijuana, MX.
- 2016. Lymph node surgery in melanoma patients. Conference. 16th WCCS and 12th EADO. Vienna, AT.
- 2016. Current standards for the management of primary skin cancer lesions in the US. Conference. 16th WCCS and 12th EADO. Vienna, AT.
- 2016. Sentinel node in skin cancer beyond melanoma. Conference. 16th WCCS and 12th EADO. Vienna, AT.
- 2016. Assembly report for the ISNS meeting. Conference. ISNS 2016 Meeting. Milan, IT.
- 2016. Moon Shots: Melanoma. Conference. GAP2016 Challenging Cancer. Sao Paulo, BR.
- 2016. AJCC melanoma staging system: Towards an 8th edition. Conference. ISNS 2016 Meeting. Milan, IT.
- 2016. Current management of localized disease and the role of adjuvant therapy in the immunotherapy era. Conference. GAP2016 Challenging Cancer. Sao Paulo, BR.
- 2016. Melanoma & Sarcoma - Discussant/Oral Presentations. Conference. GAP2016 Challenging Cancer. Sao Paulo, BR.
- 2016. Round table discussion. Conference. 8th International Conference of Contemporary Oncology. Poznan, PL.
- 2016. Therapeutic and prognostic advances in melanoma. Conference. 8th International Conference of Contemporary Oncology. Poznan, PL.
- 2015. TNM and new biomarkers in melanoma. Conference. VI Symposium GEM 2015. Valencia, ES.
- 2015. Sentinel node staging. Conference. VI Symposium GEM 2015. Valencia, ES.
- 2014. The Cancer Genome Atlas Project. Conference. IMI Annual Congress. Venice, IT.
- 2014. Towards the new AJCC staging system for melanoma. Conference. IMI Annual Meeting. Venice, IT.
- 2014. Balancing the costs and benefits of new melanoma therapies. Conference. American Society of Clinical Oncology 2014 Annual Meeting. Chicago, US.
- 2014. Invited Discussant, Melanoma/Skin Cancers Oral Abstract Session. Conference. 2014 Annual Meeting of the ASCO. Chicago, US.
- 2014. Peter Mac Sister-Institution Signing Ceremony. Conference. Peter Mac Sister-Institution Signing Ceremony. Melbourne, AU.
- 2013. Diagnosis and New Procedures Session - AJCC classification, the Melanoma Cancer Genome Atlas Program (TCGA), and beyond: Integrated models in the molecular era. Conference. Diagnosis and New Procedures Session - AJCC classification, the Melanoma Cancer Genome Atlas Program (TCGA), and beyond: Integrated models in the molecular era. Naples, IT.
- 2013. AJCC classification, the melanoma TCGA, and beyond: integrated models in the molecular era. Conference. AJCC classification, the melanoma TCGA, and beyond: integrated models in the molecular era. Hamburg, DE.
- 2013. Education Session - Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy - Discuss the value of sentinel lymph node biopsy for thin melanoma. Conference. American Society of Clinical Oncology 2013 Annual Meeting. Chicago, US.
- 2013. Use of novel agents in the adjuvant and neoadjuvant setting. Conference. Joint International Oncology Congress. San Francisco, US.
- 2012. Testing in melanoma in US. Conference. 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres and 8th EADO Congress. Barcelona, ES.
- 2012. The evaluation of sentinel lymph node in 2012: Controversies and future trends. Conference. 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres and 8th EADO Congress. Barcelona, ES.
- 2012. Quality assurance of skin cancer centers in USA. Conference. 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres and 8th EADO Congress. Barcelona, ES.
- 2012. The evaluation of sentinel lymph node in 2012: controversies and future trends. Conference. 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres and 8th EADO Congress. Barcelona, ES.
- 2011. Meet the Professor: Tissue is the issue: Acquiring, banking and using primary and metastatic melanoma specimens. Conference. 2011 International Melanoma Congress. Tampa, US.
- 2011. Multi-institutional clinical and research datasets. Conference. 2011 International Melanoma Congress. Tampa, US.
- 2011. Beyond the AJCC/UICC melanoma staging system: Current concepts and future directions in melanoma staging and prognosis. Conference. Melanoma Research: A Bridge from Naples to the World meeting. Naples, IT.
- 2011. Indications for SLN biopsy in thin melanoma. Conference. 2011 International Melanoma Congress. Tampa, US.
- 2011. Next staging classification. Conference. 7th EADO Congress. Nantes, FR.
- 2010. Quality Assurance in Melanoma Surgery session - What we do to guarantee QA. Conference. 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting. Sydney, AU.
- 2010. Economics issues facing melanoma services in the US. Conference. 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting. Sydney, AU.
- 2010. Prognostic impact of SLN biopsy for melanoma: Recent lessons learned and future perspectives. Conference. 7th International Sentinel Node Society Meeting. Yokohama, JP.
- 2010. Mitotic rate and sentinel lymph node biopsy in cutaneous melanoma: Impact of the 7th edition AJCC melanoma staging system. Conference. 7th International Sentinel Node Society Meeting. Yokohama, JP.
- 2010. Invited Discussant, Discussion of clinical cases. Conference. VIII Course on Advances in Dermatologic Surgery and Melanoma. Pamplona, ES.
- 2010. New approach on the segment of the melanoma. Conference. Hospital AC Camargo 10th Annual Skin Oncology Conference. Sao Paolo, BR.
- 2010. Redefining stage III melanoma - impact on prognosis and clinical decision-making. Conference. Glaxo Smith-Kline Satellite Symposium. Athens, GR.
- 2010. Evidence-based revisions to the AJCC/UICC melanoma staging system - 2010. Conference. 8th ICATTM & 6TH EADO. Athens, GR.
- 2010. Current approach on the treatment of skin sarcomas. Conference. Hospital AC Camargo 10th Annual Skin Oncology Conference. Sao Paolo, BR.
- 2010. The new AJCC Melanoma Staging System. Conference. Hospital AC Camargo 10th Annual Skin Oncology Conference. Sao Paolo, BR.
- 2009. The new AJCC melanoma classification. Conference. 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers. Berlin, DE.
- 2009. Roundtable discussion leader, Leveraging the new AJCC Melanoma Staging System in the molecular era: Insights and future directions in contemporary staging and prognosis. Conference. 2009 International Melanoma Congress. Boston, US.
- 2009. Should all patients with melanoma have PET Imaging?. Conference. XVIII Brazilian Congress of Cancerology. Curitiba, BR.
- 2009. Management of early-stage melanoma. Conference. XVIII Brazilian Congress of Cancerology. Curitiba, BR.
- 2009. Evidence-based follow-up for the melanoma patient?. Conference. XVIII Brazilian Congress of Cancerology. Curitiba, BR.
- 2009. Therapeutic Targeting of the Lymphatic System. Conference. 3rd International Symposium on Cancer Metastasis and the Lymphovascular System. San Francisco, US.
- 2009. Staging and prognosis for regional metastases (Stage III). Conference. 7th World Congress on Melanoma and the 5th Congress of the European Association of Dermato-Oncology (EADO). Vienna, AT.
- 2009. Groin Dissection for Melanoma - Update 2009. Conference. 7th World Congress on Melanoma and the 5th Congress of the European Association of Dermato-Oncology (EADO). Vienna, AT.
- 2008. Creating a functional melanoma database. Conference. 2nd Annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers. Clearwater Beach, US.
- 2008. Adjuvant therapy: What have we learned?. Conference. 7th International Conference of Adjuvant Therapy on Malignant Melanoma and the 4th European Association of Dermato-Oncology Congress. Marseille, FR.
- 2008. Poster Discussant. Conference. 2008 ASCO Annual Meeting. Chicago, US.
- 2008. Risk markers: disease staging - present and future. Conference. 7th International conference of Adjuvant Therapy on Malignant Melanoma and the 4th European Association of Dermato-Oncology Congress. Marseille, FR.
- 2008. How can we select subgroups for adjuvant therapy?. Conference. 7th International Conference of Adjuvant Therapy on malignant Melanoma and the 4th European Association of Dermato-Oncology Congress. Marseille, FR.
- 2008. Current status of sentinel node biopsy in melanoma. Conference. 20th International Pigment Cell conference and 5th International Melanoma Research Congress. Sapporo, JP.
- 2007. Melanoma poster discussion session. Conference. 43rd Annual meeting of the American Society of Clinical Oncology. Chicago, US.
- 2007. Targeting the lymphovascular system. Conference. 2nd International Symposium on Cancer Metastasis and the Lymphovascular System. San Francisco, US.
- 2007. Invited Participant. Conference. International Melanoma Classification Workshop. Monterey, US.
- 2006. Sentinel node biopsy: Unusual indications and controversies in melanoma - In-transit/local recurrence. Conference. 5th Biennial International Sentinel Node Society Meeting. Rome, IT.
- 2006. The role of the lymph node in melanoma, Meet the professor session (2 sessions). Conference. 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, US.
- 2006. Melanoma poster discussion session. Conference. 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, US.
- 2006. What is the role of PET scanning on the diagnosis and follow-up in melanoma management?. Conference. Third International Symposium on Melanoma and Other Cutaneous Malignancies. New York, US.
- 2005. Satellite Symposium: Advancing the Treatment of Melanoma. AJCC staging guidelines. Conference. 6th World Congress on Melanoma. Vancouver, CA.
- 2005. Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. Conference. 6th World Congress on Melanoma. Vancouver, CA.
- 2005. Isolation and molecular characterization of human sentinel afferent lymphatic endothelial cells. Conference. 1st International Symposium on Cancer Metastasis and the Lymphovascular System. San Francisco, US.
- 2004. Molecular characterization of human sentinel lymphatic endothelial cells: emerging insights into the biology of melanoma lymphatic metastasis. Conference. 2nd International Melanoma Research Congress. Phoenix, US.
- 2002. AJCC Stage III (nodal) criteria accurately predict survival in sentinel node-positive melanoma patients. Conference. 3rd International Sentinel Node Congress. Yokohama, JP.
- 2002. Melanoma and the challenges of lymphedema. Conference. 5th International Lymphedema Network Meeting. Chicago, US.
- 2002. The sentinel lymph node status in malignant melanoma. Conference. IV Course on Advances In Dermatologic Surgery. Pamplona, ES.
- 2002. Meet the Professor Session - Cancer and lymphedema. Conference. 5th International Meeting of the National Lymphedema Network. Chicago, US.
- 2001. Patterns of failure and survival analysis in sentinel lymph node positive melanoma patients. Conference. 37th Annual Meeting of the ASCO. San Francisco, US.
- 2001. Current research in melanoma. Conference. Melanoma Advisory Exchange. Venice, IT.
- 2001. Melanoma cell tumor growth is augmented by the dominant-negative transcription factor AP-2B. Conference. Fifth World Conference on Melanoma. Venice, IT.
- 2001. Lymphatic drainage to unusual sentinel nodal sites in patients with primary cutaneous melanoma: frequency and significance. Conference. Fifth World Conference on Melanoma. Venice, IT.
- 2000. The prognostic significance of microscopic tumor burden in 945 melanoma patients undergoing sentinel lymph node biopsy. Conference. 36th Annual Meeting of the ASCO. New Orleans, US.
- 2000. Lymphatic mapping in breast cancer. Conference. XVIII Annual Meeting of the National Cancer Institute -Mexico. San Jose, CR.
- 1999. Regional perfusion in the management of malignant melanoma. Conference. 16th Annual Meeting of the Instituto Nacional De Cancerologia de Mexico. Manzanillo, MX.
- 1999. State of the art of malignant melanoma and lymphatic mapping for melanoma. Conference. 16th Annual Meeting of the Instituto Nacional De Cancerologia de Mexico. Manzanillo, MX.
- 1997. Routine histologic examination of the sentinel lymph node (SLN) understages the nodal basin in stage I and II melanoma patients. Conference. 33rd Annual meeting of the ASCO. Denver, US.
- 1997. Prognostic significance of the sentinel lymph node (SLN) in stage I or II melanoma patients. Conference. 4th World Conference on Melanoma. Sydney, AU.
- 1997. Nodal failure after lymphatic mapping (LM) and negative sentinel lymph node (SLN) biopsy in stage I or II melanoma patients. Conference. 4th World Conference on Melanoma. Sydney, AU.
- 1989. Anti-IL-1 receptor monoclonal antibodies attenuate metabolic changes in inflammation. Conference. The Second International Conference on Cytokines. Hilton Head, US.
Formal Peers
- 2024. Contemporary Management of Patients with High-Risk Clinically Localized Primary Cutaneous Melanoma. Invited. Phoenix, AZ, US.
- 2023. Keynote Speaker - The MD Anderson Melanoma Moon Shot: Sharing lessons learned from a high risk, high reward model to reduce melanoma incidence and mortality through integrated research efforts spanning the melanoma continuum. Invited. Lublin, PL.
- 2023. Keynote Speaker - Melanoma. Invited. Jacksonville, FL, US.
- 2023. Grand Rounds - Contemporary Management of Patients with Clinically Node-Negative and Regionally Metastatic Cutaneous Melanoma…and a Bit More!. Invited. Jacksonville, FL, US.
- 2022. Leveraging cancer prevention initiatives at the state, national, and international levels: Reflections and opportunities from an MD Anderson – Poland indoor tanning public policy initiative. Invited. Buffalo, NY, US.
- 2020. Educational updates on cancer Moonshots. Invited. Phoenix, AZ, US.
- 2019. Melanoma as a Paradigm for Leveraging Opportunities in Global Cancer Prevention. Invited. Warsaw, PL.
- 2019. What is new in the 8th Edition AJCC Melanoma Staging System?. Invited. Scottsdale, AZ, US.
- 2018. Integrating research into lifelong clinical practice? Yes, you (probably) can!. Invited. Hartford, CT, US.
- 2018. Collaborative opportunities - melanoma. Invited. Stockholm, SE.
- 2018. Invited speaker, Controversies and Advances in melanoma Symposium. Invited. Hartford, CT, US.
- 2018. Approach to the nodal basin: Should we just leave it alone?. Invited. Atlanta, GA, US.
- 2018. Update on new AJCC staging system for melanoma: What are changes and why?. Invited. Atlanta, GA, US.
- 2018. Key Note Address - Melanoma prognosis and staging: Where to from here?. Invited. Sydney, AU.
- 2018. Keynote speaker. Visiting. Sydney, AU.
- 2017. Melanoma for the practicing dermatologist: Update 2017. Visiting. Dallas, TX, US.
- 2016. Melanoma Moon Shot - Personalized management and the new AJCC Melanoma Staging System. Visiting. Trondheim, NO.
- 2016. AJCC Staging. Invited. Boston, MA, US.
- 2016. The MD Anderson Melanoma Moon Shot Program. Visiting. Cape Town, ZA.
- 2016. Melanoma management (and prevention) for the practicing clinician: Update 2016. Visiting. Cape Town, ZA.
- 2016. Therapeutic and prognostic advances in melanoma. Visiting. Krakow, PL.
- 2016. Therapeutic and prognostic advances in melanoma. Visiting. Warsaw, PL.
- 2015. 2015 ACS CAN Oklahoma Policy Forum/The Public Health Burden of Melanoma and Skin Cancer: Challenges and Opportunities. Invited. Tulsa, OK, US.
- 2015. The public health burden of melanoma and skin cancer: challenges and opportunities. Visiting. New York, NY, US.
- 2015. The evolving role of surgery in advanced melanoma in the molecular era. Visiting. New York, NY, US.
- 2015. Keynote Speaker - Staging and prognosis for cutaneous melanoma. Invited. Memphis, TN, US.
- 2015. New horizons in melanoma: Treatment advances, public policy, and the Melanoma Cancer Genome Atlas project. Visiting. Los Angeles, CA, US.
- 2015. Invited speaker, CDC Grand Rounds April Session. Invited. Atlanta, GA, US.
- 2015. New horizons in melanoma: Treatment advances, public policy, and the Melanoma Cancer Genome Atlas Project. Visiting. Dallas, TX, US.
- 2014. Contemporary Staging and Management of Early-Stage Melanoma: Overview and Update in the Molecular Era. Visiting. Boston, MA, US.
- 2014. AJCC classification and staging, The Melanoma Cancer Genome Atlas Program (TCGA), and beyond: Integrated models in the molecular era...[that every surgeon should know]. Visiting. Baltimore, MD, US.
- 2014. AJCC Classification, The Melanoma Cancer Genome Atlas Program (TCGA), and Beyond: Integrated Models in the Molecular era. Visiting. Santa Monica, CA, US.
- 2011. Melanoma in the Sentinel Node Biopsy Era: Lessons Learned and Still Learning. Visiting. Buffalo, NY, US.
- 2011. Biology of Melanoma Metastasis – A Surgical Oncologist's Perspective. Visiting. New York, NY, US.
- 2011. Melanoma in the Sentinel Node Biopsy Era: Lessons Learned and Future Directions. Visiting. New York, NY, US.
- 2010. Melanoma - Update 2010. Invited. Chattanooga, TN, US.
- 2010. International Visiting Research Fellow. Visiting. Sydney, AU.
- 2009. Melanoma Disease Management Team. Invited. New York, NY, US.
- 2009. Management of Early-Stage Melanoma - Update 2009. Visiting. Vienna, AT.
- 2009. Management of Early-Stage Melanoma - An Inaugural Update. Visiting. Baltimore, MD, US.
- 2007. Advances in Melanoma: Update in Melanoma Staging. Invited. Miami, FL, US.
- 2004. Sentinel Node Biopsy for Melanoma: Lessons Learned and Insights into the Biology of Lymphatic Metastasis. Visiting. New York, NY, US.
- 2004. Sentinel Lymph Node Biopsy in Melanoma: What have we learned and where are we now?. Visiting. New York, NY, US.
- 2002. Sentinel Lymph Node Biopsy for Melanoma - State of the Art. Visiting. Chicago, IL, US.
- 2002. Advances in Melanoma Staging: Sentinel Node Biopsy, the New AJCC Staging System, and Beyond. Department of Surgery. Visiting. Dallas, TX, US.
- 2002. Current Surgical Treatment of Melanoma. Invited. Dallas, TX, US.
- 2001. Advances in Melanoma Staging: Sentinel Node Biopsy, the New AJCC Staging System, and Beyond. Visiting. Tucson, AZ, US.
- 2001. Sentinel Lymphadenectomy (Videotape). Houston, TX, US.
- 2000. Lymphatic Mapping and Sentinel Lymph Node Biopsy: Current State and Future Directions. Visiting. Hershey, PA, US.
- 2000. Recent Advances in the Surgical Management of Patients with Primary Melanoma. Invited. Houston, TX, US.
- 2000. Lymphoscintigraphy and Sentinel Lymph Node Mapping in Patients with Melanoma. Invited. Houston, TX, US.
- 1999. Recent Advances in the Surgical Management of Patients with Primary Melanoma. Visiting. Houston, TX, US.
- 1999. Recent Advances in the Surgical Treatment of Patients with Primary Melanoma. Visiting. San Diego, CA, US.
- 1998. Current Surgical Treatment of Melanoma. Visiting. Springfield, MO, US.
- 1998. Tumor Board Meeting, Surgical Advances in the Treatment of Malignant Melanoma including Lymphoscintigraphy. Invited. Webster, TX, US.
Grant & Contract Support
| Date: | 2025 - 2026 |
| Title: | Melanoma Moon Shot |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Overall Moon Shot Leader |
| Date: | 2024 - 2029 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| Date: | 2022 - 2027 |
| Title: | Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 U01 CA271407-01 |
| Date: | 2021 - 2022 |
| Title: | Early Melanoma Detection |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-Lead Project 4 |
| Date: | 2020 - 2023 |
| Title: | Molecular predictors and vulnerabilities of melanoma brain metastasis |
| Funding Source: | ACS & MRA |
| Role: | Co-I |
| ID: | MRATCCG-134148 |
| Date: | 2020 - 2022 |
| Title: | Molecular predictors and vulnerabilities of melanoma brain metastasis |
| Funding Source: | Melanoma Research Alliance |
| Role: | Co-I |
| ID: | 687055 |
| Date: | 2019 - 2025 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Administrative Co-Director (Core 2) |
| ID: | 5 P50 CA221703-04 (CORE 2) |
| Date: | 2019 - 2025 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 P50 CA221703-01A1 |
| Date: | 2019 - 2025 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in melanoma |
| Funding Source: | NIH/NCI |
| Role: | Administrative Core Director (Core 1) |
| ID: | 5 P50 CA221703-04 (CORE 1) |
| Date: | 2018 - 2023 |
| Title: | Translational Team Science Award/Improving early detection, screening and prognosis for nodular melanoma: Combining behavioral, clinicopathological and molecular factors to reduce melanoma mortality |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Administrative Principal Investigator (PI) and Co-PI |
| ID: | DOD, CA170374 |
| Date: | 2018 - 2023 |
| Title: | Integration of Clinical, Molecular, and Immune Features to Improve Risk Stratification and Outcomes in Melanoma Patients with Sentinel Lymph Node Metastasis |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XW1810144 |
| Date: | 2018 - 2022 |
| Title: | Facebook Intervention for Young Onset Melanoma Patients and Families |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA221854 |
| Date: | 2013 - 2016 |
| Title: | Studies on the mechanism(s) of resistance to RAF inhibitor-based therapies |
| Funding Source: | Melanoma Research Alliance |
| Role: | PI-MDACC |
| Date: | 2013 - 2018 |
| Title: | Targeting BRAF-mutant melanoma brain metastases |
| Funding Source: | Melanoma Research Alliance (MRA) |
| Role: | Collaborator |
| Date: | 2011 - 2014 |
| Title: | Clinical and molecular characterization of combined BRAF and MEK inhibitor treatment in patients with metastatic melanoma resistant to BRAF inhibitor alone |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP120505 |
| Date: | 2011 - 2012 |
| Title: | Nucleic acid extraction protocol development |
| Funding Source: | NIH/SAIC-Frederick, Inc |
| Role: | PI |
| Date: | 2011 - 2014 |
| Title: | Clinicopathologic and molecular staging & prognosis in early-stage melanoma |
| Funding Source: | Melanoma Research Alliance, Team Science Award |
| Role: | PI |
| Date: | 2011 - 2016 |
| Title: | The role of the PI3k-AKT pathway in melanoma brain metastases |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2010 - 2017 |
| Title: | UT MD Anderson Cancer Center SPORE in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | P50 CA093459 |
| Date: | 2010 - 2017 |
| Title: | UT MD Anderson Cancer Center SPORE in Melanoma (Core B) |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| ID: | P50 CA093459 |
| Date: | 2009 - 2010 |
| Title: | Unraveling prognostic heterogeneity in stage IV melanoma between Australia and the United States |
| Funding Source: | Brigham and Women's Hospital/NIH |
| Role: | PI |
| ID: | 5 P50 CA093683 07 |
| Date: | 2008 - 2011 |
| Title: | Mechanisms of melanoma metastasis: The effect of the tumor microenvironment |
| Funding Source: | Baylor College of Medicine/M. D. Anderson, MRP |
| Role: | Project 6 Principal Investigator |
| Date: | 2008 - 2012 |
| Title: | Melanoma Cancer Genome Atlas Program (TCGA) |
| Funding Source: | NIH/SAIC-Frederick, Inc |
| Role: | Tissue Source Site Leader (MD Anderson) |
| Date: | 2006 - 2009 |
| Title: | International Evidence-Based Assessment of the Melanoma Staging System |
| Funding Source: | American Joint Committee on Cancer |
| Role: | PI |
| Date: | 2006 - 2009 |
| Title: | Research Supplement to Promote Diversity in health-related research grant, DNA methylation in colon cancer metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | NIH 5RO1CA09800 6-02 |
| Date: | 2005 - 2009 |
| Title: | Biology and Significance of Melanoma Lymphatic Metastasis |
| Funding Source: | American Cancer Society Research Scholar Grant |
| Role: | PI |
| ID: | RSG-05-250-01-CSM |
| Date: | 2004 - 2005 |
| Title: | Melanoma Informatics & Pathology Database. Expansion of Melanoma Database |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2004 - 2009 |
| Title: | Melanoma |
| Funding Source: | NIH/NCI SPORE |
| Role: | Co-Director |
| Date: | 2004 - 2009 |
| Title: | Biology and therapeutic targeting of IL-8 and MUC18 blockade on melanoma growth and metastasis in an animal model (Project 4; PI: Menashe Bar-Eli) |
| Funding Source: | Melanoma NIH/NCI SPORE |
| Role: | Co-I |
| Date: | 2004 - 2010 |
| Title: | Melanoma Informatics, Tissue Resource, and Pathology Core (Core B) |
| Funding Source: | Melanoma NIH/NCI SPORE |
| Role: | Co-Director |
| Date: | 2004 - 2009 |
| Title: | Molecular Epidemiology of Genetic Markers in Melanoma (Project 2, PI: Qingyi Wei) |
| Funding Source: | Melanoma NIH/NCI SPORE |
| Role: | Co-I |
| Date: | 2004 - 2009 |
| Title: | NIH/NCI Skin SPORE InterSPORE Tissue Microarray Working Group |
| Funding Source: | NIH/NCI SPORE |
| Role: | Member |
| Date: | 2004 - 2007 |
| Title: | A targeted, family-focused intervention for melanoma prevention |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | RSG-PB-04-010-01-CPB |
| Date: | 2004 - 2005 |
| Title: | Melanoma NIH/NCI SPORE Developmental Award, Biology of Melanoma Lymphatic Metastasis |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2003 - 2008 |
| Title: | Genetic predictors for DNA repair phenotype in CMM |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Co-I |
| ID: | RO1 CA 100264-01 A1 |
| Date: | 2003 - 2004 |
| Title: | Clinical Investigator Program - Assessing outcomes in patients with melanoma |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Mentor |
| Date: | 2003 - 2005 |
| Title: | Role of vascular endothelial growth factor-D (VEGF-D) in the biology of melanoma lymphatic metastasis |
| Funding Source: | Melanoma Research Foundation |
| Role: | PI |
| Date: | 2002 - 2007 |
| Title: | Heterogeneity of human melanoma, cytokines and iNOS |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01 CA90282-01 |
| Date: | 2000 - 2001 |
| Title: | Feasibility study to determine the agreement of sentinel lymph node status and melastatin mRNA expression in primary cutaneous malignant melanoma |
| Funding Source: | Becton Dickinson Biosciences and The University of Texas M. D. Anderson Cancer Center sponsored agreement |
| Role: | PI |
| ID: | CS00-224, LAB00-227 |
| Date: | 1999 - 2001 |
| Title: | Role of the Transcription Factor AP-2 in the progression of human melanoma |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center Physician Scientist Program |
| Role: | PI |
| Title: | Multicenter Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node |
| Funding Source: | John Wayne Cancer Institute |
| Role: | Local site Principal Investigator |
| Title: | Molecular determinants of risk, progression and treatment response in melanoma |
| Funding Source: | Australian Government - National Health and Medical Research Council |
| Role: | Associate Investigator |
| ID: | APP1093017 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Mike Hogg Fund |
| Role: | Collaborator |
| Title: | Multi-Institutional Data Sharing/Biomarker Development - The Skin SPORE/P01 Model |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Title: | Genetic Determinants of Apoptosis and Risk of Cutaneous Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Diagnostic and Prognostic Potential of Phosphorylated GSK3 in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | CA152535 |
Selected Publications
Peer-Reviewed Articles
- Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R. Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 41838361.
- Deutsch JS, Scolyer RA, Burton E, Busam KJ, Chen KY, Cimino-Mathews A, Cottrell TR, de Andrea CE, Fiset PO, Long GV, Messina J, Rawson RV, Salgado R, Schurch CM, Seethala RR, Sholl LM, Signoretti S, Topalian SL, van de Wiel BA, Xu X, Gershenwald JE, Tetzlaff MT, Taube JM. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort. Ann Oncol 37(2):141-154, 2026. e-Pub 2026. PMID: 41469296.
- Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 15(12):2574, 2025. e-Pub 2025. PMID: 41327972.
- Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
- Balch CM, Liao N, Lam D, Weitzel JN, Xu R, Attard G, Bunn PA, Eggermont AMM, He J, Kitagawa Y, Lim ST, Esquivel B, Fan X, Cho L, Liu E, Said HM, Niederhiber JE, Rubio IT, Zaghloul A, Arrieta O, Audisio RA, Beets GL, Coimbra FJF, Escobar JG, Garber JE, Gronchi A, Heineman V, Kurian AW, Mutebi M, Mori M, Olopade OI, Rutkowski P, Saleh M, Maldonado WS, Sawaya R, Thompson JF, Tumusiime, Sologuren CV, Whiteman DC, Wu Y, Yawe DKT, Zahrani NAA, Zoras O, Fabian CJ, Gershenwald JE, Gradishar WJ, Klimberg VS, Lee VHF, Lorusso D, Mok TSK, He J, Perrier ND, Rugo HS, Ulrich C. The Global Cancer Crisis: A Review of Growing Burden, Deepening Inequality and Prevention Initiatives. eCancer. e-Pub 2025.
- Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol 43(26):2856-2862, 2025. e-Pub 2025. PMID: 40638872.
- Janczewski LM, Gress DM, Gershenwald JE, Asare EA. A Refresher on the Key Terminologies and Principles of the American Joint Committee on Cancer (AJCC) Staging System. J Natl Compr Canc Netw 23(7), 2025. e-Pub 2025. PMID: 40639406.
- Lo, S, Gjorup, C, Chakera, AH, Hölmich, LR, Moncrieff, M, MacKenzie-Ross, A, Cassell, O, Ma, J, Weitemeyer, MM, Bagge, RO, Klausen, S, Calsavara, VF, Duprat Neto, JP, Bertolli, E, Ch'Ng, S, Saw, RP, Shannon, K, Spillane, A, Nieweg, OE, Stretch, JR, Mann, GJ, Geh, JL, Haydu, LE, Martin, RC, Sharon, CE, Karakousis, G, Kashani-Sabet, M, Adigbli, G, El Sharouni, MA, Gershenwald, JE, Scolyer, RA, Thompson, JF, Varey, AH. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients with Primary Cutaneous Melanoma. JAMA Dermatology 161(6):589-596, 2025. e-Pub 2025. PMID: 40202725.
- Kumar, S, Pelster, MS, Hasanov, M, Guerrieri, R, Hudgens, CW, Ledesma, D, Wang, F, Fischer, G, Simon, JM, Haydu, LE, Katlowitz, KV, Yennu Nanda, VG, McQuade, JL, Kwong, L, Huse, J, Lazar, A, Tetzlaff, M, Gershenwald, JE, Joon, A, Chen, K, Li, Z, Ram, P, Ferguson, SD, Davies, MA. Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis. Acta Neuropathol Commun 13(1):75, 2025. e-Pub 2025. PMID: 40229864.
- Lo SN, Gjorup C, Chakera AH, Holmich LR, Moncrieff M, MacKenzie Ross A, Cassell O, Ma J, Weitemeyer MB, Bagge RO, Klausen S, Calsavara VF, Duprat Neto JP, Bertolli E, Ch'ng S, Saw RPM, Shannon KF, Spillane AJ, Nieweg OE, Stretch JR, Mann GJ, Geh JLC, Haydu LE, Martin RCW, Sharon C, Karakousis GC, Kashani-Sabet M, Adigbli G, El Sharouni MA, Gershenwald JE, Scolyer RA, Thompson JF, Varey AHR. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. JAMA Dermatol, 2025. e-Pub 2025. PMID: 40202725.
- Yoon, CH, Ross, MI, Gastman, B, Luke, JJ, Ascierto, PA, Long, GV, Rutkowski, P, Khattak, A, Del Vecchio, M, de la Cruz-Merino, L, Mackiewicz, J, Chiarion-Sileni, V, Schadendorf, D, Carlino, MS, Zhao, Y, Fukunaga-Kalabis, M, Krepler, C, Eggermont, AM, Gershenwald, JE, Sondak, V. Adjuvant Pembrolizumab in Stage II Melanoma. Annals of surgical oncology 32(4):2756-2764, 2025. e-Pub 2025. PMID: 39893343.
- Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Gershenwald JE, Sondak VK. Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial 32(4):2756-2764, 2025. e-Pub 2025. PMID: 39893343.
- Buller DB, Berteletti J, Heckman C, Schroth KRJ, Geller AC, Stapleton JL, Adjei I, Mitarotondo A, Guild SR, Gershenwald JE, Dellavalle R, Pagoto S. Bills to Restrict Access to and Harm From Indoor Tanning Facilities in US State Legislatures, 1992‒2023. Am J Public Health 115(2):191-200, 2025. e-Pub 2025. PMID: 39571132.
- Guerrieri RA, Fischer GM, Kircher DA, Joon AY, Cortez JR, Grossman AH, Hudgens CW, Ledesma DA, Lazcano R, Onana CY, Knighton BG, Kumar S, Hu Q, Gopal YNV, McQuade JL, Deng W, Haydu LE, Gershenwald JE, Lazar AJ, Tetzlaff MT, Holmen SL, Davies MA. Oxidative Phosphorylation (OXPHOS) Promotes the Formation and Growth of Melanoma Lung and Brain Metastases. bioRxiv, 2025. e-Pub 2025. PMID: 39896644.
- Kalinski P, Kokolus KM, Ahluwalia I, Balu M, Balwicki L, Baran B, Beine L, Berezin M, Berindan-Neagoe I, Beznosenko A, Borowiec B, Bozsanyi S, Bramson J, Czerniecki B, Everatt R, Fendler W, Forsyth P, Gershenwald JE, Goniewicz M, Guru K, Hyland A, James S, Kirac I, Koczkodaj P, Kotula L, Luba M, Lugowska I, Luke E, Lungulescu C, Matosevic S, Nanavati K, Nemeth M, Nowak K, Noyes K, Parascandola M, Priebe W, Rutkowski P, Seshadri M, Sheffer CE, Stanciu IM, Stanson J, Stewart T, Suziedeliene E, Suziedelis K, Tanasiichuk I, Vlad AM, Wei WZ, Williams D, Wojtowicz M, Zdrojewski T. Meeting Highlights The 4th Marie Sklodowska-Curie Symposium on cancer research and care: Mechanisms of support for regional & international collaborations. Wiad Lek 78(2):232-247, 2025. e-Pub 2025. PMID: 40125737.
- Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea AM, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbe C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. Lancet Oncol 26(1):12-14, 2025. e-Pub 2025. PMID: 39756440.
- Turcios Escobar S, Yang R, Nelson KC, Gershenwald JE, Tawbi H, Aung PP, Patel SP, Torres-Cabala CA. Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol 51(9):644-648, 2024. e-Pub 2024. PMID: 38757469.
- Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch'ng S, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Rtshiladze M, Stretch JR, Nieweg OE, van Akkooi A, Sullivan RJ, Boland GM, Gershenwald JE, van Diest PJ, Scolyer RA, Long GV, Thompson JF, Lo SN. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. J Clin Oncol 42(10):1169-1180, 2024. e-Pub 2024. PMID: 38315961.
- Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi ÁJ, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open 7(2):e2356479, 2024. e-Pub 2024. PMID: 38363565.
- Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma. J Transl Med 21(1):508, 2023. e-Pub 2023. PMID: 37507765.
- Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med 21(1):265, 2023. e-Pub 2023. PMID: 37072748.
- Cass S, Cope B, Bishop AJ, Chiang YJ, Ashleigh Guadagnolo B, Farooqi A, Morrison W, Witt RG, Seervai RNH, Garden AS, Fuller CD, Goepfert RP, Ross M, Gershenwald JE, Wong M, Aung PP, Keung EZ, Mitra D. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol 188:109892, 2023. e-Pub 2023. PMID: 37659660.
- Wei AZ, Chen LN, Orloff M, Ariyan CE, Asgari M, Barker CA, Buchbinder E, Chandra S, Couts K, Frumovitz MM, Futreal A, Gershenwald JE, Hanna EY, Izar B, LeBlanc AK, Leitao MM, Lipson EJ, Liu D, McCarter M, McQuade JL, Najjar Y, Rapisuwon S, Selig S, Shoushtari AN, Yeh I, Schwartz GK, Guo J, Patel SP, Carvajal RD. Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell Melanoma Res 36(6):542-556, 2023. e-Pub 2023. PMID: 37804122.
- Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL, Nelson KC. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol 159(10):1076-1084, 2023. e-Pub 2023. PMID: 37647056.
- Gershenwald JE. Top Melanoma Articles from 2021 to Inform Your Cancer Practice. Ann Surg Oncol 30(11):6325-6331, 2023. e-Pub 2023. PMID: 37493893.
- Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel SH, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JE. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol 128(2):313-321, 2023. e-Pub 2023. PMID: 37010038.
- Lucci A, Addanki S, Chiang YJ, Meas S, Sarli VN, Upshaw JR, Manchem M, Patel SP, Wargo JA, Gershenwald JE, Ross MI. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel) 15(14):3630, 2023. e-Pub 2023. PMID: 37509290.
- Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol 25(7):1310-1320, 2023. e-Pub 2023. PMID: 36510640.
- Cortés-Ciriano, I, Lee, JK, Xi, R, Jain, D, Jung, YL, Yang, L, Gordenin, D, Klimczak, LJ, Zhang, CZ, Pellman, D, Akdemir, KC, Alvarez, EG, Baez-Ortega, A, Beroukhim, R, Boutros, PC, Bowtell, DD, Brors, B, Burns, KH, Campbell, PJ, Chan, K, Chen, K, Cortés-Ciriano, I, Dueso-Barroso, A, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Langerod, A, Lazar, A, Lichter, P, Mills, GB, Myklebost, O, Sood, AK, Thompson, A, Van Loo, P, Wang, L, Weinstein, JN, Yuan, Y, Zhu, H. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nature Genetics 55(6):1076, 2023. e-Pub 2023. PMID: 36944733.
- Zapatka, M, Borozan, I, Brewer, D, Iskar, M, Grundhoff, A, Alawi, M, Desai, N, Sültmann, H, Moch, H, Alawi, M, Borozan, I, Brewer, DS, Cooper, CS, Desai, N, Eils, R, Ferretti, V, Grundhoff, A, Iskar, M, Kleinheinz, K, Lichter, P, Nakagawa, H, Ojesina, AI, Pedamallu, C, Schlesner, M, Su, X, Zapatka, M, Cooper, CS, Eils, R, Ferretti, V, Lichter, P, Aaltonen, LA, Abascal, F, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Czerniak, BA, Fan, Y, Gershenwald, JE, von Kalle, C, Lazar, A, Mills, GB, Sood, AK, Su, X, Thompson, A, Van Loo, P, Weinstein, JN, Yuan, Y. The landscape of viral associations in human cancers. Nature Genetics 55(6):1077, 2023. e-Pub 2023. PMID: 36944734.
- Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, R, Beroukhim, R, Campbell, PJ, Chin, L, Dixon, JR, Futreal, A, Akdemir, KC, Alvarez, EG, Baez-Ortega, A, Boutros, PC, Bowtell, DD, Brors, B, Burns, KH, Campbell, PJ, Chan, K, Chen, KS, Cortés-Ciriano, I, Dueso-Barroso, A, Dunford, AJ, Akbani, R, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Langerod, A, Lazar, A, Li, J, Lichter, P, Mills, GB, Myklebost, O, Sood, AK, Thompson, A, Van Loo, P, Wang, L, Weinstein, JN, Yuan, Y, Zhu, H. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nature Genetics 55(6):1079, 2023. e-Pub 2023. PMID: 36944735.
- Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ, Yang, Y, Martincorena, I, Creighton, CJ, Weinstein, JN, Xu, Y, Han, L, Kim, HL, Nakagawa, H, Park, K, Campbell, PJ, Liang, H, Aaltonen, LA, Abascal, F, Abeshouse, A, Aburatani, H, Adams, DJ, Agrawal, N, Ahn, KS, Ahn, SM, Aikata, H, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Langerod, A, Lazar, A, Lichter, P, Mills, GB, Myklebost, O, Sood, AK, Thompson, A, Van Loo, P, Wang, L. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nature Genetics 55(6):1078, 2023. e-Pub 2023. PMID: 36944732.
- Yakneen, S, Waszak, SM, Aminou, B, Bartolome, J, Boroevich, KA, Boyce, R, Brooks, AN, Buchanan, A, Buchhalter, I, Butler, A, Byrne, NJ, Cafferkey, A, Campbell, PJ, Chen, Z, Cho, S, Choi, W, Clapham, P, Davis-Dusenbery, BN, De La Vega, FM, Eils, R, Akbani, R, Akdemir, KC, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Wang, L, Li, J, Liang, H, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Ueno, NT, Wang, L, Wang, W, Weinstein, JN, Yuan, Y. Butler enables rapid cloud-based analysis of thousands of human genomes. Nature biotechnology 41(4):577, 2023. e-Pub 2023. PMID: 36944844.
- Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 615(7953):E23, 2023. e-Pub 2023. PMID: 36894629.
- Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D, Mitchell, TJ, Rubanova, Y, Anur, P, Yu, K, Tarabichi, M, Deshwar, A, Wintersinger, J, Kleinheinz, K, Vázquez-García, I, Haase, K, Jerman, L, Sengupta, S, Macintyre, G, Malikic, S, Donmez, N, Livitz, DG, Cmero, M, Demeulemeester, J, Schumacher, S, Fan, Y, Zhu, H, Wang, W, Van Loo, P, Fan, Y, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Czerniak, BA, Eils, R, El-Naggar, AK, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Lichter, P, Mills, GB, Sood, AK, Wang, L, Weinstein, JN. The evolutionary history of 2,658 cancers. Nature 614(7948):E42, 2023. e-Pub 2023. PMID: 36697833.
- Aaltonen, LA, Abascal, F, Abeshouse, A, Aburatani, H, Adams, D, Agrawal, N, Ahn, KS, Ahn, SM, Aikata, H, Akbani, R, Akdemir, KC, Al Ahmadie, H, Al-Sedairy, ST, Al-Shahrour, F, Alawi, M, Aldape, KD, Plass, C, Broaddus, R, Langerod, A, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Weinstein, JN, Yuan, Y, Zhu, H. Pan-cancer analysis of whole genomes. Nature 614(7948):E39, 2023. e-Pub 2023. PMID: 36697834.
- Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y, Kahles, A, Lehmann, KV, Liu, F, Shiraishi, Y, Soulette, CM, Urban, L, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y, Kahles, A, Lehmann, KV, Liu, F, Shiraishi, Y, Soulette, CM, Urban, L, Greger, L, Li, S, Liu, D, Perry, MD, Xiang, Q, Zhang, F, Zhang, J, Bailey, PJ, Erkek, S, Hoadley, KA, Hou, Y, Huska, M, Kilpinen, H, Korbel, JO, Marin, MG, Markowski, J, Chakravarty, D, Chong, Z, El-Naggar, AK, Fan, Y, Gershenwald, JE, Huse, J, von Kalle, C, Lazar, A, Mills, GB, Sood, AK, Van Loo, P, Weinstein, JN. Genomic basis for RNA alterations in cancer. Nature 614(7948):E37, 2023. e-Pub 2023. PMID: 36697831.
- Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K, Khurana, E, Waszak, S, Korbel, JO, Haber, JE, Imielinski, MB, Akdemir, KC, Alvarez, EG, Baez-Ortega, A, Beroukhim, R, Boutros, PC, Bowtell, DD, Brors, B, Burns, KH, Campbell, PJ, Chan, K, Chen, K, Cortés-Ciriano, I, Dueso-Barroso, A, Dunford, A, Edwards, PA, Estivill, X, Etemadmoghadam, D, Feuerbach, L, Fink, JL, Frenkel-Morgenstern, M, Garsed, DW, Chakravarty, D, Chong, Z, El-Naggar, AK, Fan, Y, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Langerod, A, Lazar, A, Lichter, P, Mills, GB, Park, K, Sood, AK, Thompson, A, Van Loo, P, Weinstein, JN. Patterns of somatic structural variation in human cancer genomes. Nature 614(7948):E38, 2023. e-Pub 2023. PMID: 36697835.
- Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y, Boot, A, Covington, KR, Gordenin, DA, Bergstrom, EN, Islam, SM, Lopez-Bigas, N, Klimczak, LJ, McPherson, JR, Morganella, S, Sabarinathan, R, Wheeler, DA, Mustonen, V, Alexandrov, LB, Akbani, R, Akdemir, KC, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Wang, L, Li, J, Liang, H, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Ueno, NT, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. The repertoire of mutational signatures in human cancer. Nature 614(7948):E41, 2023. e-Pub 2023. PMID: 36697836.
- Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res 29(1):154-164, 2023. e-Pub 2023. PMID: 36166093.
- Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, Al-Shahrour, F, Atwal, G, Bailey, PJ, Biankin, AV, Boutros, PC, Campbell, PJ, Chang, DK, Cooke, SL, Desphande, V, Faltas, B, Lazar, A, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature communications 13(1):7573, 2022. e-Pub 2022. PMID: 36481665.
- Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LP, Vazquez, M, Kahraman, A, Pulido-Tamayo, S, Barenboim, J, Wadi, L, Dhingra, P, Shrestha, R, Getz, G, Lawrence, MS, Pedersen, JS, Chakravarty, D, Chen, K, Park, K, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. Pathway and network analysis of more than 2500 whole cancer genomes. Nature communications 13(1):7566, 2022. e-Pub 2022. PMID: 36481610.
- Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N, Deshwar, AG, Dentro, SC, Leshchiner, I, Gerstung, M, Jolly, C, Haase, K, Tarabichi, M, Eils, R, Plass, C, Broaddus, R, Cao, S, Wang, W, Van Loo, P, Akbani, R, Akdemir, KC, Aldape, KD, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Wang, L, Weinstein, JN, Yuan, Y, Zhu, H. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nature communications 13(1):7567, 2022. e-Pub 2022. PMID: 36482170.
- Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, Aaltonen, LA, Abascal, F, Abeshouse, A, Aburatani, H, Adams, D, Agrawal, N, Ahn, KS, Ahn, SM, Aikata, H, Akbani, R, Akdemir, KC, Plass, C, Broaddus, R, Aldape, KD, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nature communications 13(1):7569, 2022. e-Pub 2022. PMID: 36481612.
- Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D, Mee, MW, Boutros, PC, Abascal, F, Amin, S, Bader, GD, Beroukhim, R, Bertl, J, Boroevich, KA, Chakravarty, D, Chen, K, Park, K, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. Integrative pathway enrichment analysis of multivariate omics data. Nature communications 13(1):7570, 2022. e-Pub 2022. PMID: 36481658.
- Shuai, S, Abascal, F, Amin, S, Bader, GD, Bandopadhayay, P, Barenboim, J, Beroukhim, R, Bertl, J, Boroevich, KA, Brunak, S, Campbell, PJ, Carlevaro-Fita, J, Chakravarty, D, Chan, CY, Chen, K, Choi, JK, Park, K, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nature communications 13(1):7571, 2022. e-Pub 2022. PMID: 36481739.
- Cmero, M, Yuan, K, Ong, CS, Schröder, J, Adams, DJ, Anur, P, Beroukhim, R, Boutros, PC, Bowtell, DD, Campbell, PJ, Cao, S, Christie, EL, Cun, Y, Eils, R, Plass, C, Broaddus, R, Deshwar, AG, Fan, Y, Van Loo, P, Wang, W, Akbani, R, Akdemir, KC, Aldape, KD, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, El-Naggar, AK, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Wang, L, Weinstein, JN, Yuan, Y, Zhu, H. Inferring structural variant cancer cell fraction. Nature communications 13(1):7568, 2022. e-Pub 2022. PMID: 36481724.
- Sieverling, L, Hong, C, Koser, S, Ginsbach, P, Kleinheinz, K, Hutter, B, Braun, DM, Cortés-Ciriano, I, Xi, R, Kabbe, R, Park, PJ, Eils, R, Schlesner, M, Akdemir, KC, Alvarez, EG, Baez-Ortega, A, Beroukhim, R, Chen, K, Akbani, R, Aldape, KD, Cao, S, Chakravarty, D, Chen, Y, Chong, Z, Czerniak, BA, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nature communications 13(1):7574, 2022. e-Pub 2022. PMID: 36481818.
- Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H, Zhang, Z, Brazma, A, Amin, SB, Awadalla, P, Bailey, PJ, Brazma, A, Brooks, AN, Plass, C, Broaddus, R, Akbani, R, Akdemir, KC, Aldape, KD, Cao, S, Chakravarty, D, Chen, K, Chen, Y, Chong, Z, Czerniak, BA, Eils, R, El-Naggar, AK, Fan, Y, Futreal, A, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Park, K, Sood, AK, Su, X, Thompson, A, Ueno, NT, Van Loo, P, Wang, L, Wang, W, Weinstein, JN, Yuan, Y, Zhu, H. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nature communications 13(1):7572, 2022. e-Pub 2022. PMID: 36481652.
- Wei X, Chen Y, Yao H, Wu D, Li H, Zhang R, Chi Z, Cui C, Bai X, Mao L, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Lian B, Kong Y, Dai J, Tang B, Wang X, Gershenwald JE, Balch CM, Guo J, Si L. Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. J Am Acad Dermatol 87(6):1287-1294, 2022. e-Pub 2022. PMID: 36075285.
- Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Nat Commun 13(1):4000, 2022. e-Pub 2022. PMID: 35810190.
- Ascierto PA, Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med 20(1):200, 2022. e-Pub 2022. PMID: 35538491.
- Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
- Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA, Investigators K. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 23(11):1378-1388, 2022. e-Pub 2022. PMID: 36265502.
- Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes after sphincter-sparing local therapy for anorectal melanoma: 1989-2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
- Study Group MSLT, Crystal JS, Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg 157(9):835-842, 2022. e-Pub 2022. PMID: 35921122.
- Bartlett EK, Grossman D, Swetter SM, Leachman SA, Curiel-Lewandrowski C, Dusza SW, Gershenwald JE, Kirkwood JM, Tin AL, Vickers AJ, Marchetti MA. Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol 29(9):5948-56, 2022. e-Pub 2022. PMID: 35583689.
- Cui C, Lian B, Zhang X, Wu D, Li K, Si L, Yang Y, Tian H, Zhou L, Chi Z, Sheng X, Kong Y, Mao L, Wang X, Bai X, Yan X, Li S, Dai J, Tang B, Wei X, Gershenwald JE, Balch CM, Guo J. An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Ann Surg Oncol 29(8):5221-5234, 2022. e-Pub 2022. PMID: 35397739.
- van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, SVMA A, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, Consortium (INMC) INM. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 29(8):5241-5242, 2022. e-Pub 2022. PMID: 35426590.
- Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol 142(7):2046-2049.e3, 2022. e-Pub 2022. PMID: 34952092.
- Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
- van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, SVMA A, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, Consortium (INMC) INM. Neoadjuvant Systemic Therapy (NAST) in patients with melanoma: Surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 29(6):3694-3708, 2022. e-Pub 2022. PMID: 35089452.
- Cope B, Witt RG, Chiang YJ, Seervai RN, Fisher SB, Lucci A, Wargo JA, Lee JE, Farooqi AS, Bishop A, Gershenwald JE, Goepfert R, Wong MKK, Guadagnolo BA, Ross MI, Aung PP, Mitra D, Keung EZY. A single-center experience of 98 patients (pts) with regionally metastatic Merkel cell carcinoma (MCC) of known (MCCKP) and unknown (MCCUP) primary at presentation. J Clin Oncol 40(16), 2022. e-Pub 2022.
- Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZ. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol 125(4):719-729, 2022. e-Pub 2022. PMID: 34904258.
- Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
- Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med 19(1):142, 2021. e-Pub 2021. PMID: 33827575.
- Ronen S, Al-Rohil RN, Keiser E, Jour G, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Middleton LP, Torres-Cabala CA, Gershenwald JE, Aung PP, Prieto VG. Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Arch Pathol Lab Med 145(12):1505-1515, 2021. e-Pub 2021. PMID: 33577643.
- Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771465.
- Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Basen-Engquist K, Gershenwald JE, Tektiridis JH, Moreno M, Williams PA, Treiman K, Garza PD, Hawk E. Be Well Communities™: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control 32(8):859-870, 2021. e-Pub 2021. PMID: 34037915.
- Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
- Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
- Dessinioti C, Geller AC, Stergiopoulou A, Dimou N, Lo S, Keim U, Gershenwald JE, Haydu LE, Dummer R, Mangana J, Hauschild A, Egberts F, Vieira R, Brinca A, Zalaudek I, Deinlein T, Evangelou E, Thompson JF, Scolyer RA, Peris K, Garbe C, Stratigos AJ. A multicenter study of nevus-associated melanoma versus de novo melanoma, tumor thickness and body site differences. Br J Dermatol 185(1):101-109, 2021. e-Pub 2021. PMID: 33454993.
- Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Foundation MR. The state of melanoma: Emergent challenges and Opportunities. Clin Cancer Res 27(10):2678-2697, 2021. e-Pub 2021. PMID: 33414132.
- Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DY. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep 11(1):9043, 2021. e-Pub 2021. PMID: 33907234.
- White MG, Szczepaniak S, loane R, Rg W, Rueben A, Gaudreau PO, Andres MC, Feng N, Jonhnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology 10(1), 2021. e-Pub 2021. PMID: 34777916.
- Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Group MC, working group PNSMCM, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, Consortium P. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):6232, 2020. e-Pub 2020. PMID: 33257764.
- Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, Scolyer RA, Long GV, Davies MA. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med 9(22):8650-8661, 2020. e-Pub 2020. PMID: 33016647.
- Goepfert RP, Myers JN, Gershenwald JE. Updates in the evidence-based management of cutaneous melanoma. Head Neck 42(11):3396-3404, 2020. e-Pub 2020. PMID: 33463835.
- Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31(11):1569-1579, 2020. e-Pub 2020. PMID: 32739408.
- Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Group MC, working group PNSMCM, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, Consortium P. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):4748, 2020. e-Pub 2020. PMID: 32958763.
- Keung EZ, Gershenwald JE. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst 112(9):875-885, 2020. e-Pub 2020. PMID: 32061122.
- Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol 156(9):1004-1011, 2020. e-Pub 2020. PMID: 32725204.
- Tzeng CD, Tran Cao HS, Roland CL, Teshome M, Bednarski BK, Ikoma N, Graham PH, Keung EZ, Scally CP, Katz MHG, Gershenwald JE, Lee JE, Vauthey JN. Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. Surg Oncol 34:182-185, 2020. e-Pub 2020. PMID: 32891326.
- Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Subtypes PT, Translation C, Boutros PC, Consortium P. Sex differences in oncogenic mutational processes. Nat Commun 11(1):4330, 2020. e-Pub 2020. PMID: 32859912.
- Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHR. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol 38(24):JCO1902362, 2020. e-Pub 2020. PMID: 32530761.
- Day RW, Taylor BM, Bednarski BK, Tzeng CD, Gershenwald JE, Lee JE, Grubbs EG. Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Ann Surg 272(2):e144-e147, 2020. e-Pub 2020. PMID: 32675519.
- Alberg AJ, LoConte NK, Foxhall L, Weinstock MA, Gomez SL, Francisco M, Moushey EA, Gershenwald JE. American Society of Clinical Oncology Policy Statement on Skin Cancer Prevention. JCO Oncol Pract 16(8):JOP1900585, 2020. e-Pub 2020. PMID: 32374709.
- Fang S, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis 41(4):452-457, 2020. e-Pub 2020. PMID: 31630191.
- Day RW, Taylor BM, Bednarski B, Tzeng CD, Gershenwald JE, Lee JE, Grubbs EG. Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Ann Surg. e-Pub 2020. PMID: 32433281.
- Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients with American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):JCO1901508, 2020. e-Pub 2020. PMID: 31990608.
- Ascierto PA, Agarwala SS, Eggermont A, Gershenwald JE, Grob JJ, Hamid O, Michielin O, Postow M, Puzanov I, Zarour HM, Caracò C, Testori A. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. J Transl Med 18(1):171, 2020. e-Pub 2020. PMID: 32299446.
- Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
- Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol 33(3):496-513, 2020. e-Pub 2020. PMID: 31383963.
- Abudu B, Cook KA, Gershenwald JE, Cohen PR, Geller AC. Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer 126(4):775-781, 2020. e-Pub 2020. PMID: 31714593.
- Genomes Consortium IPAOW. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
- Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep 30(2):510-524.e6, 2020. e-Pub 2020. PMID: 31940493.
- Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
- Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 16(3):4429-4438, 2020. e-Pub 2020. PMID: 31870188.
- Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres-Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross M, Gershenwald JE, Prieto VG. Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma. Clin Cancer Res 25(24):7585-7593, 2019. e-Pub 2019. PMID: 31570567.
- Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJ. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. J Natl Cancer Inst 111(12):1314-1322, 2019. e-Pub 2019. PMID: 30863861.
- Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE. Role of immune response, inflammation and tumor immune response-related cytokines/chemokines in melanoma progression. J Invest Dermatol 139(11):2352-2358.e3, 2019. e-Pub 2019. PMID: 31176707.
- Lillemoe HA, Scally CP, Adams CL, Bednarski BK, Balch CM, Aloia TA, Gershenwald JE, Lee JE, Grubbs EG. Complex general surgical oncology fellowship applicants: Trends over time and the impact of board certification eligibility. Ann Surg Oncol 26(9):2667-2674, 2019. e-Pub 2019. PMID: 31168736.
- Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Research Network CGA, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The immune landscape of cancer. Immunity 51(2):411-412, 2019. e-Pub 2019. PMID: 31433971.
- Malke JC, Jin S, Camp SP, Lari B, Kell T, Simon JM, Prieto VG, Gershenwald JE, Haydu LE. Enhancing case capture, quality, and completeness of primary melanoma pathology records via natural language processing. JCO Clin Cancer Inform 3:1-11, 2019. e-Pub 2019. PMID: 31442076.
- Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Andtbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Consortium members INM, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 20(7):e378-e389, 2019. e-Pub 2019. PMID: 31267972.
- Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
- Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang THO, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Calidano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lam A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Research Network TCGA, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The immune landscape of cancer. Cell Press 48(4):812-30, 2019. e-Pub 2019. PMID: 29628290.
- Group W, Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80(1):208-250, 2019. e-Pub 2019. PMID: 30392755.
- Nelson KC, Gershenwald JE, Savory SA, Wilson JM, Simon JM, Burton EM, Haydu LE. Telementoring and smart-phone-based answering systems to optimize dermatology resident dermoscopy education. J Am Acad Dermatol. e-Pub 2019. PMID: 30703459.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
- Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE. Case report of myeloid sarcoma masquerading as in-transit metastasis at a previous melanoma site: avoiding a diagnostic pitfall. Am J Dermatopathol 40(11):831-835, 2018. e-Pub 2018. PMID: 29863571.
- Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, Martin RCG, Scoggins CR, McMasters KM. A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. J Surg Oncol 118(6):922-927, 2018. e-Pub 2018. PMID: 30259521.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
- Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma. Cancer Res 78(19):5680-5693, 2018. e-Pub 2018. PMID: 30115691.
- Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Research Network CGA, Weinstein JN, Mishra L, Akbani R. A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
- Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Research Network CGA, Camargo F, Liang H. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep 25(5):1304-1317.e5, 2018. e-Pub 2018. PMID: 30380420.
- Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
- Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M. Role of elevated PHIP copy number as a prognostic and progression marker for cutaneous melanoma. Clin Cancer Res 24(17):4119-4125, 2018. e-Pub 2018. PMID: 29776954.
- Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29(8):1861-1868, 2018. e-Pub 2018. PMID: 29945191.
- Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS. Variability in predictions from online tools: A demonstration using internet-based melanoma predictors. Ann Surg Oncol 25(8):2172-2177, 2018. e-Pub 2018. PMID: 29470818.
- Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Research Network CGA, Rätsch G. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 34(2):211-224.e6, 2018. e-Pub 2018. PMID: 30078747.
- Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, Group MC, Research Network CGA, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive characterization of cancer driver genes and mutations. Cell 174(4):1034-1035, 2018. e-Pub 2018. PMID: 30096302.
- Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Research Network CGA, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 23(12):3698, 2018. e-Pub 2018. PMID: 29925010.
- Kwong LN, De Macede MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological validation of RNA sequencing data from formalin-fixed paraffin-embedded primary melanomas. JCO Precision Oncology(2):1-19, 2018. e-Pub 2018.
- Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med 16(1):101, 2018. e-Pub 2018. PMID: 29665799.
- Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, Research Network CGA, Thorsson V, Bass AJ, Laird PW. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell 33(4):721-735.e8, 2018. e-Pub 2018. PMID: 29622466.
- Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, Research Network CGA, Bathe OF, Liang H. Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep 23(1):255-269.e4, 2018. e-Pub 2018. PMID: 29617665.
- Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Research Network CGA, Sanchez Y, Greene CS. Machine learning detects pan-cancer Ras pathway activation in The Cancer Genome Atlas. Cell Rep 23(1):172-180.e3, 2018. e-Pub 2018. PMID: 29617658.
- Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Research Network CGA, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep 23(1):181-193.e7, 2018. e-Pub 2018. PMID: 29617659.
- Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Research Network CGA, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep 23(1):194-212.e6, 2018. e-Pub 2018. PMID: 29617660.
- Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Research Network CGA, Piwnica-Worms H, Ma L, Liang H. Integrated genomic analysis of the ubiquitin pathway across cancer types. Cell Rep 23(1):213-226.e3, 2018. e-Pub 2018. PMID: 29617661.
- Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Working Group FA, Research Network CGA, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep 23(1):227-238.e3, 2018. e-Pub 2018. PMID: 29617662.
- Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Research Network CGA, Monnat RJ, Xiao Y, Wang C. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. e-Pub 2018. PMID: 29617664.
- Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ, Research Network CGA, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic analysis of splice-site-creating mutations in cancer. Cell Rep 23(1):270-281.e3, 2018. e-Pub 2018. PMID: 29617666.
- Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Research Network CGA, Buonamici S, Yu L. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep 23(1):282-296.e4, 2018. e-Pub 2018. PMID: 29617667.
- Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Research Network CGA, Hu H. An Integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400-416. e11, 2018. e-Pub 2018. PMID: 29625055.
- Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Research Network CGA, Liang H. A pan-cancer analysis of enhancer expression in nearly 9000 patient samples. Cell 173(2):386-399.e12, 2018. e-Pub 2018. PMID: 29625054.
- Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Research Network CGA, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173(2):338-354.e15, 2018. e-Pub 2018. PMID: 29625051.
- Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Research Network CGA, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173(2):321-337.e10, 2018. e-Pub 2018. PMID: 29625050.
- Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Research Network CGA, Xie W, Yang D. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell 33(4):706-720.e9, 2018. e-Pub 2018. PMID: 29622465.
- Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Research Network CGA, Weinstein JN, Mills GB, Levine DA, Akbani R. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33(4):690-705.e9, 2018. e-Pub 2018. PMID: 29622464.
- Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Research Network CGA, Sood AK, Gunaratne PH, Sumazin P. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep 23(1):297-312.e12, 2018. e-Pub 2018. PMID: 29617668.
- Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Atlas Network CG, Stuart JM, Benz CC, Laird PW. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173(2):291-304.e6, 2018. e-Pub 2018. PMID: 29625048.
- Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G, Research Network CGA. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 173(2):305-320.e10, 2018. e-Pub 2018. PMID: 29625049.
- Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Research Network CGA, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. Pathogenic germline variants in 10,389 adult cancers. Cell 173(2):355-370.e14, 2018. e-Pub 2018. PMID: 29625052.
- Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Research Network CGA, Cherniack AD, Beroukhim R, Meyerson M. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33(4):676-689.e3, 2018. e-Pub 2018. PMID: 29622463.
- Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Research Network CGA, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 23(1):313-326.e5, 2018. e-Pub 2018. PMID: 29617669.
- McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19(3):310-322, 2018. e-Pub 2018. PMID: 29449192.
- Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L, Group MC, Research Network CGA. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst 6(3):271-281.e7, 2018. e-Pub 2018. PMID: 29596782.
- Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, Atlas Network CG. Pan-cancer alterations of the MYC oncogene and its proximal network across The Cancer Genome Atlas. Cell Syst 6(3):282-300.e2, 2018. e-Pub 2018. PMID: 29596783.
- Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med 7(3):583-593, 2018. e-Pub 2018. PMID: 29464914.
- Narula N, Gershenwald JE, Gottumukkala VNR, Kim BJ, Davis CH, Royal RE, Wargo J, Lucci A, Cormier, Lee JE, Ross MI, Aloia T. Safety and efficacy of liposomal bupivacaine in patients undergoing lymph node dissection for melanoma. Ann Surg Oncol 25(1):S179, 2018. e-Pub 2018.
- Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
- Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
- Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Network TR, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 33(1):151, 2018. e-Pub 2018. PMID: 29316429.
- Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, Expert Panel FMOTAJCOCM, Melanoma Database TI, Platform D. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472-492, 2017. e-Pub 2017. PMID: 29028110.
- Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol 137(8):1792-1795, 2017. e-Pub 2017. PMID: 28442307.
- Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, MWJM W, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376(23):2211-2222, 2017. e-Pub 2017. PMID: 28591523.
- Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161(5):1246-1254, 2017. e-Pub 2017. PMID: 28081955.
- Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2017. PMID: 27864417.
- Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2017. PMID: 27911979.
- Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
- Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 67(2):93-99, 2017. e-Pub 2017. PMID: 28094848.
- Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of compliance with Texas legislation banning indoor UV tanning by minors. JAMA Dermatol 153(2):228-229, 2017. e-Pub 2017. PMID: 27829081.
- Prieto PA, Amaria R, Reuben A, Gopalakrishnan V, Spencer C, Jiang H, Zhang J, Tetzlaff M, Lazar A, Burton E, Woodman S, Hwu P, Hwu W, Patel S, Tawbi H, Davies M, Diab A, Glitza I, Bassett R, Cormier J, Gershenwald J, Lee JE, Lucci A, Royal R, Ross M, Wargo JA. Novel neoadjuvant targeted therapy trial with dabrafenib plus trametinib yields high response rates and improved relapse-free survival over standard of care (SOC) therapy in patients with high-risk resectable BRAF-Mutant melanoma. Ann Surg Oncol 24(1 Suppl):S7, 2017. e-Pub 2017.
- Bhutiani N, Egger ME, Stromberg AJ, Martin RCG, Scoggins C, Ross M, Gershenwald J, McMasters KM. Predicting non-sentinel node positivity in melanoma patients with a single positive sentinel lymph node. Ann Surg Oncol 24(1 Suppl):S17, 2017. e-Pub 2017.
- Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE. Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness. J Invest Dermatol 137(1):253-257, 2017. e-Pub 2017. PMID: 27506587.
- Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
- Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
- Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PA. Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol 23(9):2753-61, 2016. e-Pub 2016. PMID: 27052645.
- Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C, Medicine Core MOTAP. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 66(5):370-4, 2016. e-Pub 2016. PMID: 26784705.
- Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Lee JE, Gershenwald JE, Gritz ER. Correlates of sun protection and sunburn in children of melanoma survivors. Am J Prev Med 51(3):e77-85, 2016. e-Pub 2016. PMID: 27067306.
- Najita JS, Swetter SM, Geller AC, Gershenwald JE, Zelen M, Lee SJ. Sex differences in age at primary melanoma diagnosis in a population-based analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol 136(9):1894-7, 2016. e-Pub 2016. PMID: 27251792.
- Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P. Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: Survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst 108(9), 2016. e-Pub 2016. PMID: 27245173.
- Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-837, 2016. e-Pub 2016. PMID: 27301722.
- Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016. PMID: 27087480.
- Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
- Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
- McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR. Final results of the sunbelt melanoma trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 34(10):1079-86, 2016. e-Pub 2016. PMID: 26858331.
- Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res 26(2):181-7, 2016. e-Pub 2016. PMID: 24977319.
- Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (Baltimore) 95(11):e3073, 2016. e-Pub 2016. PMID: 26986135.
- Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
- Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak B. CDC Grand Rounds: Prevention and Control of Skin Cancer. Am J Transplant 16(2):717-20, 2016. e-Pub 2016. PMID: 26824446.
- Prieto PA, Cooper Z, Gopalakrishnan V, Tetzlaff MT, Bassett R, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu P, Hwu W, Patel SP, Yee C, Burton EM, Simpson LM, Royal RE, Cormier J, Lucci A, Lee JE, Gershenwald J< Ross M, Wargo J. Treatment with neoadjuvant targeted therapy yields high response rates and pathologic complete responses in patients with resectable metastatic melanoma. Ann Surg Oncol 23(1 Suppl):S130, 2016. e-Pub 2016.
- Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
- Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Stewart BR, Shaitelman SF, Cormier JN. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol 112(8):834-40, 2015. e-Pub 2015. PMID: 26477877.
- Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl) 24(5):724-33, 2015. e-Pub 2015. PMID: 25809989.
- Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. Association of common genetic polymorphisms with melanoma patient IL-12p40 blood levels, risk, and outcomes. J Invest Dermatol 135(9):2266-72, 2015. e-Pub 2015. PMID: 25848976.
- Bulger AL, Mayer JE, Gershenwald JE, Guild SR, Gottlieb MA, Geller AC. Enforcement provisions of indoor tanning bans for minors: An analysis of the first 6 US states. Am J Public Health 105(8):e10-2, 2015. e-Pub 2015. PMID: 26066916.
- Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
- Cancer Genome Atlas Network, Watson IR, Gershenwald JE, Chin L. Genomic classification of cutaneous melanoma. Cell 16(7):1681-96, 2015. e-Pub 2015. PMID: 26091043.
- Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol 33(12):1389-96, 2015. e-Pub 2015. PMID: 25779565.
- Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136(8):1874-80, 2015. e-Pub 2015. PMID: 25196740.
- Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol 17(3):311-21, 2015. e-Pub 2015. PMID: 25686251.
- Gottlieb M, Balk SJ, Geller AC, Gershenwald JE. Teens and indoor tanning: time to act on the US Food and Drug Administration's black-box warning. Ann Surg Oncol 22(3):701-3, 2015. e-Pub 2015. PMID: 25515195.
- Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini R. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A 112(8):2521-6, 2015. e-Pub 2015. PMID: 25659743.
- Burns WR, Watson IR, Wu C, Scolyer RA, Chin L, Gershenwald JE. Molecular characterization of cutaneous melanoma for the surgical oncologist: Insights from the Cancer Genome Atlas Program. Ann Surg Oncol 22(1):s25, 2015. e-Pub 2015.
- Wargo J, Gershenwald J, Cormier JN, Lee J, Griffin KC, Amaria R, Ross MI. Is it time for a shift in the treatment of advanced resectable stage III and stage iv oligometastatic melanoma? Results of a pilot trial and plans for a randomized trial of neoadjuvant therapy vs upfront surgery. Ann Surg Oncol 22(1 Suppl):S127, 2015. e-Pub 2015.
- Voss RK, Cromwell KD, Chiang Y, Armer JM, Ross MI, Lee JE, Gershenwald J, Royal RE, Lucci A, Stewart BR. The long-term risk of upper extremity lymphedema is two-fold higher in breast cancer compared to melanoma patients. Ann Surg Oncol 22(1 Suppl):S112, 2015. e-Pub 2015.
- Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
- Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak B. CDC Grand Rounds: Prevention and control of skin cancer. MMWR Morb Mortal Wkly Rep 64(47):1312-4, 2015. e-Pub 2015. PMID: 26633233.
- Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 20(21):5527-36, 2014. e-Pub 2014. PMID: 25165098.
- Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, Gershenwald JE, Royal RE, Cormier JN. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 259(6):1215-22, 2014. e-Pub 2014. PMID: 24096759.
- Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget 5(10):2912-7, 2014. e-Pub 2014. PMID: 24913145.
- Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VK. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol 21(4):1075-81, 2014. e-Pub 2014. PMID: 24531700.
- Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, Yu SS, Johnson TM, Liegeois NJ, Byrd D, Sober A, Nghiem P. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 70(4):637-43, 2014. e-Pub 2014. PMID: 24521828.
- Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, Sequencing Program NC, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. J Invest Dermatol 134(2):452-60, 2014. e-Pub 2014. PMID: 24008424.
- Boland G, Caudle A, Warneke C, Prieto V, Lee JE, Curry J, Cormier JN, Royal RE, Ross MI, Gershenwald JE. Predictors of survival in contemporary era patients (pts) with thin melanoma who underwent sentinel node biopsy (SNB). Ann Surg Oncol 21(1 Suppl):S23, 2014. e-Pub 2014.
- Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the Melanoma Bridge meeting, Napoli, December 5th-8th 2013. J Transl Med 12(1):277, 2014. e-Pub 2014. PMID: 25348889.
- Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 2013. e-Pub 2013. PMID: 23922205.
- Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20(12):3961-8, 2013. e-Pub 2013. PMID: 23838920.
- Cheng CS, Rai K, Garber M, Hollinger A, Robbins D, Anderson S, Macbeth A, Tzou A, Carneiro MO, Raychowdhury R, Russ C, Hacohen N, Gershenwald JE, Lennon N, Nusbaum C, Chin L, Regev A, Amit I. Semiconductor-based DNA sequencing of histone modification states. Nat Commun 4:2672, 2013. e-Pub 2013. PMID: 24157732.
- Gritz ER, Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Urbauer DL, Fellman BM, Lee JE, Gershenwald JE. Randomized controlled trial of a sun protection intervention for children of melanoma survivors. Cancer Epidemiol Biomarkers Prev 22(10):1813-24, 2013. e-Pub 2013. PMID: 24097199.
- Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, Sequencing Program NC, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110(33):13481-6, 2013. e-Pub 2013. PMID: 23901115.
- Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res 23(4):290-7, 2013. e-Pub 2013. PMID: 23752305.
- Slingluff CL, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/ Mel47). Clin Cancer Res 19(13):3611-20, 2013. e-Pub 2013. PMID: 23620404.
- Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol 133(7):1813-21, 2013. e-Pub 2013. PMID: 23407396.
- Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Variants in melanocortin 1 receptor gene contribute to risk of melanoma - a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res 26(3):422-5, 2013. e-Pub 2013. PMID: 23360207.
- Ross MI, Gershenwald JE. Sentinel lymph node biopsy for melanoma: A critical update for dermatologists after two decades of experience. Clin Dermatol 31(3):298-310, 2013. e-Pub 2013. PMID: 23608449.
- Chu VH, Tetzlaff MT, Torres-Cabala CA, Prieto VG, Bassett R, Gershenwald JE, McLemore MS, Ivan D, Wang WL, Ross MI, Curry JL. Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the classification of thin cutaneous melanomas. Biomed Res Int 2013:898719, 2013. e-Pub 2013. PMID: 24369020.
- Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
- Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-23, 2012. e-Pub 2012. PMID: 22180178.
- Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell 150(2):251-63, 2012. e-Pub 2012. PMID: 22817889.
- Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol 180(5):2170-81, 2012. e-Pub 2012. PMID: 22465753.
- Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin RC, Schacherer CW, Edwards MJ, Urist MM, Ross MI, Stromberg AJ, McMasters KM. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg 214(4):608-17; discussion 617-9, 2012. e-Pub 2012. PMID: 22342785.
- Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res 22(2):169-75, 2012. e-Pub 2012. PMID: 22198560.
- Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 3(3):336-44, 2012. e-Pub 2012. PMID: 22488042.
- Chodkiewicz HM, Cohen PR, Kim KB, Ivan D, Gershenwald JE. A lupus-like reaction to subcutaneous interferon alpha at injection sites. J Drugs Dermatol 11(3):393-8, 2012. e-Pub 2012. PMID: 22395592.
- Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JN. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 22(5):376-85, 2012. e-Pub 2012. PMID: 22914178.
- Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, Investigators G, MacGregor S, Hayward NK, Martin NG, Duffy DL, Investigators Q, Mann GJ, Cust A, Hopper J, Investigators A, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 20(24):5012-23, 2011. e-Pub 2011. PMID: 21926416.
- White RL, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP, Working Group SLN. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 18(13):3593-600, 2011. e-Pub 2011. PMID: 21647761.
- Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 2011. e-Pub 2011. PMID: 22049339.
- Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JN. Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. Value Health 14(6):900-6, 2011. e-Pub 2011. PMID: 21914512.
- Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 2011. e-Pub 2011. PMID: 21632855.
- Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29(16):2199-205, 2011. e-Pub 2011. PMID: 21519009.
- Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan A. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 253(6):1211-5, 2011. e-Pub 2011. PMID: 21451389.
- Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Sequencing Program NC, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-6, 2011. e-Pub 2011. PMID: 21499247.
- Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 66(3):224-36, 2011. e-Pub 2011. PMID: 21295201.
- Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer 47(1):107-15, 2011. e-Pub 2011. PMID: 20655738.
- Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119-26, 2011. e-Pub 2011. PMID: 21946352.
- Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63(5):751-61, 2010. e-Pub 2010. PMID: 20646783.
- Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, Sequencing Program NC, Rosenberg SA, Davies MA, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res 8(11):1513-25, 2010. e-Pub 2010. PMID: 21047771.
- Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 17(10):2764-72, 2010. e-Pub 2010. PMID: 20336388.
- Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 17(8):2015-23, 2010. e-Pub 2010. PMID: 20369298.
- Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, Task Force AM. Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 17(8):2006-14, 2010. e-Pub 2010. PMID: 20379784.
- Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234-41, 2010. e-Pub 2010. PMID: 20187100.
- Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28(14):2452-9, 2010. e-Pub 2010. PMID: 20368546.
- Scoggins CR, Martin RC, Ross MI, Edwards MJ, Reintgen DS, Urist MM, Gershenwald JE, Sussman JJ, Dirk Noyes R, Goydos JS, Beitsch PD, Ariyan S, Stromberg AJ, Hagendoorn LJ, McMasters KM. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 17(3):709-17, 2010. e-Pub 2010. PMID: 19967459.
- Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR. Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia 12(2):173-82, 2010. e-Pub 2010. PMID: 20126475.
- Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229-35, 2010. e-Pub 2010. PMID: 20975100.
- Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129-42, 2010. e-Pub 2010. PMID: 21081714.
- Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-206, 2009. e-Pub 2009. PMID: 19917835.
- Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15(24):7538-7546. e-Pub 2009. PMID: 19996208.
- Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 36(11):1157-63, 2009. e-Pub 2009. PMID: 19222695.
- Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19(3):146-55, 2009. e-Pub 2009. PMID: 19441164.
- Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 2009. e-Pub 2009. PMID: 19309746.
- Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Roe AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield, PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-9, 2009. e-Pub 2009. PMID: 19430405.
- Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60(5):872-5, 2009. e-Pub 2009. PMID: 19389531.
- Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 29(12):1443-51, 2008. e-Pub 2008. PMID: 18563783.
- Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265-8, 2008. e-Pub 2008. PMID: 18813315.
- Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 68(20):8419-28, 2008. e-Pub 2008. PMID: 18922915.
- Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, Mansfield PF, Ross MI, Zagars GK. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 73(5):1376-82, 2008. e-Pub 2008. PMID: 18774657.
- Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68(11):4392-7, 2008. e-Pub 2008. PMID: 18519701.
- Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer 122(9):2077-84, 2008. e-Pub 2008. PMID: 18183598.
- Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030-7, 2008. e-Pub 2008. PMID: 18320602.
- Gershenwald JE, Andtbacka RHI, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26(26):4296-4303, 2008. e-Pub 2008. PMID: 18606982.
- Mortenson MM, Xing Y, Weaver S, Lee JE, Gershenwald JE, Lucci A, Mansfield PF, Ross MI, Cormier JN. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol 6:63, 2008. e-Pub 2008. PMID: 18564433.
- Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Brit J Cancer 99(5):734-40, 2008. e-Pub 2008. PMID: 18728664.
- Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 112(10):2249-57, 2008. e-Pub 2008.
- Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, Contribute to Risk of Cutaneous Melanoma. J Invest Dermatol 128(6):1585-8, 2008. e-Pub 2008. PMID: 18049450.
- Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Met 25(3):191-9, 2008. e-Pub 2008.
- Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 195(3):363-85; discussion 368-9, 2008. e-Pub 2008.
- Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Gershenwald JE, Ross MI. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 25(17):2442-8, 2007. e-Pub 2007. PMID: 17557957.
- Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma?. Nat Clin Pract Oncol 4(5):278-9, 2007. e-Pub 2007. PMID: 17389881.
- Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 127(2):276-80, 2007. e-Pub 2007. PMID: 16990805.
- Tellez CS, Davis DW, Prieto VG, Gershenwald JE, Johnson MM, McCarty MF, Bar-Eli M. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 127(2):387-93, 2007. e-Pub 2007. PMID: 16946713.
- Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer 109(8):1570-8, 2007. e-Pub 2007.
- Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Pelvic Lymph Node dissection is beneficial in subsets of patients with node-positive melanoma. Surg Oncol 14(10):2867-75, 2007. e-Pub 2007.
- Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev 15(12):2526-32, 2006. e-Pub 2006. PMID: 17164380.
- Gannon CJ, Rousseau DL, Jr, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 107(11):2647-52, 2006. e-Pub 2006. PMID: 17063497.
- Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12(22):6709-15, 2006. e-Pub 2006. PMID: 17121890.
- Li C, Liu Z, Wang LE, Strom SS, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis 27(9):1894-901, 2006. e-Pub 2006. PMID: 16621887.
- Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 166(17):1907-14, 2006. e-Pub 2006. PMID: 17000949.
- Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ. Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 8(9):747-57, 2006. e-Pub 2006. PMID: 16984732.
- Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, Ross MI, Cormier JN. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 13(7):902-9, 2006. e-Pub 2006. PMID: 16788750.
- Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol 187(1):W117-9, 2006. e-Pub 2006. PMID: 16794124.
- Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 24(18):2858-65, 2006. e-Pub 2006. PMID: 16782925.
- Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, Coit D. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13(6):809-16, 2006. e-Pub 2006. PMID: 16604476.
- Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106(9):2012-20, 2006. e-Pub 2006. PMID: 16568458.
- Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey JN. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13(5):712-20, 2006. e-Pub 2006. PMID: 16538410.
- Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16(4):253-63, 2006. e-Pub 2006. PMID: 16538172.
- Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B, Hoekstra HJ, Garberoglio C, White RL, Jr, Chu D, Biel M, Charney K, Wanebo H, Avisar E, Vetto J, Soong SJ. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg 132(4):370-3, 2006. e-Pub 2006. PMID: 16618904.
- Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188-96, 2006. e-Pub 2006. PMID: 16540670.
- Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 106(4):900-6, 2006. e-Pub 2006. PMID: 16411225.
- Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64(1):106-13, 2006. e-Pub 2006. PMID: 16182463.
- Doherty SD, George S, Prieto VG, Gershenwald JE, Duvic M. Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online 12(7):22, 2006. e-Pub 2006.
- Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65(23):11185-92, 2005. e-Pub 2005. PMID: 16322269.
- Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei Q. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst 97(24):1822-31, 2005. e-Pub 2005. PMID: 16368944.
- Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol 23(25):6054-62, 2005. e-Pub 2005. PMID: 16135473.
- Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12(8):587-96, 2005. e-Pub 2005. PMID: 16021533.
- Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM, Jr, Sturgis EM, Morrison WH, Gershenwald JE, Ross MI, Weber RS, Ang KK. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. Head Neck 27(8):718-21, 2005. e-Pub 2005. PMID: 15952196.
- Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588-90, 2005. e-Pub 2005. PMID: 16034040.
- Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11(12):1079-84, 2004. e-Pub 2004. PMID: 15576833.
- Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. e-Pub 2004. PMID: 15389473.
- Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HM. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth 16(5):332-41, 2004. e-Pub 2004. PMID: 15374553.
- McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, Sussman JJ, Gershenwald JE, Ross MI. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 86(4):212-23, 2004. e-Pub 2004. PMID: 15221928.
- Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54(3):131-49; quiz 182-4, 2004. e-Pub 2004. PMID: 15195788.
- Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100(7):1478-83, 2004. e-Pub 2004. PMID: 15042682.
- Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM, Jr, Gershenwald JE, Morrison WH, Lee JE, Oswald MJ, Ross MI, Ang KK. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 100(2):383-9, 2004. e-Pub 2004. PMID: 14716775.
- Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121(6):1510-4, 2003. e-Pub 2003. PMID: 14675203.
- McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJ. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res 13(4):379-87, 2003. e-Pub 2003. PMID: 12883364.
- Rousseau DL, Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10(5):569-74, 2003. e-Pub 2003. PMID: 12794025.
- Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, Cremona F, Gershenwald JE, Chase JL, Lozano RD, Patt YZ, Fornage BD, Vauthey JN, Woodall ML, Gonzalez KB, Ellis LM. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 10(4):348-54, 2003. e-Pub 2003. PMID: 12734081.
- Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang K. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97(7):1789-96, 2003. e-Pub 2003. PMID: 12655537.
- Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 95(4):308-15, 2003. e-Pub 2003. PMID: 12591987.
- Amato, Esmaeli B, Ahmadi A, Tehrani M, Gershenwald JE, Ross M, Delpassand E. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophth Plast Recon Surg 19(2):102-106, 2003. e-Pub 2003.
- Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20(23):4555-8, 2002. e-Pub 2002. PMID: 12454112.
- Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei Q. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1142-3, 2002. e-Pub 2002. PMID: 12376526.
- Sumner WE, 3rd, Ross MI, Mansfield PF, Lee JE, Prieto VG, Schacherer CW, Gershenwald JE. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer 95(2):354-60, 2002. e-Pub 2002. PMID: 12124836.
- Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 9(6):587-93, 2002. e-Pub 2002. PMID: 12095976.
- Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science 296(5574):1811-2, 2002. e-Pub 2002. PMID: 12052939.
- Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52(4):964-72, 2002. e-Pub 2002. PMID: 11958890.
- Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Gershenwald JE, Coit DG, McMasters KM, Balch CM, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8(10):766-70, 2001. e-Pub 2001. PMID: 11776489.
- Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 108(11):2101-5, 2001. e-Pub 2001. PMID: 11713086.
- Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy for conjunctival melanoma. Ophthal Plast Reconstr Surg 17(6):436-42, 2001. e-Pub 2001. PMID: 11766025.
- Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622-34, 2001. e-Pub 2001. PMID: 11504744.
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-48, 2001. e-Pub 2001. PMID: 11504745.
- Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar-Eli M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 20(26):3363-75, 2001. e-Pub 2001. PMID: 11423987.
- McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, Noyes RD, Viar V, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol 8(3):192-7, 2001. e-Pub 2001. PMID: 11314933.
- Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 8(2):116-22, 2001. e-Pub 2001. PMID: 11258775.
- Porter GA, Ross MI, Berman RS, Sumner WE, 3rd, Lee JE, Mansfield PF, Gershenwald JE. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. Surgery 128(2):306-11, 2000. e-Pub 2000. PMID: 10923009.
- Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 7(4):256-61, 2000. e-Pub 2000. PMID: 10819364.
- Gershenwald JE, Berman RS, Porter G, Mansfield PF, Lee JE, Ross MI. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 7(3):226-31, 2000. e-Pub 2000. PMID: 10791854.
- Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Jr, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88(6):1484-91, 2000. e-Pub 2000. PMID: 10717634.
- Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 7(2):160-5, 2000. e-Pub 2000. PMID: 10761797.
- Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976-83, 1999. e-Pub 1999. PMID: 10071292.
- Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, Ames FC, Schusterman MA, Singletary SE. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 5(6):529-38, 1998. e-Pub 1998. PMID: 9754762.
- Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124(2):203-10, 1998. e-Pub 1998. PMID: 9706139.
- Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli M. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273(26):16501-8, 1998. e-Pub 1998. PMID: 9632718.
- Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 5(4):322-8, 1998. e-Pub 1998. PMID: 9641453.
- Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16(6):2253-60, 1998. e-Pub 1998. PMID: 9626228.
- Talmor, Hydo L, Gershenwald JE, Barie PS. Beneficial effects of chest tube drainage of pleural effusion in acute respiratory failure refractory to positive end-expiratory pressure ventilation. Surgery 123:137-143, 1998. e-Pub 1998.
- Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151(4):1105-13, 1997. e-Pub 1997. PMID: 9327744.
- He W, Fong Y, Marano MA, Gershenwald JE, Yurt RW, Moldawer LL, Lowry SF. Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis 165(5):859-64, 1992. e-Pub 1992. PMID: 1569335.
- Fong, Moldawer LL, Wei H, Marano MA, Keogh CV, Gershenwald JE, Lowry SF. Tumour location influences local cytokine production and host metabolism. Surg Oncol 1:65-71, 1992. e-Pub 1992.
- Gershenwald JE, Fong YM, Fahey TJ, 3rd, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LL. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A 87(13):4966-70, 1990. e-Pub 1990. PMID: 1695006.
- Gershenwald JE, Bensadoun A, Saluja A. Monoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography. Biochim Biophys Acta 836(3):286-95, 1985. e-Pub 1985. PMID: 4041471.
Invited Articles
- Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Holler C, Lebbe C, Lee RJ, Long GV, Lorigan P, Munoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 36(1):10-30, 2025. e-Pub 2025. PMID: 39550033.
- Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous Melanoma. Lancet 402(6th):485-502, 2023. e-Pub 2023. PMID: 37499671.
- Asare EA, Grubbs EG, Gershenwald JE, Greene FL, Aloia TA. Setting the "stage" for Surgical Oncology fellows: Pierre Denoix and TNM staging. J Surg Oncol 119(7):823, 2019. e-Pub 2019. PMID: 30729519.
- Keung EZ, Gershenwald JE. The Eighth Edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 18(8):775-784, 2018. e-Pub 2018. PMID: 29923435.
- Ferguson PM, Gershenwald JE, Scolyer RA. Staging of cutaneous melanoma: Is there room for further improvement?. JAMA Network, 2018. e-Pub 2018.
- Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin 66(6):460-80, 2016. e-Pub 2016. PMID: 27232110.
- Boland GM, Gershenwald JE. Principles of Melanoma Staging. Cancer Treat Res 167:131-48, 2016. e-Pub 2016. PMID: 26601861.
- Asare EA, Washington MK, Gress DM, Gershenwald JE, Greene FL. Improving the quality of cancer staging. CA Cancer J Clin 65(4):261-3, 2015. e-Pub 2015. PMID: 25952338.
- Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book 2013:320-5, 2013. e-Pub 2013. PMID: 23714536.
- Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J 18(2):185-91, 2012. e-Pub 2012. PMID: 22453020.
- Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 104(4):379-85, 2011. e-Pub 2011. PMID: 21858832.
- Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol 104(4):341-53, 2011. e-Pub 2011. PMID: 21858828.
- Gershenwald JE, Ross MI. Sentinel lymph node biopsy for cutaneous melanoma. N Engl J Med 364(18):1738-45, 2011. e-Pub 2011. PMID: 21542744.
- Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103(6):538-49, 2011. e-Pub 2011. PMID: 21480247.
- Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE. Lymphangiogenesis and hemangiogenesis: Potential targets for therapy. J Surg Oncol 103(6):489-500, 2011. e-Pub 2011. PMID: 21480241.
- Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: Critical assessment at its twentieth anniversary. Surg Oncol Clin N Am 20(1):57-78, 2011. e-Pub 2011. PMID: 21111959.
- Davies MA, Gershenwald JE. Targeted therapy for melanoma: A primer. Surg Oncol Clin N Am 20(1):165-80, 2011. e-Pub 2011. PMID: 21111965.
- Gershenwald JE. Preface. Melanoma. Surg Oncol Clin N Am 20(1):xv-xvi, 2011. e-Pub 2011. PMID: 21111955.
- Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 20(1):1-17, 2011. e-Pub 2011. PMID: 21111956.
- Balch CM, Mihm MC, Jr, Gershenwald JE, Soong SJ. The revised melanoma staging system and the impact of mitotic rate. The Melanoma Letter 28(3), 2010. e-Pub 2010.
- Berman R, Kurtzman S, Posner M, Gershenwald. Society of Surgical Oncology fellowship training - Where we have been, where we are now, and where we are going. J Surg Oncol 100(3):179-81, 2009. e-Pub 2009. PMID: 19444817.
- Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 7(3):308-17, 2009. e-Pub 2009. PMID: 19401063.
- Gershenwald JE, Petrelli N. Fellowship training in surgical oncology - an international affair. Surg Oncol 17(4):277-9, 2008. e-Pub 2008. PMID: 18672361.
- Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Onc Clin N Am 16(2):430-30, 2007. e-Pub 2007.
- Gershenwald JE, Ross MI. Practice point: Is sentinel-node biopsy superior to nodal observation in melanoma?. Nat Clin Pract Oncol 4(5):278-9, 2007. e-Pub 2007.
- Witte MH, Jones K, Wilting J, Dictor M, Selg M, McHale N, Gershenwald JE, Jackson DG. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev 25(2):159-84, 2006. e-Pub 2006. PMID: 16770531.
- Gershenwald JE. Introduction - Lymphadenectomy for cancer. Operative Techniques in General Surgery, 8(2):65, 2006. e-Pub 2006.
- Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 42(7):460-534, 2005. e-Pub 2005. PMID: 16099230.
- Pawlik TM, Gershenwald JE. Sentinel lymph node biopsy for melanoma. Contemp Surg 61(4):175-82, 2005. e-Pub 2005.
- Rousseau DL, Jr, Gershenwald JE. The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol 31(3):415-25, 2004. e-Pub 2004. PMID: 15190500.
- Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol 11(4):362-74, 2004. e-Pub 2004. PMID: 15070595.
- Gershenwald JE, Bar-Eli M. Gene expression profiling of human cutaneous melanoma: are we there yet?. Cancer Biol Ther 3(1):121-3, 2004. e-Pub 2004. PMID: 14764994.
- Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am 83(2):385-403, 2003. e-Pub 2003. PMID: 12744615.
- Balch CM, Sober AJ, Soong SJ, Gershenwald JE. The new melanoma staging system. Semin Cutan Med Surg 22(1):42-54, 2003. e-Pub 2003. PMID: 12773013.
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 21(1):43-52, 2003. e-Pub 2003. PMID: 12923915.
- Gershenwald JE. Melanoma Highlights: ASCO 2001. Oncologist 6(5):402-6, 2001. e-Pub 2001. PMID: 11675517.
- Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Clin Lab Med 20(4):785-815, 2000. e-Pub 2000. PMID: 11221515.
- Gershenwald JE, Fischer D, Buzaid AC. Clinical classification and staging. Clin Plast Surg 27(3):361-76, viii, 2000. e-Pub 2000. PMID: 10941558.
- Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Hematol Oncol Clin North Am 12(4):737-65, 1998. e-Pub 1998. PMID: 9759577.
Review Articles
- Balch CM, Liao N, Lam DSC, Weitzel JN, Xu RH, Attard G, Bunn PA, Eggermont AMM, He J, Kitagawa Y, Lim ST, Cazap E, Esquivel B, Fan X, Chow LWC, Liu ESF, Said HM, Niederhuber JE, Rubio IT, Zaghloul AS, Arrieta OG, Audisio RA, Beets GL, Coimbra FJF, Gallardo JE, Garber JE, Gronchi A, Heinemann V, Kurian AW, Mutebi M, Mori M, Olopade FI, Rutkowski P, Saleh M, Sanchez WM, Sawaya R, Thompson JF, Tumusiime G, Vallejos CS, Whiteman DC, Wu Y, Yawe KT, Zahrani NAA, Zoras O, Arun BK, Fabian CJ, Gershenwald JE, Gradishar WJ, He J, Kimberg VS, Lam RMK, Lee VHF, Lorusso D, Mok TSK, Perrier ND, Rugo HS, Ulrich C, Are C, Vignat J, Soerjomataram I. The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection. Ecancermedicalscience 20:2071, 2026. e-Pub 2026. PMID: 41877745.
- Scolyer RA, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VG. Melanoma pathology reporting and staging. Mod Pathol 33(Suppl 1):15-24, 2020. e-Pub 2020. PMID: 31758078.
- Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials. Cancer 125(1):18-44, 2019. e-Pub 2019. PMID: 30281145.
- Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 28(2):135-47, 2015. e-Pub 2015. PMID: 25113308.
- Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge from Naples to the world. Napoli, December 5th-6th, 2011". J Transl Med 10(1):83. e-Pub 2012. PMID: 22551296.
Professional Educational Materials
- Gershenwald JE, Asare AE. Melanoma - Wide Excision. The SCORE Portal, 2019.
- Scolyer RA, Balamurgan T, Busam K, Elder D, Evans A, Gershenwald J, Frishberg DP, McMenamin M, Prieto VG, Shiau C, Swetter S, van den Oord J. Invasive Melanoma, Histopathology Reporting Guide. International Collaboration on Cancer Reporting, 2019.
- Shot MM, Prevention C, Platform C, Health Policy OO. Skin Cancer Prevention Toolkit, 2016.
- Gershenwald JE. Risk of indoor tanning, 2015.
- Gershenwald JE. Patient Education Handbook/Questions and Answers: Melanoma, 2008.
- Gershenwald JE. Is survival benefit necessary for sentinel lymph node biopsy to be standard of care, 2006.
- . The MD Anderson Surgical Oncology Handbook. Lippincott Williams & Wilkins, 2006.
- Gershenwald JE. Sentinel lymph node biopsy for melanoma and other cutaneous malignancies, 2005.
- Gershenwald JE. Management of sentinel lymph node positive patients, 2004.
- Gershenwald JE. Intraoperative lymphatic mapping and sentinel lymph node biopsy, 2002.
- Editor GJ, Developer. Melanoma. Surgical Oncology: yesterday, today and tomorrow (An Annotated Bibliography of Important literature on Common Problems in Surgical Oncology). Society of Surgical Oncology, 2002.
- Gershenwald JE. Operative technique: How to do it and interesting cases. Surgical approach to lymphatic mapping and sentinel lymphadenectomy for melanoma, 2001.
- Editor GJ, Developer. Melanoma. Surgical Oncology: yesterday, today and tomorrow (An Annotated Bibliography of Important literature on Common Problems in Surgical Oncology). Society of Surgical Oncology, 2001.
- Gershenwald JE. New staging criteria. Second Symposium on Advances in the Biology and Treatment of Cutaneous Melanoma, 2001.
- Dackiw A, Gershenwald JE, Ross, MI, Mansfield, PF, Lee JE. Epitrochlear and Popliteal Node Dissection (Videotape), 2000.
- Gershenwald JE. Perspectives in melanoma IV: State-of-the-art at the turn of the century. Current evaluation of prognostic factors and the proposed AJCC staging system, 2000.
- Editor GJ, Developer. Melanoma. Surgical Oncology: yesterday, today and tomorrow (An Annotated Bibliography of Important literature on Common Problems in Surgical Oncology). Society of Surgical Oncology, 2000.
Other Articles
- Nagarajan, P, Piao, J, Ning, J, Noordenbos, LE, Curry, JL, Torres Cabala, CA, Diwan, AH, Ivan, D, Aung, PP, Ross, MI, Royal, RE, Wargo, J, Wang, W, Samdani, RT, Lazar, A, Rashid, A, Davies, MA, Prieto, V, Gershenwald, JE, Tetzlaff, M Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma. Modern Pathology 38(8), 2025. PMID: 40541156.
- Vellano, CP, White, MG, Andrews, MC, Chelvanambi, M, Witt, RG, Daniele, J, Titus, M, McQuade, JL, Conforti, F, Burton, EM, Lastrapes, M, Ologun, G, Cogdill, AP, Morad, G, Prieto, PA, Lazar, A, Chu, Y, Han, G, Khan, MA, Helmink, BA, Davies, MA, Amaria, RN, Kovacs, J, Woodman, SE, Patel, SP, Hwu, P, Peoples, M, Lee, JE, Cooper, Z, Zhu, H, Gao, G, Banerjee, H, Lau, M, Gershenwald, JE, Lucci, A, Keung, EZ, Ross, MI, Pala, L, Pagan, E, Segura Lazcano, R, Liu, Q, Borthwick, MS, Lau, E, Yates, MS, Westin, SN, Wani, K, Tetzlaff, M, Haydu, LE, Mahendra, M, Ma, X, Logothetis, CJ, Kulstad, Z, Johnson, S, Hudgens, CW, Feng, N, Federico, L, Long, GV, Futreal, A, Arur, S, Tawbi, H, Moran, AE, Wang, L, Heffernan, TP, Marszalek, JR, Wargo, J Author Correction. Nature 613(7945):E3, 2023. PMID: 36627494.
- Ley PB, Gershenwald JE Tanning beds: Here's why minors under 18 should not be allowed to use them. Clarion Ledger, 2019.
- Gershenwald JE Cancer Staging: Important Work of the AJCC. CollabRx, 2018.
- Gershenwald JE, Tripp M Of topical interest for kids: sun safety, 2015.
- Gershenwald JE Melanoma diagnosis and staging: evolving practice. Clinical Care Options Oncology, Melanoma Treatment Update, Online, 2008.
- Balch, S-j S, Buzaid AC, Gershenwald JE, Staging Committee TAM The new melanoma staging system and factors predicting melanoma survival. Clinical Oncology Updates 5(3):1-19, 2002.
Editorials
- Gershenwald JE. Mitotic rate in primary cutaneous melanoma: Cell division matters. Cancer 129(15):2290-2293, 2023. PMID: 37162402.
- Gershenwald JE. Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned … and still learning. Cancer 127(13):2177-2180, 2021. PMID: 33826746.
- Faries MB, Testori AAE, Gershenwald JE. Sentinel node biopsy for primary cutaneous melanoma. Ann Oncol 32(3):290-292, 2021. PMID: 33484834.
- Berman RS, Gershenwald JE. Completion node dissection for sentinel node-positive melanoma: can a systematic review bring one discussion to a close while leaving the broader conversation still open?. Ann Surg Oncol 26(4):921-923, 2019. PMID: 30737667.
- Haydu LE, Thompson JF, Scolyer RA, Gershenwald JE. Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. Eur J Cancer 112:9-11. PMID: 30884440.
- Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 25(Suppl 3):993-994, 2018. PMID: 30105437.
- Gershenwald JE, Nelson KC. Skin Cancer: Have melanoma and skin cancer finally met their match?. Nat Rev Clin Oncol 14(5):267-268, 2017. PMID: 28422116.
- Gershenwald JE, Halpern AC, Sondak VK. Melanoma prevention-avoiding indoor tanning and minimizing overexposure to the sun. JAMA 316(18):1913-1914, 2016. PMID: 27824997.
- Gershenwald JE, Guy GP. Stemming the rising incidence of melanoma: Calling prevention to action. J Natl Cancer Inst 108(1):1-3, 2016. PMID: 26563358.
- Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med 370(7):663-4, 2014. PMID: 24521113.
- Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 19(11):3301-3, 2012. PMID: 22868918.
- Gershenwald JE, Soong SJ, Balch CM. 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 17(6):1475-77, 2010. PMID: 20300965.
- Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Ann Surg Oncol 15(3):670-3, 2008.
- McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, Fenske N, Glass F, Balch CM, Coit DG. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 19(11):2851-5, 2001. PMID: 11387357.
- Gershenwald. Issues of regret after contralateral prophylactic mastectomy. Breast Diseases: A Year Book Quarterly 11(1):81, 2000.
- Gershenwald. Patient regrets after bilateral prophylactic mastectomy. Breast Diseases: A Year Book Quarterly 10(2):238, 1999.
Abstracts
- Rechis R, Oestman K, Aquino M, Gershenwald JE. Promoting sun safety and melanoma prevention in the community through a multi-component community-wide intervention. 2025 ASCO Annual Meeting 43(e22613), 2025. e-Pub 2025.
- Miura J, Farooq MS, Gimotty PA, Mitchell TC, Amaravadi RK, Schuchter LM, Mitnick S, Xu X, Huang ACC, Davies MA, Amaria RN, Chesney JA, Weiser R, Gershenwald JE, McMasters K, Karakousis GC. Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma. 2025 ASCO Annual Meeting 4(16):606s, 2025. e-Pub 2025.
- Amouzegar A, Hasanov M, Ali A, Milton DR, Simon J, Samuels J, Wani KM, Ledesma DA, Burton EM, Hudgens C, Tawbi HA, Gershenwald JE, Lazar AJ, Davies MA. Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM). 2025 ASCO Annual Meeting 43(16):9521, 2025. e-Pub 2025.
- Simon JM, Gohil L, Haydu LE, McArthur GA, Gyorki D, Henderson M, Long GV, Scolyer RA, Gershenwald JE. Melanoma Staging Today, Tomorrow, and Beyond: International Melanoma Database and Discovery Platform (IMDDP) Staging and Outcome Modeling Across the Melanoma Continuum. Poster presented at the AMC2024 (Australasian Melanoma Conf), 2024.
- Gershenwald JE, Simon J, Asare E, Scolyer R. Beyond the American Joint Committee on Cancer (AJCC) 8th Edition Melanoma Staging System – The Future is Now!. Poster presented at the AMC2024 (Australasian Melanoma Conf), 2024.
- . Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma. European Society for Medical Oncology (ESMO) Congress 2024 35(Supplement 2):S712-S748, 2024. e-Pub 2024.
- . Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 42(Supplement 16), 2024. e-Pub 2024.
- Long GV, Eggermont AMM, Gershenwald JE, Schadendorf D, Ascierto PA, Dummer R, Hauschild A, Carlino MS, Ribas A, Robert C, Scolyer RA, Sondak VK, Cohen JE, Khattak MA, Zhang J, Grebennik D, Krepler C, Luke JJ. KEYVIBE-010 Trial in Progress: Coformulated Vibostolimab with Pembrolizumab for Stage II-IV melanoma. Accepted for oral presentation at the Japanese Skin Cancer Society (JSCS 2024), 2024. e-Pub 2024.
- . Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma. American Association for Cancer Research (AACR) Annual Meeting 2024 84(Supplement 6):3605, 2024. e-Pub 2024.
- Varey AHR, Li I, Sharouni E, MA, Simon J, Dedeilia A, Saw R, Spillane A, Shannon K, Stretch JR, Sullivan RJ, Boland GM, Gershenwald JE, van Diest P, Scolyer R, Long GV, Thompson J, Lo SN. An externally validated online tool to calculate personalized probabilities of recurrence-free and overall-survival in stage II melanoma patients. Abstract presented at the SSO 2024 Annual Meeting, 2024. e-Pub 2024.
- . A single dose of perioperative cefazolin disrupts the gut microbiome and immunity in patients (pts) with early-stage melanoma. American Association for Cancer Research (AACR) Annual Meeting 2024 84(Supplement 6):2806, 2024. e-Pub 2024.
- Luke J, Eggermont AMM, Gershenwald JE, Ascierto PA, Reinhard D, Carlino M, Ribas, A, Robert C, Scolyer R, Sondak V, Grebennik D, Krepler C, Long G. Adjuvant coformulated Vibostolimab with Pembrolizumab (MK-7684A) versus Pembrolizumab alone in high-risk stage II-IV melanoma: Study design of the randomized, double-blind, phase 3 KEYVIBE-010 Trial. Poster presentation at Dermato-Oncology 2023, 2023. e-Pub 2023.
- Long GV, Eggermont AMM, Gershenwald JE, Schadendorf D, Ascierto PA, Dummer R, Hauschild A, Carlino MS, Ribas A, Robert C Scolyer RA, Sondak VK, Cohen JE, Zhang J, Grebennik D, Krepler C Luke JJ. A Study of Adjuvant Coformulated Vibostolimab With Pembrolizumab Versus Adjuvant Pembrolizumab in Patients With High-Risk Stage II-IV Melanoma (KEYVIBE-010): Trial in Progress. Poster accepted for presentation at ASCO 2023, 2023. e-Pub 2023.
- Yoon C, Ross MI, Luke J, Long G, Ascierto P, Rutkowski P, Khattak A, Del Vecchio M, Merino LD, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino M, Zhao Y, Kalabis M, Gershenwald JE, Sondak VK. Adjuvant pembrolizumab (pembro) in stage II melanoma: outcomes in histopathologic subgroups in the phase 3 KEYNOTE-716 study. Oral presentation at the 2023 SSO conference, 2023. e-Pub 2023.
- Cope B, Bishop A, Guadagnolo BA, Morrison W, Witt R, Chiang YJ, Farooqi A, Seervai R, Garden A, Fuller C, Goepfert R, Gershenwald J, Ross M, Wong M, Aung P, Keung E, Mitra D. Anatomic variability in patterns of care for locoregional merkel cell carcinoma (MCC) management at a large referral center. Poster presentation at ASTRO 64th Annual Meeting, 2022. e-Pub 2022.
- Varey AHR, El Sharouni MA, Simon J, Gershenwald JE, Long GV, Scolyer RA, Thompson JF, Lo SN. Predicting recurrence-free survival for patients with stage II melanoma - a validated tool to guide selection for adjuvant systemic therapy. Poster presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2022, 2022. e-Pub 2022.
- Cass S, Witt RG, Meng X, Sahasrabhojane P, Bassett RL, Shelburne S, Chang HY, Somaiya K, Mungovan K, Fisher SB, Lucci A, Lee JE, Ross MI, Gershenwald JE, Duncan S, Ajami NJ, Roland CL, Wargo JA, Keung EZ. Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Poster Presentation at the 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
- Cope B, Witt RG, Chiang YJ, Seervai RN, Fisher SB, Lucci A, Wargo JA, Lee JE, Farooqi AS, Bishop A, Gershenwald JE, Foepfert R, Wong MKK, Guadagnolo BA, Ross MI, Aung PP, Mitra D, Keung EZY. A single center experience of 98 patients (pts) with regionally metastatic Merkel cell carcinoma (MCC) of known (MCCKP) and unknown (MCCUP) primary at presentation, 2022. e-Pub 2022.
- Varey A, Long GV, Scolyer RA, Gershenwald JE, Simon J, Thompson JF, Lo SN. A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma 40(16), 2022. e-Pub 2022.
- Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi A, Gershenwald JE, Wargo J, Keung E, Fisher S, Davies M, Amaria R, Ross MI, Guadagnolo BA. 30-Year Experience Managing Anorectal Melanoma With Sphincter-Sparing Local Excision and Hypofractionated Radiation Therapy. Int J Radiat Oncol Biol Phys 111(3S):e60, 2021. e-Pub 2021. PMID: 34701843.
- Hahn AW, Xu M, Li J, Haydu LE, Wadud Khan MA, Gide TN, Menzies AM, Hudgens CW, Nowicki TS, Gershenwald JE, Ribas A, Tetzlaff MT, Lazar AJ, Willmott J, Wargo J, Futreal A, Zhang J, Davies MA, McQuade JL. Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM). Cancer Res, 2021. e-Pub 2021.
- Fischer GM, Guerrieri RA, Hu Q, Carapeto FC, Joon AY, Gopal VY, Knighton B, Deng W, Haydu LE, Gershenwald JE, Lazar AJ, Tetzlaff MT, Davies MA. The role of oxidative phosphorylation (OXPHOS) in melanoma brain metastasis (MBM) formation and growth. Cancer Res 81(13), 2021. e-Pub 2021.
- Amaria RN, Postow MA, Tetzlaff MT, Ross MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R, Keung EZY, Fisher SB, Milton DR, Patel SP, Diab A, Simpson L, Davies MA, Wargo JE, Burton EM, Ariyan CE, Tawbi HAH. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J Clin Oncol 39(15), 2021. e-Pub 2021.
- Hasanov M, Milton DR, Patel SP, Tawbi HAH, Glitza AC, Ferguson SD, Ledesma DA, Torres-Cabala CA, Lazar AJ, Burton EM, Gershenwald JE, Haydu LE, Davies MA. Incidence, timing, and predictors of CNS metastasis in patients (pts) with clinically localized cutaneous melanoma (CM). J Clin Oncol 39(15), 2021. e-Pub 2021.
- Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian CM, Posada E, Gershenwald JE, Torres-Cabala CA, Huse JT, Tawbi HAH, Glitza IC, Li J, Chung C, Yeboa D, Opusunju S, Kim BYS, Lang FF, Haydu LE, Davies MA, Ferguson SD. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. J Clin Oncol 39(15), 2021. e-Pub 2021.
- Hahn AW, Xu M, Li J, Haydu LE, Khan MAW, Gide TN, Menzies AM, Hudgens CW, Nowicki TS, Gershenwald JE, Ribas A, Tetzlaff MT, Lazar AJ, Willmott J, Wargo J, Futreal A, Zhang J, Davies MA, McQuade JL. Obesity is associated with lower tumor oxidative phosphorylation in metastatic melanoma. Poster presented at the American Association of Cancer Research (AACR) Annual Meeting, 2021. e-Pub 2021.
- Colen RR, Ologun GO, Zinn P, AK M, Arora R, Burton EM, Glitza IC, Tawbi HAH, Patel SP, Diab A, Wong MK, McQuade L, Ross MI, Ahmed S, Elshafeey N, Gershenwald JE, Davies MA, Tetzlaff MT, Amaria RN, Wargo JA. Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy. j Clin Oncol 38(15):10067, 2020. e-Pub 2020.
- Luke JJ, Ascierto PA, Carlino MS, Eggermont AMM, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Gershenwald JE, Poklepovic AS, Ross MI, Scolyer RA, Yoon C, Anderson JR, Ahsan S, Ibrahim N, Sondak VK. Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. J Clin Oncol 37(8), 2019. e-Pub 2019.
- Amaria RN, Haymaker CL, Forget MA, Bassett R, Cormier JN, Davies MA, Diab A, Gershenwald JE, Glitza C, Lee JE, Lucci A, McQuade JL, Patel SP, Royal RE, Ross MI, Tawbi HAH, Wargo JA, Wong MKK, Bernatchez C, Hwu P. Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). J Clin Oncol (suppl; abstr 9543)-Poster presentation 37, 2019. e-Pub 2019.
- Carlino MS, Ascierto PA, Eggermont AM, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross MI, Scolyer RA, Sondak VK, Yoon C, Poklepovic AS, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Luke JJ. Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage Ii melanoma: Phase 3 KEYNOTE-716 study. J Clin Oncol (suppl; abstr TPS9596)-Poster presentation 37, 2019. e-Pub 2019.
- Pradhan D, Malpica A, Prieto VG, Curry JL, Torres-Cabala CA, Ivan DS, Aung PP, Gershenwald JE, Davies MA, Tetzlaff MT, Nagarajan P. Primary mucosal melanoma of the uterine cervix: Clinicopathological and molecular analysis. Poster presented at the 108th Annual Meeting of The United States and Canadian Academy of Pathology, 2019. e-Pub 2019.
- Hauschild A, Ascierto P, Carlino M, Eggermont K, Gershenwald J, Grob JJ, Kirkwood J, Luke J, Peter M, Caroline R, Ross M, Scolyer R, Yoon C, Poklepovic A, Rutkowski P, Anderson J, Sama A, Nageatte I, Long G. Adjuvant Pembrolizumab (pembro) in Patients (pts) With Resected High-Risk Stage II Melanoma: Phase 3 KEYNOTE-716 With Crossover or Rechallenge. Abstract presented at the SMR 2019 Annual Meeting, 2019. e-Pub 2019.
- Ahsan S, Sondak V, Kirkwood J, Poklepovic A, Robert C, Ascierto PA, Anderson J, Long G, Scolyer R, Gershenwald JE, Luke J, Grob JJ, Carlino M, Mohr P, Eggermont AMM, Ibrahim N, Ross MI. Phase 3 KEYNOTE-716 Study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. Poster presented at ASCO-SITC 2019, 2019. e-Pub 2019.
- Nagarajan P, Piao J, Ning J, Curry JL, Torres-Cabala CA, Aung PP, Wang WL, Ross MI, Royal RE, Wargo JA, Rashid A, Samdani R, Noordenbos LE, Lazar AJ, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival(DSS) in anorectal melanoma (AM). Poster presented at the 2018 American Society of Clinical Oncology Annual Meeting, 2018. e-Pub 2018.
- LoConte NK, Gershenwald JE, Thomson CA, Crane TE, Harmon GE, Rechis R. Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. Am Soc Clin Oncol Educ Book 38:88-100, 2018. e-Pub 2018. PMID: 30231343.
- Gershenwald JE, Oelker RR, Brewster AL, Gardner JM, Nelson KC, Walsh MT, Burton EM, Davies MA. Personalized prognostic assessment and prevention initiatives in the era of personalized melanoma therapy. GAP2018 Conference, 2018. e-Pub 2018.
- Gopalakrishnan V, Spencer C, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, p H, Sharma P, Allison JP, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. J Clin Oncol 35(7), 2018. e-Pub 2018.
- Nagarajan P, Prieto V, Gershenwald J, Davies MA, Ning J, Piao J, Curry JL, Ivan D, Torres Cabala CA, Aung PP, Wang WL, Lazar A, Ross MI, Royal RE, Wargo J, Samdani R, Rashid A, Tetzlaff M. Primary anorectal melanoma: A retrospective analysis of 160 patients. 54th Annual Meeting of The American Society of Dermatopathology (ASDP) 2017 (#0954-000215), 2017. e-Pub 2017.
- Gershenwald JE, Burton E, Moreno M, Tripp MK, Steger C. Skin Cancer Prevention in Action: Empowering public policymakers to make informed decisions regarding the dangers of indoor tanning. Presented at the 2017 CDC Cancer Conference, 2017. e-Pub 2017.
- Royal RE, Vence, LM, Wray T, Cormier JN, Lee JE, Gershenwald JE, Ross MI, Wargo JA, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu W, Patel SP, Woodman SE, Overwijk WW, Hwu P. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. Poster presented at the 2017 American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
- Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu W, Glitza IC, Tawbi HA, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Association of the diversity and composition of the gut microbiome with, 2017. e-Pub 2017.
- Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA, Hwu P, Hwu W, Glitza IC, Tawbi HA, Cormier JN, Lee JE, Patel SP, Simpson L, Burton EM, Bassett Jr RL, Ross MI, Gershenwald JE, Davies MA, Woodman SE. Relapse-free survival and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. Poster presented at the 2017 American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
- Chen W, Andrews MC, Spencer HA, Tawbi A, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu W, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma(mm) patients(pts). Poster presented at the 2017 American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
- Bhutiani N, Egger ME, Stromberg AJ, Martin RCG, Scoggins C, Ross M, Gershenwald J, McMasters KM. Predicting non-sentinel node positivity in melanoma patients with a single positive sentinel lymph node. Presented at the 70th Annual Society of Surgical Oncology Cancer Symposium, 2017. e-Pub 2017.
- Prieto PA, Amaria R, Reuben A, Gopalakrishnan V, Spencer C, Jiang H, Zhang J, Tetzlaff M, Lazar A, Burton E, Woodman S, Hwu P, Hwu W, Patel S, Tawbi H, Davies M, Diab A, Glitza I, Bassett R, Cormier J, Gershenwald J, Lee JE, Lucci A, Royal R, Ross M, Wargo JA. Novel neoadjuvant targeted therapy trial with Dabrafenib + Trametinib yields high response rates and improved relapse free survival over standard of care (SOC) therapy in patients. Presented at the 70th Annual Society of Surgical Oncology Cancer Symposium, 2017. e-Pub 2017.
- Kim DW, Haydu LE, Joon A, Bassett RL, Siroy A, Tetzlaff MT, Lazar A, Woodman SE, Gershenwald JE, Davies MA. Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts). J Clin Oncol, 2016. e-Pub 2016.
- Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, W-J H, Davies MA, Pradyuman Patel SP, Diab A, Glitza IC, Tawbi HA, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma(MM). J Clin Oncol, 2016. e-Pub 2016.
- Tripp MK, Pandit Talati P, Winter E, Galvan C, Haydu LE, Feng H, Gershenwald JE. Skin cancer prevention in adolescents: effects of an ultraviolet (UV) photography intervention on socio-cognitive factors. Ann Behav Med 50:S189, 2016. e-Pub 2016.
- Prieto PA, Cooper Z, Gopalakrishnan V, Tetzlaff MT, Bassett R, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu P, Hwu W, Patel SP, Yee C, Burton EM, Simpson LM, Royal RE, Cormier J, Lucci A, Lee JE, Gershenwald J< Ross M, Wargo J. Treatment with neoadjuvant targeted therapy yields high response rates and pathologic complete responses in patients with resectable metastatic melanoma. Poster presented at the 69th Annual Society of Surgical Oncology Cancer Symposium, 2016. e-Pub 2016.
- Haydu LE, Calderone TL, Miller J, Bassett RL, Joon A, Zhang J, Morgan MB, Shaw KR, Cooper ZA, Burton EM, Siroy A, Wani KM, Stingo F, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Lazar AJF, Davies MA, Gershenwald JE. Comparison of DNA and RNA analyte extraction and melanin removal methods from formalin-fixed, paraffin-embedded (FFPE) melanoma. 2015 American Society of Clinical Oncology Annual Meeting, 2015. e-Pub 2015.
- Amaria RN, Wargo JA, Cooper AZ, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu WJ, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF inhibition yields responses in patients (pts) with high risk borderline resectable stage III melanoma. 2015 American Society of Clinical Oncology Annual Meeting, 2015. e-Pub 2015.
- Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). Poster presented at the 2015 American Society of Clinical Oncology Annual Meeting, 2015. e-Pub 2015.
- Wargo JA, Amaria RN, Ross MI, Saw RPM, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford R, Scolyer RA, Rizos H, Thompson L, Davies MA, Long GV. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. Poster presented at the 2015 American Society of Clinical Oncology Annual Meeting, 2015. e-Pub 2015.
- Roszik J, Joon A, Siroy A, Haydu LE, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff MT, Wargo JA, Chen JQ, Radvanyi LG, Bernatchez C, Gershenwald JE, Lazar, AJF, Davies MA, Woodman SE. A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. Poster presented at the 2015 American Society of Clinical Oncology Annual Meeting, 2015. e-Pub 2015.
- Watson IR, Wu CJ, Zou L, Gershenwald JE, Chin L. Genomic classification of cutaneous melanoma. Poster presentation at the 2015 American Association for Cancer Research Annual meeting, 2015. e-Pub 2015.
- Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox P, Patel K, Estrella J, Broaddus R, Davies MA, Routbort M, Lazar AJ, Prieto VG, Hwu WJ, Gershenwald JE, Woodman S, Torres-Cabala CA, Curry JL. Utility of BRAFV600E immunohistochemistry (IHC) expression pattern as a surrogate of BRAFV600 mutation status in 154 patients with advanced stage melanoma. Poster presentation at the 2015 United States & Canadian Academy of Pathology Annual Meeting, 2015. e-Pub 2015.
- Tripp MK, Peterson SK, Prokhorov AV, Lee JE, Gershenwald JE, Gritz ER. Psychometric properties of the impact of event scale in melanoma survivors. Poster presented at the 39th Annual Meeting of the American Society of Preventive Oncology, 2015. e-Pub 2015.
- Wargo J, Gershenwald J, Cormier JN, Lee J, Griffin KC, Amaria R, Ross MI. Is it time for a shift in the treatment of advanced resectable stage III and stage IV oligometastatic melanoma? Results of a pilot trial and plans for a randomized trial of neoadjuvant therapy versus upfront surgery. Poster presented at the 68th Annual Society of Surgical Oncology Cancer Symposium, 2015. e-Pub 2015.
- Voss RK, Cromwell KD, Chiang Y, Armer JM, Ross MI, Lee JE, Gershenwald JE, Royal RE, Lucci A, Stewart BR, Cormier JN. The long-term risk of upper extremity lymphedema is two-fold higher in breast cancer compared to melanoma patients. Poster presented at the 68th Annual Society of Surgical Oncology Cancer Symposium, 2015. e-Pub 2015.
- Burns WR, Watson IR, Wu C, Scolyer RA, Chin L, Gershenwald JE. Molecular characterization of cutaneous melanoma for the surgical oncologist: Insights from the Cancer Genome Atlas Program. Presented at the 68th Annual Society of Surgical Oncology Cancer Symposium, 2015. e-Pub 2015.
- Joon A, Haydu L, Baladandayuthapani V, Stingo F, Woodman SE, Rodabe A, Wargo J, Shaw K, Meric-Bernstam F, Mills GB, Gershenwald JE, Hwu P, Lazar AJ, Davies MA. Next generation sequencing of 201 cancer-related genes in melanoma. Presented at the Society for Melanoma Research 2014 International Congress, 2014. e-Pub 2014.
- Watson IR, Wu CJ, Zou L, Gershenwald JE, Chin L. Comprehensive genomic characterization of cutaneous melanoma. Presented at the Society for Melanoma Research 2014 International Congress, 2014. e-Pub 2014.
- Cooper AB, Griffin KC, Chiang YS, Ross MI, Lee JE, Gershenwald JE, Royal RE, Lucci A, Cormier JN. Do patient-reported quality-of-life responses in melanoma patients vary by stage?. Presented at the 2014 American Society of Clinical Oncology Meeting, 2014. e-Pub 2014.
- Bhatia S, Iyer JG, Storer B, Moshiri A, Parvathaneni U, Byrd DR, Sondak VK, Gershenwald JE, Sober A, Nghiem P. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base. Presented at the 2014 American Society of Clinical Oncology Meeting, 2014. e-Pub 2014.
- Watson IR, Wu CJ, Zou L, Boland GM, Burns III WR, Lazar A, Tsai KY, Woodman SE, Cherniack AD, Delman KA, Robertson AG, Reynolds S, Cope L, Danilova L, Scolyer RA, Mann GJ, Ciriello G, Korkut A, Sandar C, Trent J, Moschos SJ, Samuels Y, Gershenwald JE, Chin L. Comprehensive genomic characterization of cutaneous melanoma. Presented at The Cancer Genome Atlas' 3rd Annual Scientific Symposium, 2014. e-Pub 2014.
- Boland G, Caudle A, Warneke C, Prieto V, Lee JE, Curry J, Cormier JN, Royal RE, Ross MI, Gershenwald JE. Predictors of survival in contemporary era patients (pts) with thin melanoma who underwent sentinel node biopsy (SNB). Presented at the 67th Annual Society of Surgical Oncology Cancer Symposium, 2014. e-Pub 2014.
- Liu H, Wei Q, Amos CI, Gershenwald JE, Prieto VG, Grimm EA, Lee JE, Han J, Wang LE. Genome-wide gene and pathway analysis in cutaneous melanoma. Presented at the Perspectives in Melanoma XVII meeting, 2013. e-Pub 2013.
- Chakravarti N, Ivan D, Ross MI, Ilagan JL, Warneke CL, Kim K, Papadopoulos NE, Cain S, Gershenwald JE, Johnson MM, Bedikian AY, Royal RE, Cormier JN, Hanna EY, Lee JE, Prieto VG, Hwu WJ. Biomarker study in patients with resectable AJCC stage IIIc or stage IV (M1a) melanoma treated in a randomized phase II neoadjuvant trial. Presented at the 2013 American Society of Clinical Oncology Meeting, 2013. e-Pub 2013.
- Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node Biopsy in melanoma. 2013 American Society of Clinical Oncology Educational Book, 2013. e-Pub 2013.
- Tripp MK, Peterson SK, Prokhorov AV, Lee JE, Gershenwald JE, Gritz ER. Psychometric properties of the impact of event scale in melanoma survivors. Poster presentation at the MDACC 2012 Cancer Survivorship Retreat, 2012. e-Pub 2012.
- Slingluff CL, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Gaucher A, Murphy CF, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin LP, Shea SM, Erdag G, Ram PT, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies. Poster presented at the 2012 American Society of Clinical Oncology annual meeting, 2012. e-Pub 2012.
- Peddi P, Oh JH, Kim KB, Gershenwald JE, Palla SL, Schacherer CW, Jakkoju R, Suarez-Almazor M. Impact of comorbidities on overall survival of high-risk and advanced melanoma. Presented at the 2012 American Society of Clinical Oncology Meeting, 2012. e-Pub 2012.
- Prickett TD, Wei X, Viloria CG, Molinolo A, Lin JC, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, Lopez-Otin C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Poster presented at the 102nd Annual Meeting of the American Association for Cancer Research, 2011. e-Pub 2011.
- Balch C, Soong SJ, Gershenwald JE, Thompson JF, Ding S, Coit DG, McMasters KM, Johnson T, Gimotty PA, Leong SP, Eggermont AM, Sondak VK. Staging and prognosis of 634 melanoma patients with intralymphatic (IL) metastases. Presented at the 2011 Society of Surgical Oncology Annual Meeting, 2011. e-Pub 2011.
- Hyngstrom JR, Ross MI, Xing Y, Chiang Y, Mungovan KS, Taylor S, Bagde ND, Lee JE, Gershenwald JE, Royal RE, Lucci A, Mansfield PF, Cormier JN. Prospective assessment of lymphedema following lymph node. Poster presented at the 2011 Society of Surgical Oncology Annual Meeting, 2011. e-Pub 2011.
- Yang AD, Macapinlac HA, Gardner J, Cormier JN, Lucci A, Mansfield PF, Royal RE, Myers JN, Weber RS, Gershenwald JE, Ross MI, Lee JE. Comparison of SPECT/CT to planar lymphoscintigraphy for sentinel lymph node biopsy of melanomas draining to the head and neck. Poster presented at the 2011 Society of Surgical Oncology Annual Meeting, 2011. e-Pub 2011.
- Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Davies MA. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology, 2011. e-Pub 2011.
- Lizee, G, Whittington MA, Chen J, Greene VR, Liu S, Bassett Jr L, Khalili J, Prieto V, Radvanyi LG, Hwu P, Grimm EA, Gershenwald JE. Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients. J Clin Oncol (suppl), 2010. e-Pub 2010.
- Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis. Abstract #8581; Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology, 2010. e-Pub 2010.
- Bowles TL, Ross MI, Kies MS, Prieto V, Myers J, Cormier JN, Mansfield PF, Lee JE, Gershenwald JE. Patterns of recurrence in 208 patients with Merkel cell carcinoma. Abstract #8556; Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology, 2010. e-Pub 2010.
- Cormier JN, Shih YT, Xu Y, Pan I, Askew RL, Ross MI, Gershenwald JE, Lee JE, Royal R, Xing Y. The impact of physician specialty on quality of melanoma care. Abstract #8563; Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology, 2010. e-Pub 2010.
- Atkins MB, Long GV, Warneke CL, Carlino M, DeRose ER, Johnson MM, Brown PT, Lee M, Kefford R, Gershenwald JE. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. Abstract #8516, Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology, 2010. e-Pub 2010.
- Caudle A. Mitotic rate predicts sentinel lymph node involvement in melanoma: Impact of the 7th Edition AJCC Melanoma Staging System. Plenary presentation at the 63rd Annual Society of Surgical Oncology Cancer Symposium, 2010. e-Pub 2010.
- Gershenwald JE, Schacherer CW, Gardner JM, Matejka GT, Davies MA, Alvarado G, Grimm EA, Hwu P, Lee JE, Prieto VG. The M. D. Anderson melanoma informatics, tissue resource, and pathology core (MelCore): a model for translational melanoma research in the 21st century. Pigment Cell Melanoma Res 23(6):899, 2010. e-Pub 2010.
- Carlino MS, Atkins MB, Warneke CL, Long GV, DeRose ER, Johnson MM, Brown PT, Lee MY, Gardner J, Hamilton A, Alvarado G, Kefford R, Gershenwald JE. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Pigment Cell Melanoma Res 23(6):946, 2010. e-Pub 2010.
- Long GV, Atkins MB, Warneke CL, Carlino MS, DeRose E, Johnson MM, Brown PT, Roberson F, Gardner J, Alvarado G, Lee MY, Kefford RF, Gershenwald JE. Unraveling the prognostic heterogeneity in patients with advanced melanoma (MM) between Australia (OZ) and the United States (US): the PHAMOUS study. Pigment Cell Melanoma Res 23(6):963, 2010. e-Pub 2010.
- McAuliffe PF, Gershenwald JE, Lee JE, Badgwell BD, Ballo MT, Cormier JN, Mansfield PF, Chang GJ, Zagers GK, Camp ER, Ross MI. Role of sentinel lymph node biopsy in anorectal melanoma. Poster presented at the 63rd Annual Society of Surgical Oncology Cancer Symposium, 2010. e-Pub 2010.
- Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Royal RE, Cormier JN. Standards for lymph node ratio in dissections for melanoma. Poster presented at the 63rd Annual Society of Surgical Oncology Cancer Symposium, 2010. e-Pub 2010.
- Goel N, Askew RL, Xing Y, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Royal RE, Cormier JN. Standards for lymph node ration in dissections for melanoma patients: can they be achieved?. Poster presented at the 63rd Annual Symposium of the Society of Surgical Oncology, 2010. e-Pub 2010.
- Mu H, Bartos D, Calderone T, Gershenwald JE. Lysophosphatidic acid-induced lymphangiogenesis in human lymphatic endothelial cells. Poster presented at the 3rd International Symposium on Cancer Metastasis and the Lymphovascular System(Abstract Section awardee), 2009. e-Pub 2009.
- Peddareddigari VR, Miller PW, Nebiyou BB, Overwijk WW, Ross MI, Lee JE, Gershenwald JE, Prieto VG, Hwu P, Radvanyi L. Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, 2009. e-Pub 2009.
- Wang DY, Wang Y, Sui D, Chun YS, McClain DM, Liu P, Bassett Jr RL, Royal RE, Mansfield PF, Lucci A, Cormier JN, Ross MI, Gershenwald JE, Lee JE. Investigation of an array of cytokines in melanoma patients confirms elevated interferon-gamma as a marker of poorer prognosis. Presented at the 7th Annual World Congress on Melanoma/5th EADO, 2009. e-Pub 2009.
- Soong SJ, Ding S, Coit DG, Thompson JF, Gershenwald JE, Gimotty P, Balch C. Predicting melanoma outcome: Model development, validation and applications. Poster presented at the 7th Annual World Congress on melanoma/5th EADO, 2009. e-Pub 2009.
- Davies M, Stemke-Hale K, Calderone T, Deng W, Lazar A Prieto VG, Aldape K, Mills GB, Gershenwald JE. Quantitative assessment of AKT activation in melanoma. Poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology, 2009. e-Pub 2009.
- Liu H, Wang Y, Kesmodel SB, Chun YS, Gershenwald JE, Ross MI, McClain DM, Liu P, Liu J, Kuyn R, Bassett RL, Reveille JD, Lee JE. Association of VEGF polymorphisms with primary melanoma tumor thickness and ulceration. Poster presented at the 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
- Niu J, Liu Z, Zhao H, Wang L, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Melanocortin 1 receptor (MC1R) gene variants and risk in cutaneous melanoma - A case-control analysis. Poster presented at the 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
- Zhao H, Wang L, Jr DA, Etzel C, Spitz M, Lee JE, Gershenwald JE, Wei Q. Building risk assessment models for cutaneous melanoma using a hospital-based case control study. Poster presented at the 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
- Bowles TL, Xing Y, Hu C, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Conditional survival estimates improve over 5 years for patients with node-positive melanoma. Poster presented at the 62nd. Annual Meeting of the Society of Surgical Oncology, 2009. e-Pub 2009.
- Chang S, Xing Y, Askew R, Mungovan K, Gershenwald J, Lee J, Lucci A, Mansfield P, Ross M, Cormier J. Prospective analysis of postoperative morbidity following inguino-femoral lymph node dissection (ILND) in patients with node positive melanoma. Poster presented at the 62nd. Annual Meeting of the Society of Surgical Oncology, 2009. e-Pub 2009.
- Xing Y, Chang GJ, Hu C, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates provide better prognostic information for melanoma survivors: result from the SEER dataset 1988-2000. Presented at the 4th Annual Academic Surgical Congress, 2009. e-Pub 2009.
- Gershenwald JE, Morton DL, Thompson JF, Kirkwood JM, Soong S, Balch CM, Eggermont AM, Sondak VK, Johnson MM, Warneke C, Task Force COTAM. Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4895 melanoma patients. Abstract #9035; Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, 2008. e-Pub 2008.
- Fournier KF, Xing Y, Ross MI, Lee JE, Gershenwald JE Mansfield PF, Lucci A, Cormier JN. Survival in patients with synchronous versus metachronous lymph node (LN) involvement in stage III melanoma: Is there a difference?. Abstract #9034; Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, 2008. e-Pub 2008.
- Chun YS, Wang Y, Wang DY, McClain DM, Lucci A, Mansfield PF, Cormier JN, Ross MI, Gershenwald JE, Lee JE. Prognostic value of S100B levels and LDH levels in melanoma patients. Abstract #9002; Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, 2008. e-Pub 2008.
- Wang Y, Kesmodel SB, Vo AH, Liu H, Chun YS, Gershenwald JE, Cormier JN, Ross MI, Wang DY, McClain DM, Schacherer CW, Henderson LM, Liu P, Johnson MM, Berry DA, Reveille JD, Lee JE. Association of the TGFbeta1 codon 10 T polymorphism with improved outcomes in early-stage melanoma patients. Poster presented at the American Association for Cancer Research 2008 Annual Meeting, 2008. e-Pub 2008.
- Chun YS, Wang Y, Vo AH, Liu H, Wang DY, Gershenwald JE, Cormier JN, Ross MI, McClain DM, Schacherer CW, Reveille JD, Lee JE. Elevated interleukin-12 is a plasma marker of poor prognosis in stage III melanoma patients. Poster presented at the American Association for Cancer Research 2008 Annual Meeting, 2008. e-Pub 2008.
- Chun YS, Wang Y, Wang DY, McClain DM, Lucci A, Mansfield PF, Cormier JN, Ross MI, Gershenwald JE, Lee JE. S100B levels are more accurate than LDH levels at predicting survival in melanoma patients. Poster presented at the 61st Annual Society of Surgical Oncology Cancer Symposium, 2008. e-Pub 2008.
- Gershenwald JE, Thompson JF, Warneke C, Ross M, Johnson M, McMasters K, Delma MK, Sabel M, Noyes D, Kraybill W, Coit D, Leong S, Eggermont A. Re-defining indications for sentinel lymph node biopsy (SLNB) in patients (pts) with thin melanomas - preliminary results of an international thin melanoma working group. Ann Surg Oncol 15(S1):4, 2008. e-Pub 2008.
- Balch C, Soong SJ, Thompson J, Gershenwald J, Coit D, Ding S, Staging Committee ATAM. Prognosis and survival of 2031 melanoma patients with nodal micrometastases. Ann Surg Oncol 15(S1):22, 2008. e-Pub 2008.
- Zager JS, Roka F, Ross MI, Prieto VG, Ballo MT, Johnson MM, Warneke C, Mansfield PF, Lee JE, Feig BW, Cormier JN, Gershenwald JE. Clinical significance of positive sentinel nodes in Merkel cell carcinoma. Poster presented at the 6th Biennial International Sentinel Node Society Meeting, 2008. e-Pub 2008.
- Lee JE, Chun YS, Wang Y, Gershenwald JE, Ross MI, Sui D, Liu J, Bassett RL, McClain DM, Reveille JD. Use of extended HLA class II region analysis to identify alleles predictive of recurrence in early-stage melanoma patients. Poster presented at the 2008 Annual Meeting of the American Society of Surgical Oncology, 2008. e-Pub 2008.
- Lee JE, Wang Y, Kesmodel SB, Chun YS, Gershenwald JE, Ross MI, Wang DY, McClain DM, Liu P, Liu J, Kuhn R, Bassett RL, Reveille JD. Association of VEGF polymorphisms with primary melanoma tumor thickness and ulceration. Presented at the NCI Translational Science Meeting, 2008. e-Pub 2008.
- Cormier JN, Webster K, Cella D, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Palmer JL. Reliability and validity of the functional assessment of cancer therapy-melanoma (FACT-M). Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, 2007. e-Pub 2007.
- Chun YS, Wang Y, Gershenwald JE, Ross MI, Johnson MM, Liu P, Schacherer CW, Reveille JD, Lee JE. HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, 2007. e-Pub 2007.
- Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Outcome analysis for melanoma patients undergoing deep pelvic lymph node dissection. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, 2007. e-Pub 2007.
- Mittendorf EA, Lim SJ, Schacherer CW, Ng C, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: Natural history and surgical management. Poster presented at the 60th Annual Society of Surgical Oncology Cancer Symposium, 2007. e-Pub 2007.
- Hayes-Jordan AA, Gershenwald JE, Lee JE, Mansfield PM, Ross MI, Lally KP, Cox CS, Prieto VE, Herzog CE. Identification and outcome of regional nodal metastasis in children with melanoma: The M. D. Anderson Cancer Center experience. Poster presented at the 60th Annual Society of Surgical Oncology Cancer Symposium, 2007. e-Pub 2007.
- Kesmodel SB, Want Y, Vo A, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. IL-10 Gene polymorphisms predict primary tumor ulceration and risk of recurrence in melanoma patients. Presented at the 60th Annual Society of Surgical Oncology Cancer Symposium, 2007. e-Pub 2007.
- Li C, Lu J, Hu Z, Wang L, Je G, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of caspases 8 and caspase 10 genes and risk of cutaneous melanoma. 15th SPORE Investigators Workshop, 2007. e-Pub 2007.
- Perna AG, Ivan D, Gershenwald JE, Ross MI, Lazar AJF. Lymph node metastasis of an atypical hidradenoma identified by sentinel lymph node biopsy. Presented at the 43rd Annual American Society of Dermatopathology Meeting, 2006. e-Pub 2006.
- Lee JE, Wang Y, Jin R, Vo A, Gershenwald JE, Ross MI, Johnson MM, McClain DM, Schacherer CW, Reveille JE. Association of HLA class II alleles with melanoma incidence. Presented at the 14th SPORE Investigators' Workshop, 2006. e-Pub 2006.
- Li C, Liu A, Wang L, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the nNOS and iNOS genes and risk of cutaneous melanoma: A case-control analysis. Presented at the 14th SPORE Investigators' Workshop, 2006. e-Pub 2006.
- Andtbacka RH, Gershenwald JE, Prieto VG, Johnson MM, Diwan H, Lee JE, Mansfield PF, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, 2006. e-Pub 2006.
- Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of Fas and the Fas ligand increase the risk of cutaneous malignant melanoma. Poster presented at the 97th Annual Meeting of the American Association for Cancer Research, 2006. e-Pub 2006.
- Tellez CS, Davis D, Prieto VG, Gershenwald JE, Johnson MM, McCarty M, Bar-Eli M. Quantitative analysis of melanocytic tissue array reveals inverse correlation between AP-2alpha and PAR-1 expression during melanoma progression. Poster presented at the 97th Annual Meeting of the American Association for Cancer Research, 2006. e-Pub 2006.
- Tellez CS, Shen L, Oki Y, Estecio MRH, Gershenwald JE, Issa JPJ. CpG island hypermethylation profile of human melanoma cell lines in relation to global methylation and mutations in BRAF and NRAS. Poster presented at the 97th Annual Meeting of the American Association for Cancer Research, 2006. e-Pub 2006.
- Gray KD, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Contemporary outcomes in stage III melanoma patients. Presented at the 59th Annual Society of Surgical Oncology Cancer Symposium, 2006. e-Pub 2006.
- Tseng JF, Schacherer CW, McClain DM< Mansfield PF, Cormier JN, Gershenwald JE, Ross MI, Lee JE. Surgical management of melanoma of the pancreas, duodenum and ampulla. Presented at the 59th Annual Society of Surgical Oncology Cancer Symposium, 2006. e-Pub 2006.
- Andtbacka RH, Bedrosian I, Ross MI, Lin E, Prieto VG, Aloia TA, Cormier JN, Lee JE, Mansfield PF, Gershenwald JE. AJCC nodal factors and microscopic tumor burden predict recurrence in sentinel lymph node positive stage III melanoma patients. Presented at the 59th Annual Society of Surgical Oncology Cancer Symposium, 2006. e-Pub 2006.
- Zager J, Gershenwald JE, Aldrink J, Lin E, Cormier JN, Cheng T, Yoo J, Lee JE, Tyler DS, Ross MI. Isolated limb infusion for locally recurrent and in-transit extremity melanoma: A combined institutional experience. Presented at the 59th Annual Society of Surgical Oncology Cancer Symposium, 2006. e-Pub 2006.
- Prieto VG, Diwan AH, Lazar AJF, Johnson MM, Schacherer CW, Gershenwald JE. Histologic quantification of tumor size in sentinel lymph node metastases. Presented at the 2006 United States and Canadian Academy of Pathology Meeting, 2006. e-Pub 2006.
- Lazar AJF, Prieto VG, Goel V, Niveiro M, Gershenwald JE, Haluska FG. PTEN expression, BRAF and NRAS mutational status in primary cutaneous melanoma. Poster presented at the Keystone Symposium: Advances in the Understanding and Treatment of Melanoma, 2006. e-Pub 2006.
- Je G, Prieto VG, Schacherer CW, Johnson MM, McClain D, Mansfield PF, Lee JE, Diwan AH, Lazar A, Cormier JN, Ross MI. Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. Poster presented at the Keystone Symposium: Advances in the Understanding and Treatment of Melanoma, 2006. e-Pub 2006.
- Zager JS, Gershenwald JE, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Ross MI. Isolated limb infusion for recurrent extremity melanoma: Minimally invasive but requiring a significant hospital stay. Presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Ross MI, Prieto VG, Johnson MM, Diwan A, Schacherer CW, McClain DM, Lee JE, Cormier JN, Mansfield PF, Gershenwald JE. A predictive model for non-sentinel node involvement in patients with a positive sentinel node: Impact on surgical management. Presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Gershenwald JE, Prieto VG, Johnson MM, Schacherer CW, McClain DM, Lee JE, Cormier JN, Mansfield PF, Diwan A, Ross MI. Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. Presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Schacherer CW, McClain DM, Lee JE, Cormier JN, Gershenwald JE. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Poster presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Du XL, Ross MI. Ethnic differences and survival in melanoma patients. Presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites: stage III or stage IV?. Presented at the 6th World Congress on Melanoma, 2005. e-Pub 2005.
- Wang Y, Yi M, Abdalla J, Gershenwald JE, Ross MI, Ioannides C, Johnson MM, Reveille JD, Lee JE. Association of the HLA class II alleles DQB1*0301 and DRB1*1101 with low IFN-y production from melanoma patient lymphocytes. Presented at the 2005 NIH SPORE Investigator's Workshop, 2005. e-Pub 2005.
- Ng CS, Szklaruk J, Kundra V, Gershenwald JE, Prieto VG, Bedi DG, Jacobson MG. The spectrum of manifestations of metastatic malignant melanoma. Presented as an electronic exhibit at the 105th Annual Meeting of the American Roentgen Ray Society, 2005. e-Pub 2005.
- Cormier JN, Xing Y, Ding M, Ross MI, Lee JE, Mansfield PF, Gershenwald JE. Population based assessment of surgical treatment trends for melanoma. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, 2005. e-Pub 2005.
- Ballo MT, Ross MI, Cormier JN, Myers JN, Gershenwald JE, Lee JE, Zagars GK. Combined modality therapy for patients with nodal metastases from melanoma. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, 2005. e-Pub 2005.
- Furukawa H, Calderone TL, Bartos DP, Mitchell J, Prieto VG, McIntyre BW, Gershenwald JE. Isolation and molecular characterization of human sentinel lymphatic endothelial cells. First International Symposium on Cancer Metastasis and the Lymphovascular System, University of San Francisco School of Medicine, 2005. e-Pub 2005.
- Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Curley SA, Capussotti L, Elias D, Vauthey JN. Distinct patterns of recurrence and prognosis after resection of hepatic metastases from ocular or cutaneous melanoma. Poster presented at the 58th Annual Society of Surgical Oncology Cancer Symposium, 2005. e-Pub 2005.
- Delman KA, McClain DM, Schacherer CW, Cormier JN, Gershenwald JE, Mansfield PF, Prieto VG, Diwan H, Ross MI, Lee JE. Melanoma metastases to cervical lymph nodes: Extent of involvement following detection by sentinel node biopsy versus clinical examination. Poster presented at the 58th Annual Society of Surgical Oncology Cancer Symposium, 2005. e-Pub 2005.
- Wong SL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Sabel MS, Gutman H McMasters KM, Tyler DS, Coit DG. Melanoma patients with positive sentinel nodes who do not undergo completion lymphadenectomy: A multi-institutional study. Presented at the 58th Annual Society of Surgical Oncology Cancer Symposium, 2005. e-Pub 2005.
- Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, Ross MI, Cormier JN. Invasive squamous cell carcinoma of the skin: Defining a high-risk group. Presented at the 58th Annual Society of Surgical Oncology Cancer Symposium, 2005. e-Pub 2005.
- Zager JS, Ross MI, Prieto VG, Mansfield PF, Lee JE, Feig BW, Cormier JN, Gershenwald JE. Clinical significance of positive sentinel nodes in merkel cell carcinoma. Presented at the 4th International Sentinel Node Conference, 2004. e-Pub 2004.
- Aloia T, Gershenwald JE, Ross MI, Lee JE, Johnson MM, Cormier JN, Ng C, Mansfield PF. Utility of CT and MRI staging in patients with sentinel lymph node-positive melanoma. Presented at the 4th International Sentinel Node Conference, 2004. e-Pub 2004.
- Pawlik TM, Gershenwald JE. Sentinel lymph node biopsy for cutaneous melanoma does not increase the risk of in-transit metastasis: An international experience of 3,413 patients. Presented at the 4th International Sentinel Node Conference, 2004. e-Pub 2004.
- Pawlik TM, Ross MI, Johnson MM, Prieto VG, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma: Is there a role?. Presented at the 4th International Sentinel Node Conference, 2004. e-Pub 2004.
- Gannon CJ, Rousseau Jr DL, Ross MI, Johnson MM, Lee JF, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy after previous wide local excision accurately reflects the status of the regional nodal basin in patients with primary melanoma. Presented at the 4th International Sentinel Node Conference, 2004. e-Pub 2004.
- Gershenwald JE, Prieto VG, Schacherer CW, Johnson MM, McClain DM, Mansfield PF, Lee JE, Ross MI. The impact of microscopic tumor burden in sentinel node-positive melanoma patients: Implications for future clinical trial design. Presented at the Second International Melanoma Research Congress, 2004. e-Pub 2004.
- Furukawa H, Calderone TL, Bartos DP, Mitchell J, Prieto VG, McIntyre B, Gershenwald JE. Molecular characterization of human sentinel lymphatic endothelial cells: Emerging insights into the biology of melanoma lymphatic metastasis. Presented at the Second International Melanoma Research Congress, 2004. e-Pub 2004.
- Ross MI, Cormier JN, Xing Y, Gershenwald JE, Lee JE, Mansfield PF. Prognosis and survival outcomes in melanoma patients with unknown primary site (MUP). Presented at the Annual Meeting of the American Society of Clinical Oncology, 2004. e-Pub 2004.
- Ng CS, Szklaruk J, Kundra V, Gershenwald JE, Prieto VG, Bedi DG, Jacobson MG. The spectrum of manifestations of metastatic malignant melanoma. Presented as an electronic exhibit at the European Congress of Radiology, 2004. e-Pub 2004.
- Delman KA, Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF. Surgical management of melanoma patients with epitrochlear or popliteal lymph node metastases. Presented at the 57th Annual Meeting of the Society of Surgical Oncology, 2004. e-Pub 2004.
- Montgomery SC, Panageas KS, Thompson JF, Gershenwald JE, Carlson GW, Leong SP, Goydos JS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: Results of a large multi-institutional study. Presented at the 57th Annual Meeting of the Society of Surgical Oncology, 2004. e-Pub 2004.
- Pawlik TM, Ross MI, Johnson MM, Bedrosian I, Schacherer CW, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Presented at the 57th Annual Meeting of the Society of Surgical Oncology, 2004. e-Pub 2004.
- Furukawa H, Langley R, Calderone TL, Bartos D, Gershenwald JE. Adhesion molecule expression on human primary culture lymphatic endothelial cells. Presented at the 95th Annual Meeting of the American Association for Cancer Research, 2004. e-Pub 2004.
- Goldflam K, Gershenwald JE, Hunt KK, Singletary SE, Mirza N, Arun B, Babiera GV, Kuerer HM, Ross MI, Meric-Bernstam F. Contralateral prophylactic mastectomy: Efficacy and determinants of significant histologic findings. Presented at the 57th Annual Meeting of the Society of Surgical Oncology, 2004. e-Pub 2004.
- Okubo Y, Bartos D, Calderone T, Prieto VG, Mansfield PF, Ross MI, He CL, Gallagher A, Gershenwald JE. Primary culture and initial signaling studies of human lymphatic endothelial cells isolated from melanoma patients undergoing sentinel lymphadenectomy. Presented at the 94th Annual Meeting of the American Association for Cancer Research, 2003. e-Pub 2003.
- Rousseau D, Ross MI, Lee JE, Mansfield PF, Gershenwald JE. Sentinel lymph node biopsy after previous wide local excision accurately reflects the status of the regional nodal basin in patients with primary melanoma. Presented at the 56th Annual Meeting of the Society of Surgical Oncology, 2003. e-Pub 2003.
- Okubo Y, Bartos D, Gallagher A, Prieto VG, Takeda A, Mansfield PF, Ross MI, Gershenwald JE. Isolation and culture of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy. Presented at the 3rd International Sentinel Node Congress, 2002. e-Pub 2002.
- Gershenwald JE, Prieto VG, Johnson M, Schacherer C, Lee JE, Mansfield PF, Ross MI. AJCC stage III (nodal) criteria accurately predict survival in sentinel node-positive melanoma patients. Presented at the 3rd International Sentinel Node Congress, 2002. e-Pub 2002.
- Amato M, Delpassand E, Ahmadi E, Tehrani MH, Gershenwald JE, Ross MI, Esmaeli B. Lymphoscintigraphy for ocular adnexal tumors. Presented at the 33rd Annual Scientific Symposium of the American Society of Ophthalmic Plastic and Reconstructive Surgery, 2002. e-Pub 2002.
- Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for patient with anal-rectal malignant melanoma. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, 2002. e-Pub 2002.
- Bedrosian I, Ross MI, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Impact of melanoma sentinel lymph node (SLN) tumor burden on incidence and extent of Stage IV disease. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, 2002. e-Pub 2002.
- Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Sprit MR, Wei Q. Polymorphisms of DNA repair genes, XRCC3 and XRCC7, and risk of cutaneous malignant melanoma: A case-control analysis. Presented (minisymposium) at the AACR 93rd Annual Meeting, 2002. e-Pub 2002.
- Lee JE, Abdalla J, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI, Ioannides C. Association of the HLA class II alleles DQB1*0301 and DRB1*1101 with low interferon-gamma production in lymphocytes from melanoma patients. Presented at the American Association for Cancer research 93rd Annual Meeting, 2002. e-Pub 2002.
- Rousseau Jr DL, Ross MI, Ball G, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised AJCC staging criteria accurately predict sentinel lymph node positivity in clinically node negative melanoma patients. Presented at the 55th Annual Meeting of the Society of Surgical Oncology, 2002. e-Pub 2002.
- Gershenwald JE, Prieto VG, Ball G, Lee JE, Mansfield PF, Ross MI. Sentinel lymph node (SLN) microscopic tumor burden predicts non-SLN involvement in melanoma patients undergoing therapeutic lymphadenectomy. Presented at the 55th Annual Meeting of the Society of Surgical Oncology, 2002. e-Pub 2002.
- Esnaola NF, Ross MI, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE. Role of intraoperative frozen-section analysis of cloquet's node during superficial groin dissection in patients with positive inguinal sentinel lymph nodes. Presented at the 55th Annual Meeting of the Society of Surgical Oncology, 2002. e-Pub 2002.
- Scaife C, Curley SA, Gershenwald JE, Fornage PB, Patt Y, Fornage B, Woodhall M, Gonzalez K, Ellis LM. Adjuvant hepatic arterial infusion (HAI) of chemotherapy following radiofrequency ablation (RFA) +/- resection in patients with hepatic metastasis from colorectal cancer. Presented at the 55th Annual Meeting of the Society of Surgical Oncology, 2002. e-Pub 2002.
- Gershenwald JE, Prieto V, Colome-Grimmer M, Giacco G, Sumner W, Mansfield P, Ross M, Lee J. The prognostic significance of microscopic tumor burden and 945 melanoma patients undergoing sentinel lymph node biopsy. Abstract #2169 presented at the 2000 ASCO Annual Meeting, 2000. e-Pub 2000.
- Gershenwald JE, Simon J, Asare E. Beyond the American Joint Committee on Cancer (AJCC) 8th Edition Melanoma Staging System. Society for Melanoma Research 22nd International Congress.
Book Chapters
- Gershenwald JE, Faries M. Evaluation and management of regional nodes in primary cutaneous melanoma. In: UpToDate. UpToDate, Inc, 2025.
- Gershenwald JE, Hyngstrom J. Surgical management of primary cutaneous melanoma or melanoma at other unusual sites. In: UpToDate. UpToDate Inc, 2025.
- Balch, CM, Gershenwald, JE, Soong, SJ, Sober, A, Kirkwood, JM. Melanoma staging and classification, 65-86, 2024.
- Gershenwald, JE, Balch, CM, Soong, SJ, Thompson, JF. Prognostic factors and natural history of melanoma, 35-64, 2024.
- Gershenwald, JE, Thompson, JF, Mozzillo, N, Balch, CM. Intraoperative mapping and sentinel node technology in patients with melanoma. In: Cutaneous Melanoma, 5th Edition. 5th, 415-446, 2024.
- Gershenwald JE, Keung E. Surgical management of primary cutaneous melanoma or melanoma at other unusual sites. In: UpToDate. UpToDate Inc, 2023.
- Gershenwald JE, Keung E. Metastatic melanoma: Surgical management. In: UpToDate. UpToDate Inc, 2023.
- Voss RK, Gershenwald JE. Melanoma. In: The MD Anderson Surgical Oncology Manual. Seventh. Wolters Kluwer, 64-104, 2023.
- Buzaid AC, Gershenwald JE. Staging work-up and surveillance of cutaneous melanoma. In: UpToDate. UpToDate, 2023.
- Buzaid AC, Gershenwald JE. Tumor, node, metastasis (TMN) staging system and other prognostic factors in cutaneous melanoma. In: UpToDate. UpToDate, 2023.
- Weiser R, Berman RS, Gershenwald JE. Wide excision of primary cutaneous melanoma. In: Operative Techniques in Breast, Endocrine, and Oncologic Surgery. 2nd. Wolters Kluwer, 1521-32, 2023.
- Keung EZ, Balch CM, Thompson JF, Kirkwood JM, Scolyer RA, Sondak VK, Gershenwald JE. Melanoma Prognosis and Staging. In: Cutaneous Melanoma. 6th. Springer, 271-297, 2020.
- Haydu LE, Gimotty PA, Coit DG, Thompson JF, Gershenwald JE. Models for predicting melanoma outcome. In: Cutaneous Melanoma. 6th. Springer, 299-314, 2020.
- Swetter S, Geller AC, Leachman SA, Kirkwood JM, Katalinic A, Gershenwald JE. Melanoma Prevention and Screening. In: Cutaneous Melanoma. 6th. Springer Nature, 525-570, 2020.
- Berman RS, Burns WR, Delman KA, Faries MB, Fujii MH, et al GJ. Melanoma – Neck, axillary, ilioinguinal, and other lymph node dissections. In: Operative Standards for Cancer Surgery. Walters Kluwer, 2018.
- Berman RS, Burns WR, Delman KA, Faries MB, Fujii MH, et al GJ. Melanoma – Wide local excision. In: Operative Standards for Cancer Surgery. Walters Kluwer, 2018.
- Egger ME, Gershenwald JE. Melanoma clinical staging (Historical and current). In: Melanoma. Springer International Publishing, 87-103, 2018.
- Berman RS, Burns WR, Delman KA, Faries MB, Fujii MH, et al GJ. Melanoma - Sentinel lymph node biopsy. In: Operative Standards for Cancer Surgery. Walters Kluwer, 2018.
- Compton CC, Hess KR, Halabi S, Balis UGJ, Gershenwald JE, Gimotty PA, Guinney J, Lazar AJ, Lu Y, Mahar AL, Mariotto A, Moons KGM, Patel SG, Sargent DJ, Weiser MR, Kattan MW. Risk models for individualized prognosis in the practice of precision oncology. In: AJCC Cancer Staging Manual. 8th. Springer, 47-54, 2017.
- Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. Organization of the AJCC Cancer Staging Manual. In: AJCC Cancer Staging Manual. 8th. Springer, 31-37, 2017.
- Gershenwald JE, Scolyer RA, Hess KR, Thompson JF, Long GV, Ross MI, Lazar AJ, Atkins MB, Balch CM, Barnhill R, Bilimoria KY, Brierley JD, Buzaid AC, Byrd DR, Chapman PB, Cochran AJ, Coit DG, Eggermont AM, Elder DE, Faries MB, Flaherty KT, Garbe C, Gardner JM, Gimotty PA, Halpern AC, Haydu LE, Johnson T, Kirkwood JM, Lee AWM, McArthur GA, Mihm MC, Prieto VG, Sober AJ, Wahl RL, Wong SL, Sondak VK. Melanoma of the Skin. In: AJCC Cancer Staging Manual. 8th. Springer, 563-85, 2017.
- Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD, Byrd DR, Compton CC, Jessup JM, Winchester DP, Amin MB, Gershenwald JE. Principles of Cancer Staging. In: AJCC Cancer Staging Manual. 8th. Springer, 3-30, 2017.
- Boland GM, Gershenwald JE. Principles of Melanoma Staging. In: Melanoma. Springer, 131-48, 2016.
- Berman RS, Gershenwald JE. Wide excision of primary cutaneous melanoma. In: Operative Techniques in Surgery. Wolters Kluwer Health, 1535-45, 2015.
- Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. In: Nat Rev Dis Primers. 3rd. Lippincott Williams and Wilkins, 15003, 2015.
- Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. In: Molecular Diagnostics for Melanoma, Methods and Protocols, 679-95, 2014.
- Boland GM, Gershenwald JE. Melanoma Survivorship Management. In: Advances in Cancer Survivorship Management. Springer, 219-40, 2014.
- Patnana M, Gershenwald JE, Hwu WJ, Ng CS. Diagnostic imaging for the radiologists, medical oncologists and surgical oncologists. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon. Bermedica Production, Ltd, 1-19, 2011.
- Gershenwald JE. Prognostic factors and staging in melanoma. In: Cancer of the Skin. 2nd. Elsevier Inc, 282-94, 2011.
- Andtbacka RI, Gershenwald JE. Lymphatic mapping and sentinel lymph node biopsy. In: Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge, 501-15, 2011.
- Gershenwald JE, Ballo MT, Myers JN. Regional management of melanoma in the clinically node-negative neck. In: Cutaneous Malignancy of the Head and Neck. Plural Publishing, Inc, 343-71, 2011.
- Gershenwald JE, Patrick H. Melanoma. In: Cancer Medicine. 8th. People's Medical Publishing House - USA, 1459-86, 2010.
- Pytowski B, Gershenwald JE. Therapeutic targeting of the lymphovascular system in cancer: The promise and challenges. In: From Local Invasion to Metastatic Cancer: Involvement of Distant Sites through the Lymphovascular System. Humana Press, 191-200, 2009.
- Gershenwald JE, Balch CM, Thompson JF. Intraoperative mapping and sentinel node technology. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
- Gershenwald JE, Balch CM, Soong S, Thompson JF. Prognostic factors and natural history of melanoma. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 35-64, 2009.
- Balch CM, Gershenwald JE, Soong S, Sober A, Kirkwood J. Melanoma staging and classification. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 65-85, 2009.
- Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd D, Buzaid AC, Cochran A, Coit DG, Ding S, Eggermont AMM, Flaherty KT, Gimotty P, Kirkwood J, McMasters K, Mihm M, Morton D, Ross MI, Sober A, Sondak VK. Melanoma of the skin. In: AJCC Cancer Staging Manual. 7th. Springer, 2009.
- Gershenwald JE, Roka F, Prieto VG. Desmoplastic melanoma. In: Encyclopedia of Cancer. 2nd. Springer, 2009.
- Gershenwald JE, Uren R, Mariani G, Thompson J. Sentinel lymph node biopsy in malignant cutaneous melanoma and Merkel cell cancer. In: Radioguided Surgery-A Comprehensive Team Approach. Springer-Verlag, Inc, 112, 2008.
- Herne K, Hymes SR, Gershenwald JE. Non-melanoma skin cancers. In: Handbook of Surgical Oncology. 4th. Lippincott Williams and Wilkins, 112-20, 2006.
- Pawlik TM, Gershenwald JE. Melanoma. In: Handbook of Surgical Oncology. 4th. Lippincott Williams and Wilkins, 60-111, 2006.
- Gershenwald JE, Ross MI, Buzaid AC. Staging systems for cutaneous melanoma. In: Textbook of Melanoma. Martin Dunitz Ltd, 164-80, 2004.
- Buzaid AC, Gershenwald JE, Ross MI. Initial staging investigations. In: Textbook of Melanoma. Martin Dunitz Ltd, 241-46, 2004.
- Barnett C, Gershenwald JE. Melanoma. In: Handbook of Surgical Oncology. 3rd. Lippincott Williams and Wilkins, 2003.
- Reintgen DS, Thompson JF, Gershenwald JE. Intraoperative mapping and sentinel node technology. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 353-77, 2003.
- Gershenwald JE, Balch CM, Thompson JF, Soong SJ, Buzaid AC. Prognostic factors and natural history. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 25-54, 2003.
- Balch CM, Soong SJ, Gershenwald JE, Buzaid AC, Thompson JF, Cascinelli N, Eggermont A. Staging and classification. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 55-76, 2003.
- Ross MI, Gershenwald JE. How we do it: The M. D. Anderson Cancer Center approach. In: Sentinel Lymph Node Biopsy. Martin Dunitz Ltd, 143-49, 2001.
- Buzaid AC, Gershenwald JE, Ross MI. Prognostic factors in melanoma--Updated 2010. In: UpToDate. UpToDate Inc, 2000.
- Buzaid AC, Gershenwald JE, Ross MI. Staging work-up for melanoma and follow-up guidelines--Updated 2010. In: UpToDate. UpToDate Inc, 2000.
- Buzaid AC, Gershenwald JE, Ross MI. American Joint Committee on Cancer staging of cutaneous melanoma--Updated 2010. In: UpToDate. UpToDate Inc, 2000.
- Ross MI, Gershenwald JE. Melanoma lymphatic mapping: scientific support for the sentinel lymph node concept and biologic significance of the sentinel node. In: Radioguided Surgery. Landes Bioscience, 48-63, 1999.
- Gershenwald JE, Fong Y, Chizzonite R, Lowry SF, Moldawer LL. The metabolic response to inflammation is attenuates by anti-Interleukin-1 receptor monoclonal antibodies. In: The Physiological and Pathological Effects of Cytokines. Wiley-Liss, Inc, 441-6, 1990.
Books (edited and written)
- Balch C, Gershenwald J, Thompson J, Atkins M, Kirkwood J, Kefford R, Sober A, Halpern A, Garbe C, Scolyer R. Cutaneous Melanoma. Ed(s) 6th. Springer Nature, 2020.
- Amin MB, Edge SB, Greene FL, Schilsky R, Gaspar L, Washington MK, Brookland RK, Brierley JD, Balch CM, Compton CC, Hess KR, Gershenwald JE, Jessup JM, Byrd DR, Winchester DP, Madera M, Asare EA, Eds. AJCC Cancer Staging Manual. Ed(s) 8th Edition. Springer, 2017.
- Gershenwald JE, Guest Editor. Surgical Oncology Clinics of North America. Ed(s) 1. Elsevier, Health Sciences, 2011.
- Gershenwald JE, Guest Editor. Lymphadenectomy for Malignant Disease. Operative Techniques in General Surgery, 2006.
Letters to the Editor
- Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. Ann Surg Oncol 30: 4359-4360, 2023.
- Asare EA, Brookland RK, Gershenwald JE, Nelson H, Washington MK. Letter to the Editor: Re: Reimagining Cancer Staging in the Era of Evolutionary Oncology. J Natl Compr Canc Netw 21: xviii, 2023.
- Scolyer RA, Gershenwald JE, Thompson JF. Isolated immunohistochemistry-positive cells without morphologic characteristics of melanoma should not result in designation as a positive sentinel lymph node according to the AJCC 8th Edition Staging System. Am J Surg Pathol 43: 1442-1444, 2019.
- Balch CM, Gershenwald JE, Soong SJ. Reply to J.M. Thomas et al. J Clin Oncol 28: e480-81, 2010.
- Gershenwald JE, Andtbacka RHI, Ross MI. In Reply to: The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor?, van Akkooi, AC. J Clin Oncol 26: 6012, 2008.
- Scolyer RA, Murali R, Gershenwald JE, Cochran AJ, Thompson JF. Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Ann Oncol 18: 806-8, 2007.
- Scolyer RA, Thompson JF, McCarthy SW, Gershenwald JE, Ross MI, Cochran AJ. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 201: 821-3; author reply 823-4, 2005.
- Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol 31: 323-4, 2005.
Patient Reviews
CV information above last modified March 31, 2026